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Abstract 
This project investigates the potential of Natural Killer (NK) cells to respond to pathogen 
associated molecular patterns (PAMP) as model adjuvants and establishes the potential of 
PAMP to aid the recovery of antigen specific T-cell responses in chronic HIV-1 infection. 
Innate immunity is mediated by through the recognition of conserved PAMP recognised by 
receptors such as the toll-like receptors (TLR), expressed by accessory cells including 
blood DC, which are responsible for initiating adaptive immune responses, but also 
activate NK cells.  NK cells are no longer seen solely as killers, but instead produce 
cytokines, including IFN-γ, and participate in the generation of adaptive immune responses 
with DC. 
HIV-1 infection potentially chronically activates TLR pathways, via recognition of the viral 
genome and as a result of damage to mucosal surfaces leading to microbial translocation 
and systemic recognition of PAMP including bacterial lipopolysaccharides.  NK cell 
activation, cytokine production, differentiation and proliferation in response to PAMP have 
therefore been examined.  NK cell responsiveness to certain TLR agonists was refractory 
in HIV-1 infected individuals although responses were maintained within CD56+CD16- NK 
cells, potentially providing help for antigen specific T-cell responses.  The effects of HIV-1 
infection on NK cell maturation were also investigated. 
T-cell activation by TLR agonists was also refractory in HIV-1 infected individuals.  The 
impact of TLR ligation on antigen specific T-cell responses was investigated, combining 
TLR agonists with peptide pools (influenza, Epstein-Barr virus and cytomegalovirus or 
HIV-1 gag antigens).  Of the TLR agonists tested, only CpG DNA resulted in enhanced 
frequencies of IFN-γ producing T-cells in HIV-1 infected individuals, whereas LPS 
demonstrated consistently reduced IFN-γ production. 
In conclusion, maintenance of responsiveness of CD56+CD16- NK cells and enhancement 
of HIV-1 antigen specific T-cell responses by CpG DNA have implications for both 
repopulation of the NK cell compartment and reconstitution of acquired immunity during 
HIV-1 infection.  
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1. Introduction 
1.1. Natural killer cells 
Natural killer (NK) cells are large granular lymphocytes that were first described by 
Kiessling et al. (1975b) for their ability to spontaneously kill target cells without prior 
exposure.  It was later discovered that NK cells were killing targets that failed to express 
class I MHC molecules and so the ‘missing self’ hypothesis was proposed by Kärre and 
coworkers (1986 & 1990), which described how NK cells could kill transformed tumour 
cells or virus-transformed cells without previous encounter.  The ‘missing self’ hypothesis 
was further clarified by the discovery of the predicted inhibitory receptors in the mouse 
(Karlhofer, Ribaudo & Yokoyama, 1992) and in humans (Ciccone et al., 1992) that could 
recognise self MHC-I molecules and inhibit a cytotoxic response.  NK cells are now known 
to function according to complex inhibitory and activatory interactions with a number of 
different ligands and to have an expanded range of functions impacting on many aspects 
of both the innate and acquired immune response  (Lotze & Thompson, 2010).  The 
spatial distribution of NK cells throughout the body gives an indication to their function and 
is discussed in detail below.  
1.1.1. NK cell phenotype and distribution 
NK cells in humans are usually phenotypically described as CD3-CD56+, and represent 5-
15% of all lymphocytes (Timonen, Ortaldo & Herberman, 1981).  Walzer et al. (2007) have 
suggested that, because CD56 is expressed on some T-cells and is not found in other 
mammals, a different marker should be used to identify true NK cells.  NKp46 is proposed 
as an alternative marker for NK cells as it has been found to be present on peripheral 
blood NK cells in all mammals (Walzer et al., 2007).  NKp46 is a natural cytotoxicity 
receptor (NCR) and is largely restricted to NK cells, but has been found at low 
concentrations on some human T-cells and so is not entirely NK cell specific (Caligiuri, 
2008).  Beyond this basic phenotype, NK cells express a variety of other receptors useful 
for their identification, the distribution of which are important in describing their functional 
capacity and maturational states. 
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NK cells are broadly split into two major subsets based on their expression of CD56 and 
the FcγRIIIa receptor CD16, which are CD3-CD56hiCD16- and CD3-CD56loCD16+. For 
consistency the CD56lo nomenclature is used throughout this thesis although other authors 
have used CD56dim or CD56low, additionally CD56hi is used throughout this thesis, but 
others have used CD56bright or CD56high to describe the same populations.  The 
CD56loCD16+ NK cells classically contain high levels of perforin and granzymes and are 
the subset primarily responsible for killing infected and/or transformed target cells 
(Caligiuri, 2008, Walzer et al., 2007).  These cells also predominate in the peripheral blood 
where they make up 85-95% of the total NK cell population.  In contrast the CD56hiCD16- 
subset only represent 5-15% of NK cells in peripheral blood, but represent the majority of 
NK cells in the secondary lyphoid tissue (SLT) (Ferlazzo et al., 2004).  CD56hiCD16- NK 
cells predominantly do not express granzyme or perforin and are therefore not naturally 
cytotoxic, instead these are cells that specialise in cytokine production, particularly IFN-γ , 
and have been described as ‘helper’ NK cells as they have been implicated as important 
for modulating and shaping adaptive immune responses toward a Th1-type response (Poli 
et al., 2009, Hanna & Mandelboim, 2007, Mailliard et al., 2005, Martin-Fontecha et al., 
2004, Mailliard et al., 2003, Cooper et al., 2001, Jacobs et al., 2001).  
1.1.2.  NK cell receptors 
Activation of NK cells is reliant on complex interactions between various families of 
receptors.  Initially the ‘missing self’ hypothesis (Karre et al., 1986) postulated the need for 
only inhibitory receptors, imagining the default NK cell setting to be set to kill. It is now 
known, however, that both inhibitory and activating receptors are necessary for NK cell 
killing and/or cytokine production to take place.  Studies have shown that NK cells do not 
spontaneously kill cells expressing mismatched MHC-I, such as in bone marrow 
transplantation, and that killing requires positive activating signals (Bryceson et al., 2006a, 
Ruggeri et al., 2002).  It is also of note that inhibitory signals dominate over activating 
signals to prevent cytotoxicity even in the presence of ligands for activating NK cell 
receptors, and this is has been shown to be exploited by tumours and viruses such as 
human cytomegalovirus (HCMV) which upregulates non-classical HLA-I molecules 
(Caligiuri, 2008, Bryceson et al., 2006a, Tomasec et al., 2000, Ulbrecht et al., 2000).  NK 
cell receptors associated with activation and inhibition are presented in Table 1.1. 
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Activation of NK cell effector function therefore relies on a balance of inhibitory versus 
activating signals, and the major receptor families are discussed below.  
 
Receptor   Ligand 
 Inhibitory Activating  
KIR2DL1 KIR2DS1 HLA-C2 
KIR2DL2 KIR2DS2 HLA-C1 
KIR2DL3  HLA-C1 
 KIR2DS4 HLA-Cw4 
KIR3DL1 KIR3DS1 HLA-Bw4 
KIR 
KIR3DL2   HLA-A3/-A11 
CD94/NKG2A/B CD94/NKG2C HLA-E Heterodimeric C-
type Lectin 
Receptors  NKG2D MIC-A/-B, ULBP-1/-2/-3 
  NKp30 
HCMV tegument protein 
pp65, HLA-B-associated 
transcript 3 
 NKp46 Influenza Haemaglutinin 
NCR 
 NKp44 Influenza Haemaglutinin 
Ig-like transcript LIR-1 (ILT-2, CD85j)   HLA-class I 
 FCγRIII (CD16) IgG - Fc portion 
 CD2 CD58 (LFA-3) 
 LFA-1 ICAM-1 
 2B4 CD48 
 NKp80 Activation-induced C-type lectin 
Activating Co-
Receptors 
 CD40L CD40 
NB. Activating KIR have the same extracellular domain as Inhibitory KIR, but it has not necessarily 
been demonstrated they have the same Ligand 
Inhibitory receptors 
As mentioned above the major ligands for NK cell inhibitory receptors are MHC class I 
molecules.  These receptors fall into two classes, firstly the immunoglobulin superfamily 
receptors, which include the killer immunoglobulin (Ig)-like receptors (KIR) and the 
leukocyte Ig-like inhibitory receptor 1 (LIR1, also known as ILT2 and CD85j).  The second 
family consists of the C-type lectin receptors and is represented by the heterodimer formed 
between CD94 and NKG2A (Stern-Ginossar & Mandelboim, 2010).   
KIR proteins are expressed on NK cells (Colonna & Samaridis, 1995, Moretta et al., 1995), 
CD8+ and γδ+ T-cells (Ferrini et al., 1994) and can be either inhibitory or activating 
Table 1.1 Natural Killer Cell Inhibitory and Activating Receptors 
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depending on the cytoplasmic tail of individual molecules; inhibitory KIR have an 
immunoreceptor tyrosine based inhibitory motif (ITIM) tail, as do the majority of inhibitory 
receptors expressed by NK cells (Stern-Ginossar & Mandelboim, 2010).  KIR are a major 
receptor family responsible for recognition of the classical MHC-I molecules HLA-A, -B and 
-C.  They are highly polymorphic and have been shown to bind with different allelic 
specificity (Stern-Ginossar & Mandelboim, 2010, Bryceson et al., 2006a, Lanier, 2005, 
Mandelboim et al., 1996). 
LIR1 is expressed on NK cells, T-cells, B-cells, monocytes, macrophages and dendritic 
cells (Colonna et al., 1997) and, similar to KIR, acts as an inhibitory receptor on NK cells 
signalling through an ITIM cytoplasmic tail.  Unlike KIR, LIR1 molecules can bind to 
various class-I MHC molecules as they bind the conserved α3 region, albeit with low 
affinity (Colonna, Nakajima & Cella, 1999).  Many viruses, such as HCMV, downregulate 
MHC-I to avoid detection by T-cells, but in doing so become targets for destruction by NK 
cell mediated lysis.  HCMV encodes for a protein, UL18, which binds LIR1 thus 
transducing the inhibitory signal (Cosman et al., 1997), demonstrating the importance of 
LIR1 and other inhibitory receptors for the control of viruses. 
The C-type lectin heterodimer CD94/NKG2A is the third major inhibitory receptor 
expressed on NK cells and, unlike KIR and LIR1, recognises the non-classical HLA-E 
molecule (Carretero et al., 1998).  HLA-E expresses leader peptides from other MHC 
molecules and, as such, CD94/NKG2A is thought to be responsible for the surveillance of 
general downregulation of MHC-I that might occur in viral infection or tumour-transformed 
tissues (Braud et al., 1998, Lee et al., 1998).  HLA-E is another protein whose expression 
is modified by HCMV, which encodes for the protein UL40 which upregulates the 
expression of HLA-E on infected cells (Tomasec et al., 2000).   
Activating receptors 
As discussed above NK cell effector functions are generally induced when there is a lack 
of inhibition and activating signals present, and are not normally induced purely through 
the lack of inhibition (Caligiuri, 2008, Lanier, 2003).  Activating receptors have cytoplasmic 
tails that associate with a variety of adapter proteins, which contain an immunodominant 
tyrosine-based activation motif (ITAM).  These proteins signal to downstream effectors, 
leading to various mechanisms of NK cell mediated lysis and or cytokine production 
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(Lanier, 2003).  The major activating receptors including the NKG2D receptor, the natural 
cytotoxicity receptors (NCR), CD16 and the activating KIR are discussed below. 
The activating NKG2D receptor is expressed by virtually all NK cells, CD8+ T-cells and γδ+ 
T-cells and, when stimulated, have been shown to induce strong cytolytic responses 
against target cells (Bauer et al., 1999, Wu et al., 1999).  Unlike other NKG2 molecules, 
NKG2D forms a homodimer and does not associate with CD94 or propagate inhibitory 
signals (Wu et al., 1999).  The first ligand described for NKG2D was the stress-induced 
molecule MHC-class-I-polypeptide-related sequence A (MIC-A), which has MHC homology 
(Bauer et al., 1999).  Subsequently MIC-B and the CMV UL16-binding proteins 1-5 
(ULBP1-5) were also described as ligands (2007).  NKG2D ligands have been shown to 
be upregulated in response to stress induced by viral infection, DNA damage and as a 
result of toll like receptor (TLR) agonist engagement (Stern-Ginossar & Mandelboim, 2010, 
Eagle & Trowsdale, 2007, Nedvetzki et al., 2007).  The CMV ULBP proteins hint at a close 
relationship with the virus, which encodes the protein UL16 capable of binding, and 
therefore sequestering, MIC-B and ULBP-1 and -2  (Dunn et al., 2003).  NKG2D function is 
also disrupted by human immunodeficiency virus 1 (HIV-1) infection, as discussed later 
(Section 1.6.4). 
The NCR family of receptors consist of three different proteins; NKp46, NKp44 and 
NKp30, which all belong to the Ig superfamily and are capable of inducing natural 
cytotoxicity (Pegram et al., 2011). NKp46 is ubiquitously expressed on NK cells almost 
exclusively, although some reports suggest a low frequency of NKp46 on CD3+ T-cells 
(Caligiuri, 2008).  NKp46 was identified through cross-linking experiments as an activation 
marker that elicited both cytokine and cytotoxic responses in NK cells (Sivori et al., 1997). 
NKp44 is expressed on activated NK cells and is not known to be expressed by other cell 
types, and has therefore been implicated as an exclusive NK cell activation marker (Vitale 
et al., 1998).  NKp30 is expressed on most NK cells in peripheral blood and tissues 
(Pende et al., 1999) with the exception of expression in the lymph nodes (LN) (Ferlazzo et 
al., 2004) or endometrium (Manaster et al., 2008).  It is also NKp30 that is proposed as the 
receptor responsible for the deletion of immature DC (Ferlazzo et al., 2002), which is 
discussed later (Section 1.3). 
CD16, the FcγRIIIa, is the receptor responsible for mediating antibody dependant cellular 
cytotoxicity (ADCC) (Lanier, Yu & Phillips, 1991, Vivier et al., 1991).  ADCC is mediated by 
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the binding to the constant region (Fc) on IgG molecules and leads to potent cytotoxic 
responses (Caligiuri, 2008, Bryceson et al., 2006a). 
Activating KIR possess different cytoplasmic tails to inhibitory KIR, which interact with 
ITAM containing the adapter molecule DAP12 (Biassoni et al., 1996, Moretta et al., 1995).  
Although little structural difference is observed in the extracellular portion of the activating 
KIR compared to inhibitory molecules, it was found that activating KIR bind their MHC-I 
ligands at a lower affinity than their inhibitory counterparts.  Alternatively, putative non-
MHC ligands expressed by tumours have been postulated as a method of activation 
through the activating KIR2DS4 (Katz et al., 2004). 
1.1.3. NK cell licensing 
As discussed above NK cell activation occurs primarily in the absence of inhibitory signals 
through MHC class I receptors, indicating that inhibitory signalling is dominant.  A 
hyporesponsive NK cell state has been described where NK cells are unable to kill MHC 
class-I-devoid target cells in both mouse models and in individuals with bare lymphocyte 
syndrome (Furukawa et al., 1999, Bix et al., 1991, Hoglund et al., 1991).   
The concept of NK cell licensing or education was therefore devised, whereby NK cells are 
first made tolerant to self MHC class I molecules in order to become functionally 
competent (Elliott & Yokoyama, 2011).  Kim et al. (2005) demonstrated that NK cells from 
mice lacking MHC class I expression did not produce IFN-γ in response to activating 
receptor cross-linking, whereas they did in cells from mice that expressed MHC class I.  A 
similar reliance on MHC class I expression for the generation of functionally competent NK 
cells has since been described in human NK cells and the requirement for KIR in the 
development of mature functional NK cells was also demonstrated (Kim et al., 2008, 
Anfossi et al., 2006).   
NK cell licensing normally occurs under non-inflammatory conditions, however recovery of 
mature hyporesponsive NK cells has been demonstrated in mice and in humans in 
response to cytokine stimulation although responses are general and not directed to 
specific target cells  (Juelke et al., 2009, Kim et al., 2002).  Finally it is noteworthy that a 
similar hyporesponsive or anergic NK cell phenotype is observed in murine studies where 
NKG2D is artificially chronically stimulated (Oppenheim et al., 2005, Wiemann et al., 
2005). 
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1.1.4. NK cell development and maturation 
NK cells originate from bone marrow haematopoietic stem cells (HSC), developing first 
into the common lymphoid progenitor, which gives rise not only to NK cells, but also the T-
cell and B-cell lineages (Kondo, Weissman & Akashi, 1997).  NK cells are traditionally 
considered cells of the innate immune system and posses many qualities and functions to 
place them in this category, although developmentally NK cells undergo processes more 
akin to those seen for adaptive T-cells and B-cells.  NK cell development is generally 
discussed according to sequential changes in the phenotypic makeup of cells and, as 
such, mouse and human NK cells must be described separately as they have different 
phenotypic characteristics, although parallels can be made. 
Kim et al. (2002) demonstrated five distinct populations of murine NK cells representing 
different developmental stages.  First, NK cell precursors that express the IL-2/IL-15Rβ 
chain (CD122) and lack the expression of the murine NK markers Ly49 or NK1.1 become 
CD122+NK1.1+CD94/NKG2A/C/E+.  These express high levels of αv integrin, low levels of 
DX5 (CD49b) and Mac-1 (CD103) integrins and low CD43 expression.  The next stage of 
development sees the expression of the murine NK marker Ly49 and c-Kit (CD117) before 
the expansion stage where αv integrin is downregulated, DX5 upregulated and cells 
undergo rapid proliferation and expansion before becoming mature NK cells.  Murine NK 
cell maturity is associated with a gradual decline in c-Kit expression, the loss of αv integrin 
and the upregulation of Mac-1 and CD43.  CD27 expression has also been shown as an 
important marker on mature murine NK cells, further sub-dividing them into CD27hi or 
CD27lo populations (Hayakawa & Smyth, 2006).  CD27lo NK cells had a higher stimulation 
threshold and were controlled by inhibitory receptors whereas CD27hi NK cells showed 
greater responsiveness to chemokines (Hayakawa & Smyth, 2006).  Interestingly CD27 is 
also found on human NK cells and its expression parallels that of CD56, as such defining 
functional NK cell subsets (Silva et al., 2008). 
Human NK cell development can be divided into similar stages to that of murine NK cells 
following a linear model of development (Freud & Caligiuri 2006), although it is worth 
noting that alternative non-linear models have been proposed (Mailliard et al. 2005) 
(Figure 1.1).  Human NK cells develop from CD34+ progenitor cells present in the bone 
marrow (Freud & Caligiuri, 2006, Freud et al., 2005).  IL-15 is present in the bone marrow 
stroma and has been shown to stimulate the differentiation of CD34+ cells toward the CD3-
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CD56+ NK cell lineage (Mrozek, Anderson & Caligiuri, 1996).  CD34dim cells expressing 
CD45RA and the integrin α4β7 have been isolated from SLT and have been suggested to 
originate in the bone marrow and migrate to LN where they give rise to CD56hi NK cells 
(Freud et al., 2005).  As a result, the LN have been proposed as the major site of 
maturation for NK cells, although specific populations of NK cells possibly mature at 
different sites such as the intestinal epithelia (Lynch et al., 2006), thymus (Vosshenrich et 
al., 2006) and uterine decidua (Ashkar et al., 2003). 
 
CD122-CD34+CD45RA+ pro-NK cells located within SLT are thought to be committed to 
the NK lineage and progress to pre-NK cells defined as 
CD122+CD34+CD45RA+CD117+CD161+/- (Freud & Caligiuri, 2006).  Pre-NK cells then give 
rise to the immature NK cell population defined as CD34-CD117+CD161+, which in turn 
develops into CD56hiCD117+/-CD94+ NK cells, expressing functional markers such as 
NKp30, NKp46, CD94/NKG2A and NKG2D, but lacking CD16 and KIR expression and 
therefore capable of a restricted set of NK cell functions (Grzywacz et al., 2006, Ferlazzo 
et al., 2004).  CD56hi NK cells can transition to CD56loCD117-CD94+/-CD16+ NK cells, and 
Figure 1.1 Linear model of human NK cell development.  In vivo model of NK cell development 
illustrating the different stages proposed by Freud & Caligiuri (2006).  Adapted from Freud & Caligiuri 
2006, and Caligiuri 2008. 
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also gain KIR expression and increased cytotoxic potential through perforin and grazyme 
production (Freud & Caligiuri, 2006, Ferlazzo et al., 2004, Jacobs et al., 2001).   
As mentioned previously, alternative pathways for human NK cell development have been 
proposed, specifically suggesting non-linear progression between CD56hi and CD56lo 
subsets (Mailliard et al., 2005, Loza & Perussia, 2004).  The linear model, however, 
although incomplete, arguably represents the most likely route of NK cell maturation 
considering that: 1) CD34+ cells stimulated in vitro first give rise to CD56hi NK cells (Freud 
et al., 2005); 2) phenotypic progression from CD56hi to CD56lo NK cells with their 
corresponding phenotypes has been directly observed (Chan et al., 2007, Ferlazzo et al., 
2004); and 3) CD56hi NK cells have been shown to have longer telomeres than CD56lo NK 
cells (Ouyang et al., 2007, Romagnani et al., 2007).  Additionally, recent reports have 
demonstrated functional intermediates between CD56hi and CD56lo NK cells based on 
both expression of CD16 on CD56hi NK cells and the declining expression of CD94 by 
CD56lo NK cells (Beziat et al., 2011, Yu et al., 2010). 
1.1.5. c-Kit and SCF biology with respect to NK cells 
The stem cell factor receptor c-Kit or CD117 is a tyrosine kinase receptor that is 
predominantly expressed on progenitor haematopoietic cells in bone marrow, where the 
majority of CD34+ cells express c-Kit (Ashman, 1999).  Whereas many different cell 
lineages have been demonstrated to express c-Kit, CD56hi NK cells are the only mature 
lymphocyte to express this receptor (Ashman, 1999, Matos et al., 1993).  SCF has been 
described for its ability to act on haematopoietic cells to promote cell survival, and to 
stimulate proliferation, differentiation, adhesion and activation. It is found in two forms, 
soluble and membrane associated (Ashman, 1999, Broudy, 1997).  The experiments by 
Matos et al. (1993) demonstrated that co-stimulation of NK cells with SCF enhanced IL-2 
mediated NK cell proliferation such that very low (pM) concentrations of IL-2 were able to 
induce cellular proliferation.  Additionally Carson et al. (1994) demonstrated in vitro that 
ligation of c-Kit with SCF on c-Kit+ NK cells induced the upregulation of the anti-apoptotic 
Bcl-2 protein thereby promoting the survival of these cells.  The authors claim there in vitro 
findings could translate to an in vivo scenario as soluble SCF is detected in human serum 
(Carson et al., 1994, Langley et al., 1993).  The fact that c-Kit is expressed predominantly 
on immature undifferentiated cells (Borge et al., 1997) adds further evidence to the theory 
that CD56hi NK cells are less mature and mature into CD56lo cells.  In further agreement 
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with this finding, it is also known that stimulation of c-Kit+ cells with growth factors and 
cytokines such as TGF-β, granulocyte macrophage-colony stimulating factor (GM-CSF) 
and IFN-γ down regulate c-Kit expression on a range of different cell types (Ashman, 
1999).   
1.1.6. NK cell function 
Natural killer cells were first described for their ability to lyse target cells without prior 
sensitisation, hence their name, and as such their cytotoxic capabilities were the first 
function described (Kiessling, Klein & Wigzell, 1975).  Since the early observations of NK 
cells as killers it has become clear that they are a cell type with multiple effector functions.  
NK cell killing is elicited through a number of different effector mechanisms and not solely 
though the lack of self-MHC class I molecules expression by target cells, as first 
described.  NK cells respond to chemokines and cytokines and themselves also secrete 
cytokines that are important for immunoregulatory activities, shaping adaptive responses 
through reciprocal interactions with DC (Mailliard et al., 2003, Biron, 1999).  One more 
recently described function for NK cells indicates a role in limiting excessive and non-
specific inflammation through killing immature DC (iDC), mediated via the CD94/NKG2A 
Receptor complex (Della Chiesa et al., 2003, Ferlazzo et al., 2003, Ferlazzo, Semino & 
Melioli, 2001). 
As described above NK cells can be split into two broad functional categories based on 
the level of CD56 expression with the CD56hi NK cells thought to mature first before 
maturing themselves to become CD56lo NK cells (Freud & Caligiuri, 2006, Freud et al., 
2005).  Functionally, the CD56hi NK cells appear to be specialist cytokine-producing cells 
with a lower capacity for cytotoxic effector functions than CD56lo cells, although the latter 
are also capable of cytokine production (Ferlazzo et al., 2004, Cooper et al., 2001, Jacobs 
et al., 2001, Fehniger et al., 1999).   
CD56hi NK cells are abundant in SLT, but only represent approximately 10% of the NK 
cells in the peripheral blood, where they express chemokine receptors such as CCR7 and 
adhesion molecules such as CD62L that enable circulating NK cells to efficiently migrate 
and enter SLT in response to chemokines (Fehniger et al., 2003, Campbell et al., 2001).  
NK cytokine production is stimulated by interactions with other cells present in the same 
parafollicular regions of SLT, such as DC, which produce a variety of cytokines shown to 
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stimulate NK cytokine production including IL-12, IL-15, IL18, IL-1 and others (Cooper et 
al., 2001).  CD56hi NK cells lack expression of perforin (Jacobs et al., 2001), CD16 and 
KIR molecules, and it has been demonstrated that cells must be stimulated with IL-2 
before they acquire cytotoxic functions (Fehniger et al., 2003).  CD56hi NK cells also 
express c-Kit, which, when stimulated by its ligand stem cell factor (SCF), enhances IL-2 
mediated NK cell proliferation even at very low IL-2 concentrations (Matos et al., 1993). 
Cytokines produced by NK cells include IFN-γ, TNF-α, TNF-β, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), IL-10 and IL-13 (Poli et al., 2009, Cooper et al., 
2001).  The combination of cytokines stimulating the NK cells influences the exact NK 
cytokines they produce, for example, stimulation with IL-12 combined with IL-18 has been 
shown as the most efficient combination to stimulate IFN-γ production, whereas IL-15 in 
combination with IL-18 was the most efficient combination for GM-CSF production (Cooper 
et al., 2001).  Cytokines produced by NK cells, particularly IFN-γ, function in various ways 
promoting macrophage maturation and IL-12 production, stimulating an increase in MHC 
class-I and class-II expression and thereby enhancing antigen presentation and promoting 
antiviral T-helper cell type 1 responses (Th1) (Schoenborn & Wilson, 2007, Martin-
Fontecha et al., 2004).  IFN-γ has also been implicated in stimulating the production of 
APOBEC enzymes such as APOBEC3G, which has direct anti-viral activity against HIV-1 
(Casartelli et al., 2010, Peng et al., 2006).  CD56hi NK cells have been described as 
‘helper’ cells by some as a way of describing their ability to enhance DC activity and 
promote Th1 polarisation (Mailliard et al., 2005). 
The CD56lo NK cells are the cells primarily responsible for cytolytic activity mediated 
through one of two different mechanisms.  Firstly, these NK cells possess high levels of 
intracellular granzymes and perforin, cytolytic components which directly induce apoptosis 
and cellular lysis through a process of degranulation (Jacobs et al., 2001).  Secondly, 
CD56lo cytotoxic cells respond to stimulation by presenting Fas ligand and TNF-related 
apoptosis inducing ligand (TRAIL), which stimulate apoptotic pathways on target cells.  
TRAIL expression by CD56hi NK cells has been demonstrated in response to IFN-α 
stimulation and during acute hepatitis C infection (Stegmann et al., 2010).  In order for 
cytotoxic responses to occur, signals must be elicited through activating receptors, but 
activation only occurs when inhibitory signals are not present (Caligiuri, 2008, Bryceson et 
al., 2006a, Moretta et al., 2000).  Figure 1.2 presents a generalised diagram of NK cell 
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mediated cytotoxicity in the absence of self-MHC class I molecules (Adapted from Fauci, 
Mavilio & Kottilil, 2005) 
 
 
For degranulation to occur, appropriate activating receptors must be engaged.  With the 
exception of CD16, multiple receptors, such as the NCR, NKG2D, NKG2A must be cross-
linked in order for degranulation to occur in resting NK cells. However, signalling through a 
single activating receptor is enough to trigger degranulation in NK cells that have been 
previously activated, with for example IL-2 (Al-Hubeshy et al., 2011, Bryceson et al., 
2006b).  Following initial engagement of activating receptors, either LFA-1 adhesion to 
ICAM-1 on target cells, or CD16 adhesion to IgG in combination with 2B4 co-receptor 
engagement with its ligand CD48, leads to increased binding affinity and avidity between 
NK cells and their target cell (Moretta et al., 2008, Bryceson et al., 2006b, Bryceson et al., 
2005).  Following adhesion, calcium-dependant cytoskeletal rearrangement occurs. This 
Figure 1.2 NK cell recognition and lysis of target cells.  Generalised diagram of NK cell killing via the 
‘missing self’ mechanism.  In this model NK inhibitory signals received via inhibitory receptors such as KIR 
are dominant and NK cell cytotoxicity will not be triggered.  In order for NK cell mediated cytotoxicity to 
occur a lack of inhibitory signal must be detected, allowing activating signals to predominate, triggering 
release of perforin and granzyme and the destruction of the target cell.  Adapted from Fauci et al. 2005 
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polarises the secretory lysosomes, which contain perforin and granzyme, directing them to 
the site of engagement with the target cell prior to degranulation (Moretta et al., 2008, 
Bryceson et al., 2005).  Perforin acts by creating pores in the plasma membrane of target 
cells, whereas granzyme is internalised by the target cell, where it acts by activating 
caspase enzymes, which in turn activate DNAse enzymes and subsequently triggers 
apoptosis through DNA cleavage (Bryceson et al., 2006a). 
Degranulation is also stimulated in NK cells triggered through CD16 stimulation in 
antibody-dependent cellular cytotoxicity (ADCC) or when the NCR are triggered.  NK cells 
also trigger surface receptors on target cells that are associated with death domains that 
promote apoptosis.  The Fas receptor and the TRAIL receptors are both TNF super family 
receptors which transmit signals through their death domains, activating various caspases 
(cysteine proteases) and leading to the induction of apoptosis (Smyth et al., 2005).  NK 
cells can be induced to express the ligands (FasL or TRAIL) for Fas and TRAIL receptors 
when stimulated with inflammatory cytokines such as IL-2, IL-15 and both type I and II 
interferons (Smyth et al., 2005). 
1.2. Toll-like receptors 
TLR are pattern recognition receptors (PRR), which are germline encoded Type I integral 
membrane glycoproteins, adapted for the innate recognition of pathogen associated 
molecular patterns (PAMP) found in viruses, bacteria, protozoa and funghi (Akira, 2011, 
Kawai & Akira, 2010, Akira, Uematsu & Takeuchi, 2006).  TLR are expressed on a variety 
of cells, including B-cells, certain types of T-cell as well as some epithelial cells such as 
airway and intestinal cells. Arguably, however, TLR expression in DC and macrophages is 
most significant, as these cells are responsible for the generation of and shaping of the 
adaptive immune responses (Akira, Uematsu & Takeuchi, 2006).  Through recognition of 
their ligands, TLR expressing DC and macrophages are responsible for the priming and 
establishment of adaptive immune responses and as such have been proposed as 
vaccine adjuvants (Lahiri, Das & Chakravortty, 2008, Iwasaki & Medzhitov, 2004, Kaisho & 
Akira, 2002). 
1.2.1. TLR ligands and distribution 
There are 9 known human TLR with defined ligands and function that recognise different 
PAMP.  TLR1, 2, 4, 5 and 6 are expressed on, and encounter their ligands at, the cell 
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surface whereas TLR3, 7, 8 and 9 are expressed within acidified endosomes, lysosomes 
and endolysosomes, where they encounter their nucleic acid ligands (Kawai & Akira, 
2010).  Table 1.2 summarises known TLR ligands and their origins and the DC subset that 
given ligands are associated with. 
 
Receptor DC Subset Distribution Ligand(s) Origin of Ligand 
Triacyl lipopeptides Bacteria & Mycobacteria 
TLR1/2 Myeloid 
Soluble factors Neisseria meningitidis 
Lipoprotein/lipopeptides  Various pathogens 
Peptidoglycan/Lipoteichoic acid Gram-positive bacteria 
Lipoarabinomannan  Mycobacteria 
Phenol-soluble modulin  Staphylococcus epidermidis 
Glycoinositolphospholipids  Trypanosoma cruzi 
Glycolipids  Treponema maltophilum 
Porins  Neisseria 
Atypical lipopolysaccharide 
Leptospira 
interrogans/Porphyromonas 
gingivalis 
TLR2 Myeloid 
Zymosan  Fungi 
TLR3 Myeloid Double-Stranded RNA Viruses 
Lipopolysaccharide  Gram-negative bacteria 
TLR4 Myeloid 
Fusion protein  Respiratory syncytial virus 
TLR5 Myeloid Flagellin Bacteria 
Zymosan Fungi 
Diacyl lipopeptides  Mycoplasma TLR6/2 Myeloid 
Lipoteichoic acid  Gram-positive bacteria 
TLR7 Plasmacytoid Single Stranded RNA Viruses 
TLR8 Myeloid Single Stranded RNA Viruses 
TLR9 Plasmacytoid CpG-containing DNA Bacteria and Viruses 
TLR10 - - - 
TLR11 - - Uropathogenic Bacteria 
 
TLR1 and TLR6 form heterodimers with TLR2; the TLR2/TLR1 heterodimer recognises 
triacylated lipopeptides of gram-negative bacteria and the TLR2/TLR6 heterodimer 
recognises diacylated lipopeptides of gram-positive bacteria (Kang et al., 2009, Jin et al., 
2007).  TLR2 has also been implicated in the recognition of other ligands including 
lipopolysaccharides (LPS), lipoteichoic acids (LTA) and various lipoproteins, glycoproteins, 
zymosan and peptidoglycan (Zahringer et al., 2008). TLR4 is the receptor for bacterial 
LPS, but requires other molecules to recognise and respond to LPS.  LPS binding protein 
(LBP) is present in plasma and binds LPS, after which CD14 binds and brings LPS to the 
Table 1.2 TLR, TLR ligands and DC subset distribution. 
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surface receptor molecule MD-2, which subsequently associates with and stimulates TLR4 
(Shimazu et al., 1999).  TLR5 recognises flagellin, a component of the flagellum from 
flagellated bacteria (Hayashi et al., 2001).  TLR5 expression on DC is particularly found at 
potential sites of infection such as in the intestinal epithelium or lung, but is expressed 
basolaterally and therefore only encounters pathogens that have crossed the epithelium 
during infection and so do not encounter commensal gut bacteria (Akira, Uematsu & 
Takeuchi, 2006).   
The nucleic acid-sensing TLR specialise in recognising viral components and not only 
trigger inflammatory cytokines, but also induce anti-viral type I IFNα and β (Akira, 2006).  
Additionally, TLR7 and TLR9 are exclusively expressed on plasmacytoid DC (pDC) which 
produce very high levels of type I IFN (Kawai & Akira, 2010).  TLR3 recognises dsRNA 
genomes of viruses and dsRNA stages of ssRNA virus replication phases, and can also be 
triggered by the synthetic compound polyinosinic-polycytidylic acid Poly(I:C) (Kawai & 
Akira, 2010, Alexopoulou et al., 2001).  TLR7 and TLR8 in humans have very close 
homology and are responsible for the sensing of viral ssRNA (Akira, Uematsu & Takeuchi, 
2006, Heil et al., 2004).  Self ssRNA is generally degraded before it can reach the 
appropriate compartments to generate an autoimmune response (Akira, 2006).  TLR9 is 
responsible for the recognition of unmethylated 2’deoxyribo(cytidine-phosphate-
guanosine) CpG DNA that is characteristic of bacterial DNA and some viral genomes 
(Kawai & Akira, 2010, Akira, 2006, Hemmi et al., 2000). pDC exclusively express TLR7 
and TLR9 whereas other myeloid cells including myeloid DC (mDC) and macrophages 
express a broader range of TLR (Akira, 2011). 
1.2.2. TLR structure and signalling 
TLR recognise PAMP via their extracellular domains, which contain leucine-rich repeats 
(LRR) (Kawai & Akira, 2010, Akira, Uematsu & Takeuchi, 2006).  Engagement of TLR with 
their ligands induces a signalling cascade through their cytoplasmic Toll/IL-1R homology 
(TIR) domain, which engages with TLR-specific TIR domain-containing adapter molecules 
leading, ultimately, to the release of cytokines and the maturation of cells (2011, Akira, 
2006).  The adapter molecules include: myeloid differentiation factor-88 (MyD88), TIR 
domain-containing adapter-inducing interferon-β (TRIF), TIR domain-containing adapter 
protein (TIRAP) and TRIF related adapter molecule (TRAM) (Akira, 2006).  There are two 
broad signalling pathways; the MyD88-dependent pathway leads to the activation of the 
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transcription factor NF-κB and the release of inflammatory cytokines such as IL-1, IL-6, IL-
12 and TNF-α; alternatively, the TRIF-dependent pathway activates IFN Regulatory Factor 
(IRF) family transcription factors and leads to the release of type I IFN molecules (Kawai & 
Akira, 2010, Lahiri, Das & Chakravortty, 2008, Akira, 2006).  The adapter molecules 
utilised vary according to which TLR is engaged, leading to different specific maturation 
profiles and, in turn, affecting which type of adaptive response is primed by TLR activated 
cells.  TLR3 is the only TLR to utilise only the TRIF dependant pathway, eventually 
activating both the NF-κB transcription factor for inflammatory cytokine release and the 
IRF3 transcription factor for type I IFN release (Kawai & Akira, 2010).  TLR4 uses both the 
MyD88 pathway and the TRIF pathway.  First TLR4 transduces conventional MyD88 
signals leading to the release of inflammatory cytokines before the receptor complex is 
internalised into an endosome and TRIF is recruited leading to IRF3 activation and release 
of type I IFN (Kawai & Akira, 2010).  TLR7 and TLR9 expressed on pDC utilise the MyD88 
and not the TRIF pathway, ultimately activating both NF-κB and IRF7, leading to the 
release of inflammatory cytokines and high concentrations of type I IFN (Kawai & Akira, 
2010, Akira, 2006). 
1.2.3. TLR as adjuvant receptors 
TLR agonists posses many of the qualities that are potentially useful for stimulating the 
robust and long term memory responses required for vaccination.  TLR allow the 
recognition of non-self organisms that express highly conserved molecular patterns 
required for survival of the organism.  By recognising these products, TLR-expressing 
cells, especially DC, provide a link to the adaptive immune response so that future 
encounter with a specific pathogen generates a rapid and potent response that prevents 
further infection and pathology.  TLR ligation of mDC predominantly occurs at the epithelial 
surface.  Following TLR engagement, mDC are induced to mature.  They upregulate 
CCR7 and migrate to the LN, MHC class I and II expression are increased, as are co-
receptors such as CD40, CD80, CD86 and CD70, and inflammatory cytokines are 
released.  All this helps DC to engage with T-cells and stimulate adaptive responses 
(Gnjatic, Sawhney & Bhardwaj, 2010, Lahiri, Das & Chakravortty, 2008, Ida et al., 2006).   
pDC are more likely come into contact with their TLR7 and TLR9 agonists in circulating 
blood, following which they also express CCR7 and migrate to the LN, express high levels 
of type I IFN, and release chemokines with the ability to induce NK cell and T-cell 
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migration (Ida et al., 2006, Fonteneau et al., 2004, Megjugorac et al., 2004).  pDC do not 
express co-stimulatory molecules to the same level as mDC, however, and it has been 
suggested that they are able to stimulate mDC through a bystander mechanism in HIV-1 
infection, and that mDC are primarily responsible for antigen presentation (Fonteneau et 
al., 2004).   
TLR agonists represent an attractive proposition for vaccine adjuvants as they mimic 
natural infection and modulate adaptive responses allowing for the manipulation towards 
certain types of immune response.  A number of studies and trials have been undertaken 
using various TLR agonists, (Gnjatic et al. 2010 and Lahiri et al. 2008).  In order for 
vaccines to be successful it has been suggested that they should enhance the expansion 
phase of T-cell proliferation and/or reduce the contraction phase, thereby providing a 
larger memory T-cell pool able to respond rapidly and robustly following infection 
(Pulendran & Ahmed, 2006).  The actions of TLR agonists on DC help to fulfil these aims 
as demonstrated in HIV-1 infection by Wille-Reece et al. (2005b, Wille-Reece et al., 
2005a) who demonstrated the generation of HIV-1 specific CD8+ T-cells was enhanced 
when using a TLR7/8 adjuvant when vaccinating mice and non-human primates. 
The engagement of TLR leads to the release of cytokines at the site of infection or 
vaccination, recruiting other DC to the area before migrating to LN where they will 
encounter antigen-specific T-cells.  By attracting other DC to the site of infection they will 
take up further antigen and also migrate to the LN, increasing the chances of interacting 
with specific T-cells (Pulendran & Ahmed, 2006).  By increasing the expression of MHC 
and therefore presenting more antigen, DC are more likely to interact with specific T-cells 
(Pulendran & Ahmed, 2006).  As DC mature they also form their characteristic dendrites, 
which provide a greater surface area to interact with potential antigen-specific cells.  The 
expression of co-stimulation molecules such as CD80 and CD86 also augments the MHC-
TCR interaction and, through binding of CD28 on T-cells, upregulates the expression of 
the CD40 ligand (CD40L).  Engagement of CD40L to CD40 leads to the release of IL-12 
and IL-18, which reciprocally induce the release of IFN-γ by T-cells, enhancing the 
generation of a Th1-type response (Lanzavecchia & Sallusto, 2001).  The release of type I 
IFN, TNF and IL-6 by pDC has also been implicated in stimulating mDC to increase the 
expression of co-stimulatory molecules (Fonteneau et al., 2004, Le Bon et al., 2003). 
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Through all of these actions TLR agonists enhance DC survival, the production of co-
stimulatory molecules and the release of cytokines, which in turn induces T-cell expansion 
(Pulendran & Ahmed, 2006). There is also some evidence that cytokines produced by DC 
including type I IFN, IL-2, IL-4, IL-7 and IL-15 also enhance T-cell survival and therefore 
possibly reduce the contraction phase of memory T-cell formation (Marrack & Kappler, 
2004). 
1.3. NK cell-DC interactions 
Following infection, DC interact with NK cells, either at the site of inflammation or within 
SLT (Moretta et al., 2008, Degli-Esposti & Smyth, 2005, Walzer et al., 2005, Dalbeth et al., 
2004, Martin-Fontecha et al., 2004, Mailliard et al., 2003).  Activated DC produce NK cell-
stimulating cytokines, and, in a reciprocal loop, are aided in maturation and activation by 
NK-produced cytokines such as IFN-γ, granulocyte/macrophage colony-stimulating factor 
(GM-CSF) and TNF (Wesa & Mailliard, 2010, 2008, Moretta, 2002).  Figure 1.3 illustrates 
basic DC-NK cell interactions leading to reciprocal activation and NK cell-mediated killing 
of immature DC (iDC) (adapted from Degli-Esposti & Smyth, 2005).  The interactions 
between NK cells and DC are complex, and there is evidence that direct cell-cell contact 
and communication through the production of soluble factors is required for reciprocal 
maturation and activation to take place (Wesa & Mailliard, 2010, Nedvetzki et al., 2007, 
Vitale et al., 2004, Gerosa et al., 2002, Fehniger et al., 1999).  DC produce IL-10 and TGF-
β following their activation, providing negative feedback signals to the NK cell population, 
limiting their activation and proliferation (Wesa & Mailliard, 2010, Caligiuri, 2008).  IFN-γ is 
known to direct DC to produce more IL-12 and direct a Th1 type T-cell response and this 
system has therefore been described as a link between the innate and the adaptive 
immune system (Caligiuri, 2008, Mocikat et al., 2003, Gerosa et al., 2002, Moretta, 2002). 
As discussed above, CD56hiCD16- NK cells are present in the SLT and also at low 
concentrations in the peripheral blood (Caligiuri, 2008); it is this NK cell subset that is 
predominantly responsible for cytokine production upon encounter with DC (Dalbeth et al., 
2004, Vitale et al., 2004).  Direct cell contact between NK cell and DC is mediated by a 
number of surface receptors responsible for the activation of NK cells.  NK cell cytotoxic 
activity is induced by activation through NKG2D, NKp46 and NKp30 (Eissmann et al., 
2010, Draghi et al., 2007, Nedvetzki et al., 2007, Jinushi et al., 2003, Ferlazzo et al., 
2002).  DC have been shown to bind IL-15 by the IL-15 receptor-α-chain and trans-present 
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IL-15 to NK cells, inducing proliferation and survival of NK cells (Lucas et al., 2007, 
Ferlazzo et al., 2004).  CD80 and CD48 expression by DC have been shown to stimulate 
NK cell IFN-γ production and proliferation through their respective CD28 and 2B4 ligands 
(Wesa & Mailliard, 2010, Newman & Riley, 2007).  It has also been shown that IL-12 is 
efficiently delivered from DC to NK cells when immune synapses form between the two 
cell types, allowing IL-12 polarisation and release directly to NK cells.  IL-18 has also been 
shown to be secreted at immune synapses (Semino et al., 2005) although IL-12 is the 
most efficient inducer of NK IFN-γ (Nedvetzki et al., 2007, Borg et al., 2004, Ferlazzo et al., 
2004).  
Although IL-12 is the most potent co-stimulator of IFN-γ, IL-18, acts in synergy with a 
number of cytokines, including IL-2, IL-15, IL-10 and type I IFN, to enhance both NK cell 
IFN-γ production and cytotoxicity (Wesa & Mailliard, 2010, Agaugue et al., 2008, Mailliard 
et al., 2005).  Type I IFN acts on NK cells by directly inducing cytotoxic effector functions, 
inducing the upregulation of FASL, perforin and NKG2D, and has been shown to directly 
enhance NK cell degranulation and killing (Benlahrech et al., 2009, Gerosa et al., 2005, 
Jinushi et al., 2003). 
NK cells respond to stimulation, either by induction of cytotoxic responses or through the 
production of pro-inflammatory cytokines, which has led to the description of NK cells as 
‘helper’ cells.  Cytokines produced by NK cells such as IFN-γ, TNF-α, GM-CSF, MIP1-α/β 
and RANTES are involved in the recruitment and activation of DC and the induction of 
maturation (Agaugue et al., 2008, Gerosa et al., 2005, Mailliard et al., 2005, Dalbeth et al., 
2004, Martin-Fontecha et al., 2004).  In the majority of circumstances NK cell release of 
IFN-γ and other cytokines has the effect of enhancing DC IL-12 production, leading to a 
Th1-polarised adaptive T-cell response (Newman & Riley, 2007, Mailliard et al., 2005, 
Martin-Fontecha et al., 2004, Fehniger et al., 2003). 
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DC also produce anti-inflammatory cytokines which limit the activation and therefore 
potential immunopathology of cells such as NK at the site of inflammation.  It has also 
been shown that NK cell killing of iDC acts as a mechanism to limit excessive infiltration of 
DC that either are not maturing or are maturing too slowly to be useful.  This would ensure 
selection of mature DC fully capable of eliciting effective T-cell responses and has been 
termed immune ‘editing’ (Della Chiesa et al., 2006, Moretta et al., 2006, Ferlazzo et al., 
2003).  iDC express low levels of HLA-E and are recognised by NK cells that express the 
CD94/NKG2A receptor, but lack KIR expression preventing NK cell inhibitory signals 
(Moretta et al., 2006, Della Chiesa et al., 2003).  The NCR NKp30 is the activating 
receptor responsible for the induction of NK cell killing of iDC and is mediated through the 
TRAIL killing pathway (Hayakawa et al., 2004, Ferlazzo et al., 2002). 
Figure 1.3 Interactions between NK cells and DC illustrating a) DC-mediated activation of NK cells via 
both contact-dependant signals and soluble signals stimulates NK cells, inducing cytokine production 
and/or cytotoxicity and promoting proliferation and NK cell survival. b) Activated NK cells are then capable 
of inducing DC maturation and activation including the production of IL-12, enhancing the generation of 
antigen-specific immune responses.  c) NK cells can kill iDC that add to inflammation without presenting 
appropriate levels of MHC via the activating NKp30.  Adapted from Degli-Esposti & Smyth 2005. 
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1.4. Antigen-specific T-cell activation 
Unlike NK cell responses, antigen-specific immunity requires prior sensitization.  Adaptive, 
antigen-specific, immune responses once generated provide robust and appropriate 
defence against specific pathogens.  Unlike cells of innate immunity, activated T-cells can 
develop into long-lived memory cells able to proliferate and respond rapidly and 
appropriately, with minimal inflammation upon reencounter with the same pathogen 
(Janeway et al., 2005b).  Educating the immune system to respond in this way to 
pathogens is the goal of most vaccination strategies. 
1.4.1. Antigen recognition 
Antigen recognition is mediated through recognition of peptide sequences complexed to 
MHC class I or class II molecules presented to the T-cell receptor (TCR) expressed by T-
cells.  Any one individual expresses a huge array of TCR such that a single individual is 
capable of potentially recognising a huge number of MHC-presented foreign antigens. 
Encounter of a TCR with its specific antigen leads to the activation and proliferation of that 
antigen-specific T-cell in a process termed clonal expansion, generating many thousands 
of armed effector cells, all bearing that one TCR and capable of clearing the infection. 
MHC class I and class II are recognised by CD8+ T-cell and CD4+ T-cells respectively and 
this has consequences for the type of immune response generated.  CD8 and CD4 are 
themselves co-receptors for MHC class I and class II respectively, and are useful 
immunological markers for defining these two different T-cell subsets.  Another important 
aspect of TCR engagement with MHC:peptide complexes is that TCR bind directly to the 
MHC molecule as well as recognising the specific peptide sequence.  As there are an 
enormous array of different MHC class I and class II, and each unique TCR recognises 
only one, the TCR is said to be MHC restricted i.e. it recognises a specific MHC molecule 
in combination with a specific peptide.   
MHC class II is expressed on specialist immune cells that are considered to be 
professional antigen presenting cells (APC); these are macrophages, DC and B-cells.  
APC actively take up antigen either by receptor-mediated endocytosis, the principal uptake 
method for B-cells, or through the sampling of the extracellular environment by 
phagocytosis (macrophages) or macropinocytosis (DC) (Janeway et al., 2005a).  Both the 
type of cell presenting the antigen and the soluble factors present are important for 
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determining the type of CD4 mediated T-helper cell generated.  Generally B-cells and IL-4 
stimulate a Th2, humoral-type response whereas DC and IFN-γ stimulate a Th1, cellular 
response.  MHC class II normally presents peptides of 13-17 amino acids in length to 
CD4+ T-cells. 
Unlike MHC class II, class I molecules are ubiquitously expressed and, as has been 
discussed, the lack of MHC class I expression is recognised by NK cells and can lead to 
NK cell-mediated killing.  MHC class I is responsible for presenting antigens for 
intracellular pathogens, including viruses and intracellular bacteria which are capable of 
infecting most cell types, and therefore all cells express MHC class I.  The majority of cells, 
however, do not express the necessary co-stimulatory factors needed to activate naïve 
CD8+ T-cells; for this, APC, mainly DC, are required (Janeway et al., 2005a).  Memory 
CD8+ T-cell activation however requires less co-stimulation and can be activated by cells 
expressing antigen from intracellular pathogens.  MHC class I presents peptide sequences 
of 8-10 amino acids in length at the cell surface. 
1.4.2. Antigen processing and presentation 
The origins of peptide antigens displayed by MHC class I and class II are different.  As 
discussed, MHC class I presents antigens from intracellular pathogens and MHC class II 
presents antigens derived from the extracellular environment. MHC molecules posses 
binding grooves in which they bind peptides with certain anchor residues at specific points 
in the peptide sequence.  Different MHC molecules have different peptide binding grooves 
that bind different amino acid side chain residues at different positions on the peptide 
sequence. There is, therefore, specificity, as certain peptides bind to certain MHC 
molecules. 
Antigens presented on MHC class I are degraded in the cytosol and actively transported 
into the endoplasmic reticulum (ER) by the TAP 1/2 heterodimer and loaded onto waiting 
MHC class I molecules.  Proteins are constantly degraded in the cytosol through the 
ubiquitin-dependant pathway by the proteosome, which not only acts to recycle misfolded 
and non-functional proteins, but also allows the production of suitable length (8-16 amino 
acids) peptides that can be loaded onto MHC class I molecules (Janeway et al., 2005a).  
Stimulation by IFN-γ, such as that produced by NK cells, has been shown to upregulate 
proteosome activity and also the synthesis of MHC class I molecules (Rosa & Fellous, 
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1988).  Peptides with amino acid sequences longer than 8-10 are able to bind to MHC 
class I, but are cleaved by aminopeptidase enzymes before they can be transported to the 
cell surface.  Only stable MHC:peptide complexes are released from the ER and 
transported to the cell surface. 
Extracellular antigens endocytosed by the specialist APC are kept within acidified 
membrane bound endosomes; these fuse with lysosomes containing cathepsins, cysteine 
proteases, which are activated at low pH.  Pathogenic material is then degraded in the 
endolysosomes, providing the source of antigenic peptides for MHC class II molecules.  
MHC class II molecules are, similarly to class I molecules, assembled and trafficked 
through the ER, but in order to prevent them binding peptides here they are complexed 
with an invariant chain (Ii) protein, which occupies the binding groove.  The MHC:Ii 
complex is then loaded onto vesicles capable of transporting the complexes to 
endolysosomes, fusion with which removes the majority of the Ii protein, leaving behind a 
class II-associated invariant chain peptide (CLIP), which occupies the binding groove.  The 
MHC-II-like molecule HLA-DM mediates CLIP removal, which catalyses its removal from 
the binding groove whilst loading peptide sequences.  HLA-DM also removes peptide that 
is too weakly bound to MHC class II, as only stable MHC:peptide complexes can be 
expressed on the cell surface (Janeway et al., 2005a). 
1.4.3. T-cell activation 
DC are considered the most potent of APC and, upon activation by encounter with 
pathogen, they migrate to local LN and present antigen to naïve T-cells, which are 
continuously circulating between the blood and lymph system (Janeway et al., 2005b).  As 
discussed earlier, activation of DC leads to a process of maturation that sees the 
upregulation of MHC molecules and the co-stimulatory molecules necessary to engage 
with and activate naïve T-cells.  Activated naïve T-cells in LN undergo a process of clonal 
expansion, which lasts for several days and generates a large population of antigen-
specific T-cells (Janeway et al., 2005b).  Toward the end of the clonal expansion process, 
T-cells develop into effector cells and it is these cells that are released from the LN and 
migrate to the site of infection or inflammation and efficiently combat and clear infections 
(Janeway et al., 2005a).   
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Interaction between T-cells and DC occurs in the T-cell region of the LN and is initially 
mediated by integrins such as lymphocyte function-associated antigen-1 (LFA-1) on DC 
with intercellular adhesion molecules-1 and -2 (ICAM-1 and -2) on T-cells.  Without 
engagement of the TCR with its specific peptide:MHC complex, this initial interaction is 
transient and the bonds are quickly broken as the T-cell continues through the LN, 
interacting with other APC as it does so.  When a TCR does bind its specific ligand there is 
a conformational change in the LFA-1 molecule such that binding affinity to ICAM-1 and -2 
is increased maintaining cell contact.  Interaction of the co-stimulatory CD80 and CD86 
molecules on DC with CD28 on T-cells is necessary for naïve T-cell activation.  The CD40 
ligand (CD40L) is upregulated on activated T-cells and interacts with CD40 on DC, eliciting 
the expansion of T-cells and the eventual differentiation into effector T-cells.  Activated T-
cells upregulate the expression of the IL-2Rα chain (CD25) and produce IL-2, which acts 
in an autocrine fashion inducing rapid proliferation (Janeway et al., 2005b).  
1.4.4. T-cell differentiation 
Following primary infection, the multitude of antigen-specific effector cells mostly die, but 
some cells remain as memory cells.  Memory T-cells do not require co-stimulation for 
activation and respond rapidly, proliferating to high numbers at a much faster rate.  
Additionally memory T-cells are divided into different groups, some of which, termed the 
effector memory (TEM) cells, are primed to carry out effector functions immediately, but do 
not proliferate when activated (Wherry et al., 2003, Champagne et al., 2001).  Central 
memory T-cells (TCM) cells express LN homing markers such as CCR7 and CD62L and 
are the cells which undergo rapid proliferation and differentiate into effector cells before 
migrating to the site of infection (Wherry et al., 2003, Champagne et al., 2001).  
1.5. Human immunodeficiency virus  
The continued spread of HIV-1 and acquired immune deficiency syndrome (AIDS) remains 
a problem of global importance, with approximately 34 million people living with HIV/AIDS 
at the end of 2010, and estimates of 2.7 million people newly infected with HIV-1 and 1.8 
million AIDS-related deaths during 2010 (UNAIDS, 2011).  There is considerable effort 
being made in the distribution of antiretroviral drugs to low and middle income countries, 
with around 3 million people receiving therapy in these countries at the end of 2007 
(UNAIDS, 2008) and an estimated 6.6 million people receiving therapy at the end of 2010 
(UNAIDS, 2011).  Current drugs are, however, expensive and their availability limited, and 
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much work has been undertaken in the search for a vaccine for HIV-1 (McMichael, 2006).  
There is also a need for improved treatment for those already infected with HIV-1 that 
would serve not only to suppress virus activity, as current anti-retroviral drugs do, but also 
to restore hosts’ own immune capabilities.  Immune-based therapies could enable the host 
immune system to limit opportunistic infections better, and could be used in conjunction 
with anti-retroviral therapy as further defense against HIV-1 infection.  Despite these 
successes much more work is still needed, if we are to fully understand, control and 
prevent HIV infections. Work is being undertaken with people who are described as either 
‘slow progressors’, ‘elite controllers’ or ‘long-term non-progressors’ (LTNP) who control 
viral loads for many years without the need for therapy and without progressing, or 
progressing exceptionally slowly to AIDS (Theze et al., 2011, Pantaleo & Fauci, 1996).  
The ability to induce this kind of state in normal progressors is one aim for immunotherapy, 
as the disease would be well tolerated and, because of sustained low viral loads, the risk 
of transmission would be greatly reduced (Autran et al., 2011). 
1.5.1. Basic HIV lifecycle and generalised course of infection 
The HIV-1 retrovirus is a lentivirus with a ssRNA genome which encodes nine genes that, 
through the generation of polyproteins, produce 15 separate proteins  (Frankel & Young, 
1998).  There are three distinct genetic groups of HIV-1; M, O and N (‘main’, ‘outlier’ and 
‘non-main, non-outlier’).  The M group is further subdivided into 11 clades A-K, which are 
observed to form geographical clusters, for example clade B virus predominates in 
Europe, Australia and North America and clade C is the most common virus found in sub-
Saharan Africa, India and Ethiopia (McMichael, 2006).  Different clades, however, have 
the ability to recombine in individuals infected with multiple clades of virus (McMichael, 
2006).  
Figure 1.4 illustrates the basic lifecycle of HIV infection and indicates the targets of action 
of various available anti-retroviral drugs (Modified from NIAD, 2012).  HIV-1, the principal 
causative agent of AIDS, binds to and infects cells that express CD4 and either of the 
chemokine receptors CXCR4 or CCR5 (Levy, 2009, Simon, Ho & Abdool Karim, 2006, 
Gallo et al., 1984, Montagnier et al., 1984, Barre-Sinoussi et al., 1983).  The HIV-1 
glycoprotein gp120, expressed on the exterior of the virion, attaches to CD4 and then to 
CXCR4 or CCR5 before fusion takes place and the virus is released into the cell (Simon, 
Ho & Abdool Karim, 2006).  Once the virus emerges in the cytoplasm the viral core 
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disassembles and the virus’s own reverse transcriptase molecules transcribe the viral RNA 
genome to DNA before another viral protein, integrase, inserts viral DNA in host 
chromosomal DNA, irreversibly transforming the cell (Simon, Ho & Abdool Karim, 2006).  
Once integrated, HIV can produce the proteins necessary for production of new infectious 
virions, which, together with the ssRNA genome, are able to exit the cell by exploiting the 
host cell’s own vesicular sorting pathway to bud from the cell surface (Simon, Ho & Abdool 
Karim, 2006).   
 46 
 
 
Following initial infection, virus replicates rapidly and disseminates to become a systemic 
infection detectable in several compartments throughout the body (Levy, 2009).  Cells of 
the innate immune system detect HIV-1 infection, and there is a corresponding rapid and 
large inflammatory cytokine response as viral load continues to increase (Stacey et al., 
2009).  Following this initial response, other cells of the innate system, particularly NK 
Figure 1.4 Basic HIV lifecycle from online resources available online for the National Institute of 
Allergy and Infectious Disease, modified to include sites of anti-retroviral drug action (summarised 
in Table 1.3). (NIAID, 2012). 
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cells, are recruited before some viral control is initiated and viral load begins to fall (Alter & 
Altfeld, 2009).  The induction of acquired immune responses are detected later, after about 
two weeks, and the viral load then drops to what is described as the viral set point where 
CD8+ T-cells are thought to be the predominant cells controlling viral replication; this marks 
onset of the chronic phase of infection (Levy, 2009, Borrow et al., 1994).  The chronic 
phase typically lasts for around 10 years when untreated, during which time there is a 
constant slow decrease in CD4+ T-cell numbers (Levy, 2009).  Once the peripheral blood 
CD4+ T-cell count drops below around 200 cells µl-1 there is significant loss of immune 
activity and patients become susceptible to opportunistic infections, which are 
characteristic of the onset of AIDS (Weiss, 2008). 
1.5.2. HIV-1 treatment 
Treatment for HIV infection is typically referred to as highly active anti-retroviral therapy 
(HAART).  Current HAART drugs target different aspects of the HIV lifecycle.  In the UK 
the British HIV Association (BHIVA) sets out guidelines for treatment of patients infected 
with HIV and up-to-date versions of these guidelines can be accessed at 
http://www.bhiva.org/ClinicalGuidelines.aspx (BHIVA, 2012).  Currently therapy is 
generally initiated based on the absolute numbers of CD4+ T-cells detected in peripheral 
blood and is begun when numbers drop below 350 cells µl-1, but may be initiated at other 
times if, for example, a high viral load is detected or if other opportunistic infections 
indicative of an immunocomprimised host are experienced.  HAART has two main 
outcomes, the gradual recovery of CD4+ T-cell numbers and the eradication of detectable 
virus (usual detection limit is 50 copies of viral genome per ml peripheral blood (BHIVA, 
2012)) (Jayasuriya, Robertson & Allan, 2007).  The outcome of these effects act to reduce 
pathogenesis and improve resistance to opportunistic infection.  Full immune 
reconstitution is not, however, seen, especially within the gut-associated lymphoid tissue 
(GALT) of the gastrointestinal (GI) tract, where a rapid and irreversible loss of immune 
cells, particularly CD4+ T-cells, is observed.  The consequences of this on chronic immune 
stimulation will be discussed later (Section 1.6.4) (Brenchley et al., 2004, Mehandru et al., 
2004).  Complete viral clearance is also not achieved and HIV-1 particles continue to 
replicate at low numbers within a viral reservoir made up predominantly of quiescent CD4+ 
T-cells (Finzi et al., 1999, Wang et al., 1999, Chun et al., 1997).  A list of currently 
approved HIV-1 medicines is listed in Table 1.3. 
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Cells of the innate immune system, such as DC and NK cells, are reduced in number and 
function during HIV-1 infection but show recovery in numbers and function following 
HAART.  Early treatment has been shown to more fully restore these cells (Azzoni et al., 
2007, Chehimi et al., 2007, Guadalupe et al., 2003).  Initiation of HAART earlier and at 
higher CD4+ T-cell numbers has thus been shown to lead to faster, more complete 
recovery of immune function, but there are problems with drug toxicity and, perhaps more 
seriously, the generation of drug-resistant virus which may be exacerbated by poor 
treatment adherence. 
 
Class Trade Name Generic name 
Combivir lamivudine and zidovudine 
Emtriva emtricitabine, FTC 
Epivir lamivudine, 3TC 
Epzicom abacavir and lamivudine 
Retrovir zidovudine, azidothymidine, AZT, ZDV 
Trizivir abacavir, zidovudine, and lamivudine 
Truvada 
tenofovir disoproxil fumarate and 
emtricitabine 
Videx EC enteric coated didanosine, ddI EC 
Videx didanosine, dideoxyinosine, ddI 
Viread tenofovir disoproxil fumarate, TDF 
Zerit stavudine, d4T 
Nucleoside Reverse 
Transcriptase Inhibitor 
Ziagen abacavir sulfate, ABC 
Edurant rilpivirine 
Intelence etravirine 
Rescriptor delavirdine, DLV 
Sustiva efavirenz, EFV 
Non-Nucleoside Reverse 
Transcriptase Inhibitor 
Viramune  nevirapine, NVP 
Agenerase amprenavir, APV 
Aptivus tipranavir, TPV 
Crixivan indinavir, IDV, 
Invirase saquinavir mesylate, SQV 
Kaletra lopinavir and ritonavir, LPV/RTV 
Lexiva Fosamprenavir Calcium, FOS-APV 
Norvir ritonavir, RTV 
Prezista darunavir 
Reyataz atazanavir sulfate, ATV 
Protease Inhibitor 
Viracept nelfinavir mesylate, NFV 
Fusion Inhibitor Fuzeon enfuvirtide, T-20 
Entry Inhibitor - CCR5 
Antagonist Selzentry maraviroc 
HIV Integrase Strand 
Transfer Inhibitor Isentress raltegravir 
Table 1.3 Current licensed anti-retroviral drugs for HIV-1 treatment approved by the US Food and 
Drug Administration (FDA), accessible at: 
http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm118915.htm 
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Current standards for HIV therapy in the West utilise multiple drugs, usually a combination 
of three (triple therapy), to avoid generation of resistant viral strains.  Standard regimes will 
use two different nucleoside reverse transcriptase inhibitors (NRTI) and a single non-
nucleoside reverse transcriptase inhibitor (NNRTI).  Other drugs are available, including 
protease inhibitors and nucleoside analogues and other drugs such as viral entry inhibitors 
are being developed to target other stages of the viral life-cycle (BHIVA, 2012). 
1.5.3. Requirement for prophylactic vaccination and immunotherapies  
The limitations of HAART to completely clear viral infection and the risk of developing 
drug-resistant strains of virus means there is still a need for both a prophylactic vaccine 
and effective immunotherapies that have the ability to restore immunocompetence and 
prevent the spread of infection by controlling viral load without being toxic or promoting 
viral resistance.  There is a known mutation of the CCR5 gene, a 32 base-pair deletion, 
which prevents CCR5 tropic virus (the most commonly transmitted form of virus) from 
entering CD4+ cells in individuals homozygous for the mutation. Furthermore, if infection is 
established in individuals heterozygous for the mutation, they are more likely to be slow 
progressors (Dean et al., 1996).  Although individuals with the CCR5 mutation are 
relatively rare, they demonstrate that blocking viral entry is an effective barrier to infection.  
It has been suggested that in order for a vaccine or immunotherapy to establish a high 
frequency of antigen-specific T-cells, such that would be required for prevention or control 
of infection, optimal antigenic priming conditions will have to be met (McMichael, 2006).  
Vaccination requires the recognition of particular epitopes by cells of the acquired immune 
system in order to generate a high frequency of antigen-specific T-cells (McMichael, 2006, 
Kaisho & Akira, 2002).  To achieve optimal conditions for antigenic priming, adjuvants 
should be selected that activate innate immune functions capable of modulating the 
magnitude and quality of adaptive immune response generated (Kaisho & Akira, 2002).  
TLR agonists have been proposed as possessing the qualities desirable for adjuvanticity, 
and their use as adjuvants in vaccination strategies has previously been proposed and is 
summarised by Kaisho and Akira (2002) and Lahiri et al. (2008). 
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1.6. Immune responses and HIV-1 infection  
HIV-1 infects CD4+ T-cells (and other immune cells expressing CD4 and CCR5 or CXCR4) 
and this presents the obvious problem of eliciting an immune response to these cells, 
ultimately removing not only cells responsible for controlling HIV infection, but also other 
infections (Levy, 2009, Pantaleo & Fauci, 1996).  Additionally there is direct pathology 
associated with acute viral infection, as demonstrated by high cytokine responses and 
damage to intestinal epithelium (Stacey et al., 2009, Mela et al., 2007, Mehandru et al., 
2004).  The eventual outcome of HIV-1 infection is AIDS, which makes patients 
susceptible to opportunistic infections that would not normally be able to establish in an 
immunocompetent host (Pantaleo & Fauci, 1996).  There is evidence that both innate and 
adaptive immune responses can provide responses beneficial to infected individuals in 
controlling HIV-1, and there is also evidence of resistance to infection, as seen, for 
example, in discordant couples (Ghadially et al., 2011, Lederman et al., 2010, Ballan et al., 
2007, Montoya et al., 2006, Scott-Algara et al., 2003).  The known factors driving 
protection and resistance are largely genetic and are discussed in the following sections. 
1.6.1. Acute HIV-1 infection  
Early events during HIV-1 infection are represented in a generalised model where an initial 
peak in viraemia is associated with a rapid decline in CD4+ T-cells, particularly in the gut 
associated lymphoid tissue (GALT).  An initial innate immune response precedes the 
development of an antigen-specific acquired CD8+ T-cell responses, leading to a rapid 
decrease in viral load and a partial recovery in CD4+ T-cell numbers (Centlivre et al., 2007, 
Pantaleo & Fauci, 1996).  A recent study by Stacey et al. (2009) measured the levels of 30 
different innate cytokines at multiple time points during the acute/early phase of HIV-1 
infection. Innate cytokines were found to be produced in a particular sequence, thus 
providing insight to the likely cell populations that are responding to HIV-1 at a given time 
point following initial infection.  IFN-α, IL-15 and TNF-α are present in the initial wave of 
cytokine production, first detected at day six, followed by IL-6, IL-8, IL-10, IL-18 and IFN-γ 
in a second wave detected between days seven to 8.5.  A third wave of cytokine 
production involving IL-4, IL-12(p70) and IL-22 occurs between days 9.5 and 12.5 (Stacey 
et al., 2009).  The high peak in IFN-α indicates that pDC initially detect HIV-1 following 
uptake of virus particles and/or ligation of TLR7 (Baenziger et al., 2009, Chang & Altfeld, 
2009, Alter et al., 2007a, Fonteneau et al., 2004).  Fonteneau et al. (2004) showed, in 
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vitro, that CD11c+ DC (mDC) were not directly activated by HIV-1 infection and that they 
are activated in a bystander fashion by TNF-α and IFN-α produced by HIV-1 activated 
pDC.  The results from this study are in agreement with the Stacey study (Stacey et al., 
2009) where IL-12 production was first detected 12.5 days after infection and 6.5 days 
after IFN-α and TNF-α are detected.   
The rapid, high and early production of IFN-α and the delayed IL-12 production would 
have consequences as to the type of adaptive response generated, as IL-12 promotes a 
CD4+ Th1-type response  (Hsieh et al., 1993).  IL-12 also promotes IFN-γ release by NK 
‘helper’ cells, which is important for DC activation and maturation, and therefore for the 
priming of acquired immune responses, particularly Th1 polarised responses (Caligiuri, 
2008, Trinchieri, 1995).  The relatively late peak in the immunoregulatory cytokines IL-10 
and IL-4 may act to slow the development of acquired immune responses by respectively 
inhibiting Th1-type responses or by enhancing unsuitable Th2-type responses, as 
suggested by the authors (Stacey et al., 2009). 
1.6.2. Adaptive immune responses to HIV-1 infection  
Following acute infection resulting in the rapid loss of CD4+ T-cells and high viraemia, an 
adaptive immune response is mounted, mediated predominantly by CD8+ cytotoxic T-
lymphocytes (CTL) (Streeck & Nixon, 2010, Borrow et al., 1994).  This antigen-specific 
response reduces the viral load and allows CD4+ T-cell recovery, although complete 
eradication of virus has not been demonstrated (Yang et al., 1997, Walker et al., 1987).  
Viral set point is reached after the initial CTL response and is correlated with disease 
progression; a low viral set point, demonstrating good control of virus, correlates with slow 
progression to AIDS (Levy, 2009, Streeck et al., 2009).  Early and irreversible damage to 
the gut mucosa is observed and there is a particularly severe loss of CD4+ T-cells from this 
compartment (Brenchley et al., 2004).  The loss of integrity that follows damage to the gut 
mucosal surface has been implicated in chronic non-specific immune activation (Brenchley 
et al., 2006). 
Shortly after adaptive immune responses are mounted, viral escape mutants appear 
(Borrow et al., 1997), to which cross-reactive or new responses are not generated (Streeck 
et al., 2009), and future antigen-specific responses are impaired.  It has, however, been 
demonstrated in so called ‘HIV-1 controllers’ (HIC), who control viral replication efficiently 
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below levels detectable by routine viral load measurement (50 copies ml-1 blood), that 
CD8+ T-cell continue to mount effective responses against virus, maintaining all aspects of 
functionality despite very low, undetectable, viral loads (Saez-Cirion et al., 2007a, 
Migueles et al., 2002). 
Although it has been demonstrated that HIV-1 preferentially infects HIV-1-specific CD4+ T-
cells (Brenchley et al., 2004, Douek et al., 2002), there is evidence from cohorts of 
patients who control viral replication that HIV-1-specific CD4+ T-cells are maintained and 
fully functional, although it is unclear if this is a cause or effect of viral control (Rosenberg 
et al., 1997).  Further work demonstrated that central memory CD4+ T-cells, the main viral 
reservoir, and effector memory cells are functionally preserved in a different cohort of 
individuals with proven long-term viral suppression (Potter et al., 2007).  Further evidence 
that CD4+ T-cell responses are important in control of HIV-1 infection are demonstrated 
through the requirement for CD4+ T-cell production of IL-2 for CD8+ T-cell maintenance, 
CTL function and proliferative responses (Lichterfeld et al., 2004).  CD4+ antigen-specific 
T-cells have also been shown to be polyfunctional in asymptomatic HIV-2 infection (Duvall 
et al., 2006) demonstrating production of both IL-2 and IFN-γ. 
In addition to the loss of overall numbers of CD4+ T-cells, early functional defects have 
also been observed that occur prior to the loss of CD4+ T-cells in peripheral blood 
(Miedema et al., 1988).  It has been shown that HIV-1-specific memory CD4+ T-cells have 
defective proliferative responses to antigen stimulation (Clerici et al., 1991).  The 
impairment of function of T-helper cells, particularly dysfunctional production of cytokines 
such as IL-2, has severe knock on effects, particularly toward CTL responsible for 
eliminating virus-infected cells (Lichterfeld et al., 2004).  
Early adaptive immune responses against HIV-1 infection mounted predominantly by 
effector CD8+ T-cells are able to drastically reduce viraemia, but escape mutants are 
rapidly generated and loss of control ensues (Borrow et al., 1997, Borrow et al., 1994).  
There are, however, genetic determinants that are associated with enhanced CTL function 
and maintenance of responsiveness against virus, with cross reactivity demonstrated 
against escape mutants continuing into chronic infection (Saez-Cirion et al., 2007b).  
Individuals who express the HLA-B alleles HLA-B27 and HLA-B57 commonly show 
sustained viral control and these alleles are frequently present in individuals who are either 
LTNP or efficient viral controllers (Flores-Villanueva et al., 2001, Migueles et al., 2000).  
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The exact mechanism underpinning protection is unknown, but it has been speculated that 
these MHC molecules might present antigens in such a way that enhances TCR 
engagement, or that the MHC molecule itself demonstrates differential binding avidity to 
TCR such that more appropriate T-cell responses are generated (Saez-Cirion et al., 
2007b).  The HLA-B27 and –B57 molecules are involved in the presentation of HIV-1 gag 
protein epitopes, which are particularly important for immune recognition and CTL activity, 
and it has been demonstrated that responses to gag peptides generate the most active 
anti-HIV-1 responses that are most capable of lowering plasma viral load (Saez-Cirion et 
al., 2009, Kiepiela et al., 2007, Edwards et al., 2002).  
HIV-1, through a number of mechanisms, modulates or downregulates CD8+ T-cell activity 
to prevent elimination.  The HIV-1 derived protein nef downregulates surface MHC class I 
expression, particularly classical HLA-A and HLA-B molecules, by disrupting the trafficking 
of molecules to the cell surface, preventing epitope presentation to CD8+ T-cells and 
therefore preventing CTL-mediated killing of infected cells (Kasper & Collins, 2003, 
Williams et al., 2002, Cohen et al., 1999, Schwartz et al., 1996).  Chronic HIV-1 infection 
upregulates the expression of inhibitory KIR on CD8+ T-cells, which are normally 
expressed at low levels on CD8+ T-cells and are more usually associated with NK cells 
and CD8+ T-cells in elderly individuals (Alter et al., 2008).  KIR+CD8+ T-cells in HIV-1 
infected individuals were found to be severely functionally impaired following antigen-
specific stimulation with pools of HIV-1 peptides, demonstrating defects in cytokine 
production, degranulation responses and proliferation (Alter et al., 2008).  Interestingly 
though, KIR+CD8+ T-cells from HIV-1 seropositive individuals were shown to be sensitive 
to non-antigenic stimulation and defects were not KIR-specific, but instead represented a 
broader dysfunction in TCR mediated activation (Alter et al., 2008).   
HIV-1-specific CD8+ T-cells demonstrate skewed maturation with an accumulation of cells 
in the TEM subset that are non-terminally differentiated and this has been associated with 
HIV-1-specific CD8+ T-cell dysfunction seen in chronic HIV-1 infection (Champagne et al., 
2001).  Chronic antigen-specific stimulation, ‘antigenemia’, ultimately leads to the 
generation of exhausted CD8+ T-cells, which in some chronic infections can lead to the 
deletion of exhausted cells (Wherry, 2011, Wherry et al., 2003).  T-cell exhaustion occurs 
during chronic infections and is associated with a loss of effector functions including 
defects in cytokine production, proliferative responses and cytotoxic functions (Wherry, 
2011).  Combined with the loss of effector function, there is an increase in the expression 
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of inhibitory receptors, particularly PD-1 or KIR, and a loss of some activating receptors 
such as NKG2D, further disrupting normal T-cell function (Blackburn et al., 2009, Alter et 
al., 2008).  Blockade of the PD-1 pathway enhanced T-cell responsiveness in chronic 
simian immunodeficiency virus (SIV) infection (Velu et al., 2009) and similar findings for 
other receptors are discussed in a review by Wherry (2011).   
Experimental addition of IL-2 has been shown to restore T-cell proliferation and function 
(Blattman et al., 2003).  Clinical trials using IL-2, however, in chronic HIV-1 infection in 
combination with HAART increased overall cell numbers, but they did not improve the 
function of HIV-1-specific T-cells or reduce viral load any faster than HAART alone 
(Michaelsson et al., 2008).  Furthermore, administering IL-2 has also been associated with 
the generation of regulatory T-cells (TReg), which inhibit anti-HIV activity (Velilla et al., 
2008, Shah et al., 2006).  Maintenance of IL-21 production during chronic HIV-1 infection 
by CD4+ T-cells maintains CD8+ T-cells and prevents them becoming exhausted and is 
associated with better viral control (Chevalier et al., 2011); CD8+ T-cells in a cohort of elite 
controllers have also been demonstrated to produce IL-21 (Williams et al., 2002).  
Expanded populations of FoxP3+CD25+ TReg cells are associated with HIV-1 progression 
(Andersson et al., 2005).  TReg cells produce the immunosuppressive cytokines TGF-β and 
IL-10 and function by suppressing immune activity, reducing inflammation and antigen-
specific immune responses (Elsaesser, Sauer & Brooks, 2009, Brooks et al., 2006). 
Finally, the minor γδ+ T-cell subset expressing the γδ-TCR may have a minor role in HIV-1 
pathogenesis (Boullier et al., 1997). The γδ-T-cells are an important subset of T-cells with 
innate cell-like properties and the γδ-TCR cannot match the αβ-TCR of CD4+ or CD8+ T-
cells in terms of antigen-specific responses (Casetti et al., 2009).  Instead of peptide-
specific recognition the γδ-TCR recognises unprocessed phosphoantigens not associated 
with MHC-molecules and can respond potently, displaying strong proliferative responses 
and cytotoxic as well as cytokine-producing properties (Poccia et al., 1999, Haas, Pereira 
& Tonegawa, 1993).  Upon activation γδ-T-cells also stimulate and boost CD8+ T-cell 
responses, and this property has led to the idea that γδ-T-cells are a useful target for 
adjuvants. Drugs targeting the γδ-TCR are already used in cancer therapy (Roelofs et al., 
2009, Kunzmann et al., 2000).  Other activating receptors such as TLR and NKG2D are 
also expressed on γδ-T-cells, further suggesting their potential use as adjuvant targets 
(Casetti & Martino, 2008).   
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Chronic HIV-1 infection leads to the increase in number, in peripheral blood, of the Vδ1 
class of γδ-T-cells, switching the normal Vδ1:Vδ2 balance (Poccia et al., 1998, Wallace, 
Malkovsky & Carding, 1995).  Furthermore clonal expansion of peripheral blood Vδ1 cells 
is not observed, and it is believed that these cells emigrate from tissue compartments, 
where they are the predominant cell type, in response to the cytokine environment created 
by HIV-1 infection (Wallace, Malkovsky & Carding, 1995).  The Vδ1 cells that traffic to the 
blood display an activated phenotype and are thought to contribute to the 
immunopathogenesis seen in HIV-1 infection (Boullier et al., 1997).  One γδ-T-cell subset, 
the Vγ9Vδ2 cells, have been demonstrated to have anti-HIV-1 cytotoxic activity towards 
HIV-1 infected cells, but is also functionally impaired in chronic infection (Wallace et al., 
1997, Poccia et al., 1996). 
1.6.3. Dendritic cells in HIV-1 infection 
DC located in the skin and in the mucosa encounter virions early in infection. DC express 
CCR5 and CXCR4 making them a viable target for HIV infection and pDC, which express 
CD4, are particularly susceptible (Borrow & Bhardwaj, 2008, Donaghy et al., 2003, 
Patterson et al., 2001).  Infected DC have been shown to transfer infectious virions directly 
to T-cells  (Yu, Reuter & McDonald, 2008) without releasing virus into the extracellular 
environment and this has been proposed as a model for dissemination of the virus to the 
secondary lymphoid tissue, prior to systemic infection and viraemia (Piguet & Steinman, 
2007).  HIV-1 infection of DC prevents normal activation and leads to dysregulation, 
interfering with their ability to promote appropriate innate and adaptive immune responses 
(Donaghy et al., 2003).   
The single stranded RNA genome of HIV-1 is innately recognised by and activates pDC 
via TLR7 and TLR8 ligation in endosomal compartments and is likely responsible for the 
high levels of IFN-α produced early in infection. IFN-α enables the activation of CD4+ and 
CD8+ T-cells in the short term, but they become unresponsive and unable to proliferate as 
infection progresses (Stacey et al., 2009, Boasso et al., 2008, Borrow & Bhardwaj, 2008, 
Alter et al., 2007a).  pDC have been shown to produce the enzyme indoleamine 2,3-
dioxygenase (IDO) following exposure to HIV, which prevents the proliferation of T-cells 
during HIV-1 infection (Boasso et al., 2008, Boasso et al., 2007).  HIV-1 infection has also 
been shown to block DC maturation and enhance IL-10 production, causing 
immunosuppression during chronic infection (Patterson et al., 2005, Granelli-Piperno et al., 
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2004).  It has been shown that the total number of pDC and mDC in peripheral blood are 
reduced during HIV-1 infection (Donaghy et al., 2001); and in lymphoid tissues in SIV-
infected rhesus macaques (Brown, Trichel & Barratt-Boyes, 2007).  TLR responsiveness 
of DC is reduced in chronically HIV-1 infected patients, who produce less IL-12 and IFN-α 
and more immunosuppressive IL-10 (Martinson et al., 2007).  The normal responses of DC 
to infection are altered during acute and chronic HIV-1 infection, which effects the 
production and maintenance of appropriate innate and adaptive immune responses. 
pDC and mDC frequency in peripheral blood recovers with HAART, although the rate of 
recovery and the full extent is correlated to baseline CD4+ T-cell number at initiation of 
treatment and/or viral set point; higher CD4+ T-cell frequencies and a lower viral set point 
correlate with more rapid and full recovery of cell frequency (Azzoni et al., 2007, Chehimi 
et al., 2007).  IFN-α production is recovered in pDC following successful treatment, as 
demonstrated by responsiveness to both CpG 2216 motifs and inactivated Influenza virus 
(Azzoni et al., 2007).  mDC show similar functional recovery in seropositive individuals 
receiving HAART and produce IL-12 in response to LPS at equivalent levels to 
seronegative individuals (Azzoni et al., 2007).  A reduction in MHC class I expression is 
also observed on both DC subsets indicating reduced chronic activation (Azzoni et al., 
2007).  It is noteworthy that other studies have demonstrated incomplete pDC recovery, 
but it is likely that individuals used in this study had more progressive disease at the 
initiation of therapy (Chehimi et al., 2002). 
1.6.4. NK Cells in HIV-1 Infection 
NK cells display functions that demonstrate a protective effect against HIV-1 infection 
when normal anti-viral function is maintained and additionally certain genetic determinants 
are associated with enhanced viral control and slow disease progression.  A subset of NK 
cells directly kill virus-infected CD4+ T-cells; NK cells lacking the KIR2DL1, -DL2 and CD94 
inhibitory receptors were able to kill HIV-1 infected CD4+ T-cells whose HLA-A and –B 
alleles had been downregulated by HIV-1 nef modulation, which prevents CTL responses 
(Bonaparte & Barker, 2004).  CD85j is an inhibitory NK cell receptor that usually functions 
by binding MHC-class I molecules, but has been shown to control HIV-1 replication in vitro 
within monocyte-derived DC via an unknown ligand and inhibitory pathway (Scott-Algara 
et al., 2003).  A further mechanism by which NK cells directly lyse HIV-1 infected cells is 
through ADCC, mediated by CD16+ NK cells in model systems using HIV-1-peptide-
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specific antibodies, demonstrating that non-neutralising antibodies directed toward 
infected cells represent a potential target for prophylactic vaccine and immunotherapeutic 
strategies (Stratov, Chung & Kent, 2008, Forthal et al., 2006, Forthal et al., 2005, Gupta et 
al., 2005). 
NK cells also indirectly inhibit HIV-1 infection by producing the CC chemokines 
macrophage inflammatory protein (MIP)-1α, MIP-1β and RANTES, which can successfully 
compete with HIV-1 for the CCR5 receptor, thereby inhibiting viral entry of target cells 
(Kottilil et al., 2003).  Inhibition via this route, however, is diminished in viraemic infection 
and the ability of NK cells to inhibit is inversely correlated to viral load. 
Increasing evidence is emerging for a link suggesting that patients with the HLA-B Bw4-
80I allele (also described as the B58Ile80 allele) are slow progressors to AIDS and that 
this effect is associated with its interaction with the activating KIR3DS1 receptor expressed 
on NK cells (Alter et al., 2007, Martin et al., 2002).  HLA-B Bw4-80I is the putative ligand 
for KIR3DS1 and it has been shown that KIR3DS1+ (and other activating KIR) NK cells are 
significantly upregulated during acute HIV infection in patients who are HLA-B Bw4-80I+. It 
has also been shown that these individuals have increased inhibitory KIR3DL1 expression 
during chronic HIV-1 infection (Alter et al., 2007b, Martin et al., 2002).  KIR3DS1+ 
KIR3DL1+ NK cells preferentially expanded during acute HIV-1 infection in vitro in the 
presence of HLA-Bw4-80I (Alter & Altfeld, 2009, Alter et al., 2007).  Furthermore, NK cells 
expressing KIR3DS1 were shown to lyse HIV-1 infected cells expressing the HLA-B Bw4-
80I allele and efficiently restricted viral replication (Alter et al., 2007). 
During acute HIV-1 infection CD56loCD16+ cells are rapidly expanded whereas 
CD56hiCD16- NK cells are not, and the proceeding responses are predominantly cytotoxic, 
demonstrating a defect in CD56hiCD16- cytokine production that is important for the 
generation of adaptive immune responses (Alter et al., 2005).  The production of IFN-γ 
remains impaired in chronic HIV-1 infection despite effective treatment that increases NK 
cell numbers and improves their cytotoxic potential (Azzoni et al., 2002).  Early initiation of 
treatment during acute infection better restores the NK cell compartment, delaying the 
onset of functional impairment, and a similar situation is observed in non-progressor 
patients who preserve NK cell cytotoxic and cytokine functions without treatment (Alter et 
al., 2005). 
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NK-derived IFN-γ impacts on maturation and activation of DC further influencing the 
formation of an appropriate adaptive response, and NK activity and IFN-γ production has 
been shown to be important in the generation of antigen-specific immune responses 
directed against HIV-1 infection (Loo et al., 2009, Alter et al., 2007b). It has been 
suggested that the apparent lack of expansion of CD56hiCD16- NK cells in peripheral 
blood may be attributed to the known capacity of these cells to migrate to SLT where T-cell 
activation occurs (Borrow & Bhardwaj, 2008).  IFN-γ production by NK cells is impaired in 
chronic HIV-1 infection and this impairment has in part been attributed to reduced IL-12 
stimulation, which in turn is attributed to reduced numbers of mDC (Yonkers et al., 2009).  
Furthermore it has been shown that NK cell IFN-γ production is maintained in LTNP and 
that the maintenance of DC numbers and DC-NK interactions, particularly the production 
of IL-12 by mDC, is a major determining factor in the control of infection (Saez et al., 
2007).  Higher levels of NK IFN-γ production are observed in individuals who have been 
exposed to HIV-1 infection through sexual contact, but remain seronegative, termed 
exposed seronegative (ESN) individuals, compared to both HIV-1 infected individuals and 
to healthy control individuals (Montoya et al., 2006).  A different cohort of ESN individuals 
exposed to HIV-1 through intravenous drug use demonstrated high activation and 
cytotoxic capacity directed toward MHC class I-devoid K562 target cells compared to 
either HIV-1 infected individuals or seronegative controls (Scott-Algara et al., 2003).  
Further studies with ESN individuals reveal that NK cells in these individuals may have a 
lower threshold for activation and increased ability to recognise HIV-1 transformed cells 
due to specific receptor repertoires on NK cells (Ravet et al., 2007).   The ESN in this 
study had high expression of activating KIR and the activating NKG2C receptor with lower 
proportions of the inhibitory NKG2A receptor and displayed high background levels of 
activation and degranulation as measured by CD69 and CD107a expression (Ravet et al., 
2007). 
Viral infections are known to subvert immune responses in order to survive in their host; 
HIV-1 expresses genes that prevent immune responses that would otherwise have a 
negative effect on the virus.  Subversion of normal NK activity occurs during HIV-1 
infection.  As described above, the HIV-1 nef protein downregulates the cell surface 
expression of the MHC class I molecules HLA-A/B, potently restricting CD8+ T-cell 
responses whilst retaining the expression of HLA-C/E alleles, downregulation of which 
normally leads to activation of NK cells and target cell killing (Alter & Altfeld, 2009, Borrow 
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& Bhardwaj, 2008).  HIV-1 nef also prevents the upregulation of surface expression of 
MIC-A and ULBP1, 2 and 3 (MHC class I homologues recognised by the NKG2D NK cell 
activating receptor) thereby reducing the ability of infected cells to activate NK cells 
(Cerboni et al., 2007).  The impairment of normal NK cell function strongly implies that NK 
cells have a role in the control of viral infection, either through direct killing of target cells or 
through the cross talk with DC that enhances antigen-specific immune responses.  The 
downregulation of NK cell activity by HIV-1 implies these mechanisms have been 
established as it is beneficial for virus survival and transmission. 
Overall numbers of CD3-CD56+ NK cells are reduced in chronic HIV-1 infection and are 
displaced in long-term infected treatment-naïve individuals by a dysfunctional CD3-CD56-
CD16+ fraction with severely impaired cytotoxic and cytokine producing functions (Mavilio 
et al., 2003).  The mechanism driving the generation of the dysfunctional CD56- NK cell 
population is not clear, although HIV-1-associated chronic immune activation may have 
some impact (Alter et al., 2005, Mavilio et al., 2005, Goodier et al., 2003).  Phenotypically, 
a high frequency of CD3-CD56-CD16+ cells express inhibitory KIR, including KIR2DL1, 
KIR2DL2 and KIR3DL1, and have low surface expression of the activating natural 
cytotoxicity receptors (NCR) NKp30 and NKp46 (Mavilio et al., 2005).   
In contrast to the above changes in NK cell receptors, the expression of inhibitory 
NKG2A/CD94 receptor is reduced in CD56+ NK cells from HIV-1 infected individuals and 
there is an increase in the activatory NKG2C/CD94 heterodimer that further disrupts NK 
cell function during HIV-1 infection (Mela et al., 2005).  The increase in the NKG2C at the 
expense of NKG2A has been linked to chronic infection and co-infection with human 
cytomegalovirus.  This may contribute to the decline in CD4+ T-cells expressing HLA-E 
and could also potentially be a mechanism driving NK cell exhaustion (Goodier & 
Coleman, 2009, Guma et al., 2006, Mela et al., 2005). 
NK cells have also been demonstrated to be responsible for the removal of HIV-1 infected 
CD4+ T-cells  (Vieillard, Strominger & Debre, 2005).  The HIV-1 protein, gp41, was shown 
to induce the presentation on CD4+ T-cells of a ligand for the NCR NKp44, which is 
upregulated on peripheral blood NK cells during chronic HIV-1 infection and NK-mediated 
cytotoxicity of infected cells has been demonstrated in an NKp44-dependant fashion 
(Vieillard, Strominger & Debre, 2005).  Furthermore, in a Simian human immunodeficiency 
virus (SHIV) model of HIV infection, macaques immunised with an anti-gp41 antibody 
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demonstrated maintenance of CD4+ T-cells by preventing the expression of the NKp44 
ligand and subsequent NK cell-mediated cytotoxicity (Vieillard et al., 2008). 
Functional impairment of NK cells and alteration of NK cell phenotype in chronic HIV-1 
infection is associated with chronic stimulation of NK cells, as demonstrated by the 
activated phenotype in NK cells from HIV-1 seropositive individuals, which, though partially 
activated are functionally deficient (Fogli et al., 2004).  The NK cells in the study by Fogli et 
al (2004) were demonstrated to have increased expression of CD69, CD25 and HLA-DR, 
but had reduced cytotoxic capabilities.    
As described in Section 1.6.3, DC numbers, particularly pDC, are reduced in chronic HIV-1 
infection (Donaghy et al., 2001) and responsiveness to TLR agonist stimulation is also 
reduced (Martinson et al., 2007).  The HIV-1 ssRNA genome is recognised by DC (Alter et 
al., 2007a), and is a potential mechanism of chronic, non-specific, immune stimulation of 
DC leading to exhausted responses and reduced innate responsiveness (Martinson et al., 
2007).  An additional mechanism of potential chronic innate stimulation has been 
demonstrated, whereby early pathology seen in GALT allows microbial translocation to 
occur and microbial products to enter the body, causing chronic, systemic immune 
activation demonstrated by increased plasma LPS in chronic HIV-1 infection (Brenchley et 
al., 2006, Brenchley et al., 2004).  It has further been demonstrated that NK cells from 
individuals with raised plasma LPS are refractory to further LPS stimulation, indicating that 
chronic stimulation, most likely through TLR4, is also responsible for DC and subsequent 
NK impairment. This has also been associated with dementia due to increased monocyte 
activation in the brain (Gregson et al., 2009, Ancuta et al., 2008).   
In healthy individuals the NK cell population in the gut is predominantly CD56hiCD16- and 
therefore has relatively low cytotoxic potential, and a population of NK cells in mucosa 
associated lymphoid tissue (MALT) produce the cytokine IL-22 involved in promoting anti-
inflammatory responses at mucosal sites, thereby limiting inflammation and damage (Cella 
et al., 2009).  Chronic HIV-1 infection reduces NK cell numbers in the gut, but this is 
partially reversed by HAART, however the NK cells that remain in the colonic lamina 
propria are CD56loCD16+ NK cells, which potentially contribute further to HIV-1 
pathogenesis observed in the gut (Goodier & Coleman, 2009, Mela et al., 2007). 
The lack of complete functional and numerical recovery of NK cells with HAART and the 
fact that NK cell recovery is slower than T-cell and DC recovery implies that for NK 
 61 
recovery to take place factors produced by these cells are required and demonstrates a 
lack of full immune control, despite recovery in CD4+ T-cell numbers and reduction of 
viraemia (Azzoni et al., 2007).   
The loss of cytokine stimulation during HIV-1 infection impacts on NK cell differentiation, 
proliferative capacity and function (Goodier & Coleman, 2009).  IL-2, -7, -15, -21 and -12 
production is reduced in HIV-1 infection and is partially recovered with HAART (Sirskyj et 
al., 2008, Marshall et al., 1999).  Different cytokine stimulation affects NK cells differently, 
but can promote differentiation, proliferation, NK cell-mediated killing of HIV-1 infected 
CD4+ T-cells and the production of cytokines, chemokines and perforin (Goodier & 
Coleman, 2009 and references therein).   
1.7. Aims of thesis 
The aims of this thesis are to provide a better understanding of innate immune 
responsiveness in chronic HIV-1 infection.  Using TLR agonists as model innate 
stimulants, work undertaken within this thesis will investigate the impact of chronic anti-
retroviral treated and untreated HIV-1 infection on both the NK cell compartment and the 
T-cell compartment and seek to further resolve functional abnormalities.  Furthermore 
peripheral blood NK cell maturation will be investigated in the context of chronic immune 
activation during HIV-1 infection.  Studies will be conducted examining the innate 
responsiveness of different memory T-cell subsets and, finally, using TLR agonists as 
model adjuvants, the ability to modulate antigen-specific T-cell responses in HIV-1 infected 
individuals will be explored. 
1.8. Hypothesis 
Responsiveness to certain classes of TLR agonists are maintained better than others 
during chronic HIV-1 infection and these TLR agonists represent potential model adjuvants 
for the recovery of HIV-1-specific T-cell responses in chronically infected individuals.  
Furthermore NK cell function is intrinsically linked to successful strategies aimed at 
improving appropriate T-cell priming conditions for effective anti-HIV-1 adaptive immunity. 
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2. Materials and methods 
2.1. Overview 
All laboratory work was carried out in the Department of Immunology, Chelsea and 
Westminster Hospital, London, UK, and was completed in accordance with local health 
and safety rules.  All work with known infectious samples was performed in a containment 
level three facility.  Full training for the use of this facility was completed, including 30 
hours observation and 30 hours supervised use by registered users before being granted 
authorisation by the facility manager.  All other work with human samples was carried out 
in containment level two laboratories.  
2.2. Ethical approval 
The Riverside Research Ethics Committee and the National Research Ethics Committee 
provided permission for all the studies conducted and presented in this thesis.  Informed, 
written consent was obtained from all individuals who provided peripheral blood samples 
for the studies conducted. 
2.3. Recruitment 
HIV-1 seropositive patients attending outpatient clinics at Chelsea and Westminster 
Hospital were recruited and peripheral blood samples collected.  HIV-1 seronegative 
samples were obtained with informed consent from local healthy volunteers.  
2.4. Sample collection 
Up to 60ml peripheral blood was collected into 6ml lithium heparin (green-capped) 
vacutainers (Becton Dickinson, Oxford, UK).  Trained phlebotomists carried out the sample 
collection, and all samples were processed within two hours of being obtained.  Recruiting 
clinicians provided patient viral load and CD4+ T-cell quantification information. 
2.5. PBMC isolation from peripheral blood 
Blood samples were pooled into 50ml screw-top tubes before up to 30ml blood was gently 
layered over 15ml hystopaque-1077 (Sigma-Aldrich, St. Louis, USA).  Samples were then 
spun in a centrifuge at 2000 RPM for 30 minutes without the use of a brake, which could 
disturb separated layers, causing mixing.  After separation was complete at least 2ml of 
the upper, plasma layer was removed and split into 500µl aliquots for storage at -80°C for 
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use in future assays.  PBMC were then transferred to 50ml centrifuge tubes and washed 
with cell culture media containing: RPMI-1640 cell culture medium supplemented with 
100IU ml-1 penicillin, 100µg ml-1 streptomycin and 2mM L-glutamine (all Sigma-Aldrich).  
Cell suspensions were first spun for seven minutes at 1800 RPM, supernatant poured out 
into virkon and then washed again with culture media before cells were enumerated.  To 
count cells, 10µl cell suspension was removed and mixed 1:1 with trypan blue (Sigma-
Aldrich) before viable cells were counted using disposable haemocytometers (Hycor, 
California, USA).  Once cells had been counted, they were spun for 7 minutes at 1500 
RPM, supernatant was discarded and cells were resuspended in culture media with 10% 
sterile foetal calf serum (FCS) or 10% pooled screened human AB sera (both Sigma-
Aldrich) at a concentration of either 1×106 cells ml-1 for innate stimulation assays (unless 
otherwise stated) or at 2.5×106 cells ml-1 for ELISpot (described in section 2.10) assays.  
FCS and human AB sera were both heat inactivated prior to use by incubating in a water 
bath at 56°C for 30 minutes. 
PBMC were then stimulated as described below and cultured in 5ml round-bottomed 
polypropylene tubes (Becton Dickinson), 96-well U-bottomed cell culture plates (Greiner 
Bio-One, Stonehouse, UK), or 96-well plates with Immobilon-P membranes (Millipore, 
Tullagreen, Ireland) for ELISpot assays.  Stimulated cell cultures were incubated at 37°C 
and 5% CO2.  
2.6. In vitro stimulations 
The majority of assays presented in this thesis involve in vitro stimulation of PBMC.  
PBMC were prepared as described above and stimulants were added directly to cell 
cultures.  All assays included a negative control of cells cultured in media alone without 
additional stimulation. 
2.6.1.  TLR agonist preparation and stimulation 
Lyophilized TLR agonists were prepared according to manufacturers’ instructions using 
sterile, endotoxin-free water.  Pam3CSK, Poly(I:C), Flagellin, Imiquimod R837 and CpG 
ODN2216 & ODN2006 (all InVivoGen, San Diego, USA) were all dissolved and stored in 
aliquots at -20°C. Heat-killed Listeria monocytogenes (HKLM), LPS, FSL-1 and ssRNA40 
& ssRNA41 were all dissolved and stored at 4°C. LPS and both ssRNA molecules were 
used within two weeks of reconstitution and HKLM and FSL-1 were stable for six and 12 
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months, respectively (All InVivoGen except LPS, Sigma-Aldrich).  TLR agonists were 
diluted in cell culture media before being directly applied to cell cultures.  Concentrations 
of agonists used are described in individual results sections. 
2.6.2. Cytokine preparation and stimulation 
For many of the assays presented in this thesis a combination of IL-12 and IL-15 was used 
as a control for stimulation.  Both cytokines were reconstituted from lyophilised 
preparations using sterile PBS and stored in aliquots at -80°C (IL-12) and -20°C (IL-15) 
(Both Peprotech, London, UK).  Cytokines were thawed and diluted in cell culture media 
before being applied to cell cultures at 1ng ml-1 for IL-12 and 20ng ml-1 for IL-15. 
2.6.3. Peptide preparation 
In some assays peptide pools were used to stimulate PBMC.  Three different pools were 
used.  1) a lyophilised pool of 32 8-12mer peptide fragments from influenza, Epstein-Barr 
virus (EBV) and cytomegalovirus (CMV) (FEC) was obtained in conjunction with the 
European Vaccines and Microbicides Network from the Centre for AIDS Reagents held at 
the National Institute for Biological Standards and Controls (NIBSC) (Appendix Table 
A.11).  2) 22 separate lyophilised HIV-1 gag p24 20mer peptide fragments with 10 amino 
acid overlaps, also obtained from the European Vaccines and Microbicides Network from 
the Centre for AIDS Reagents at NIBSC (Appendix Table A.12).  3) 36 8-11mer HIV-1 gag 
p24 (majority 9mer and referred to as ‘9mer pool’) peptide fragments (dissolved in cell 
culture media and stored at -80°C) (HIV-1 gag 9mer peptides kindly provided by Dr N. 
Imami, Department of Immunology, Imperial College London). An additional six individual 
lyophilised HIV-1 gag p24 9mer peptide fragments were obtained from the European 
Vaccines and Microbicides Network at NIBSC (Appendix Table A.13).  
The lyophilised FEC peptide pool was dissolved in sterile PBS at 1mg ml-1 and stored in 
aliquots at -80°C.  Lyophilised HIV-1 gag p24 20mer and 9mer peptides were dissolved in 
cell culture medium before being pooled and diluted at 20µg ml-1 for storage in aliquots at  
-20°C.  
Peptides were thawed, and where necessary diluted further in cell culture medium, before 
being applied directly to cell cultures at 5µg ml-1, unless otherwise stated. 
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2.6.4. Phytohaemagglutinin preparation 
Phytohaemagglutinin (PHA) (Sigma-Aldrich) was used as a positive mitogen control in 
ELISpot assays.  This was diluted in cell culture medium to 10µg ml-1 and stored in 
aliquots at -20°C.  PHA was thawed and applied directly to cell cultures at a final 
concentration of 5µg ml-1.  
2.7. Antibody staining for flow cytometry assays 
Many of the assays presented in this thesis involve the use of flow cytometry involving 
various different staining techniques.  Individual monoclonal antibody cocktails for various 
assays are listed in Appendix Section A.1.  Antibodies were titrated for optimal staining. 
2.7.1. Surface staining 
Supernatant was first removed without disturbing cells, and was stored at -80°C for future 
assays.  PBMC for staining were transferred to 4.5ml round-bottomed polystyrene FACS 
tubes (Becton Dickinson), 2ml of FACS buffer was added to tubes before being spun for 
four minutes at 1200 RPM.  FACS buffer contained: 500ml PBS + 1% FCS (both Sigma-
Aldrich) + 1% EDTA (Invitrogen, Paisley, UK) + 0.05% NaN3 (Sigma-Aldrich).  Excess 
buffer and culture media were then poured off into virkon and fluorochrome-conjugated 
monoclonal antibody cocktails were added to each tube and mixed thoroughly before 
incubation for 30 minutes at 4°C.  Tubes were then washed again with 2ml FACS buffer 
and spun for four minutes at 1200 RPM.  Depending on the assay, excess FACS buffer 
and antibodies were then poured off into virkon and cells were fixed in an appropriate 
volume of 2% paraformaldehyde (PFA) prior to acquisition by flow cytometry or further 
processed and stained as described below.  
2.7.2. Intracellular cytokine staining 
Intracellular cytokine staining (ICCS) of IFN-γ required further processing than for surface 
staining alone.  Firstly, prior to the surface stain procedure described above, GolgiPlug 
(Becton Dickinson) (containing Brefeldin A) was incubated with cell cultures for four hours 
at a final volume of 1µl per ml of culture.  Brefeldin A is a protein transport inhibitor, which 
prevents the release of cytokines such as IFN-γ, resulting in their accumulation within the 
cell.  After four hours, surface staining was carried out as described, and prior to fixation in 
PFA cells were incubated with 500µl of FACS fixation/permeabilising solution (Perm2 – 
 66 
Becton Dickinson) diluted 1:10 with distilled water, vortexed, and incubated at room 
temperature for 10 minutes.  Permeabilisation creates holes in the cell membrane, 
allowing antibodies targeting intracellular components to pass into cells and bind to their 
targets.  Following permeabilisation, cells were washed again in FACS buffer and spun for 
five minutes at 2000 RPM and the excess was poured off.  Cells are then incubated for 30 
minutes at room temperature in the dark with anti-IFN-γ monoclonal antibodies before 
being washed in FACS buffer and spun for five minutes at 2000 RPM.  Cells were then 
fixed in 2% PFA prior to acquisition.  
2.7.3. Degranulation; CD107a staining 
CD107a is used as a marker for lymphocyte activation and degranulation for some assays 
(Alter et al., 2004b, Betts et al., 2003).  Following stimulation and culture of PBMC, cells 
are incubated for one hour with anti-CD107a monoclonal antibody at 37°C and 5% CO2.  
Following incubation with antibody, GolgiPlug (Becton Dickinson) was incubated with cells 
(1µl per ml of culture, as for ICCS) for four hours at 37°C and 5% CO2 before surface 
staining was carried out (as described in 2.8.1). 
2.7.4.  MHC class I pentamer staining 
Antigen-specific CD8+ T-cells expressing specific MHC class I-peptide complexes were 
stained using fluorochrome-conjugated MHC class I pentamers (ProImmune, Oxford, UK).  
PBMC were washed in FACS buffer and centrifuged for four minutes at 1200 RPM.  Cells 
were then incubated with pentamers for 10 minutes at room temperature before washing 
with FACS buffer and centrifugation for four minutes at 1200 RPM.  Surface staining was 
then carried out as described in section 2.8.1, except that this was performed on ice for 20 
minutes.  
2.8. Isolation or purification of lymphocyte subsets by magnetic cell 
separation 
A number of assays have been carried out using magnetic cell separation to either remove 
a particular lymphocyte population or isolate a single lymphocyte population.  For all 
assays, a sample of cells was taken before and after separation to determine the purity of 
recovered populations. 
 67 
2.8.1. Isolation of untouched total peripheral blood NK cells  
NK cell isolation was carried out using an NK cell isolation kit (Miltenyi-Biotec, Bergisch 
Gladbach, Germany), according to the manufacturers instructions.  In order to isolate an 
untouched pure NK cell population, PBMC isolated as described in section 2.6, were 
enumerated and resuspended in MACS buffer (sterile PBS containing 1% FCS (both 
Sigma-Aldrich) + 1% EDTA (Invitrogen, Paisley, UK)).  The required volume of cells was 
transferred to 15ml centrifuge tubes and MACS buffer was added to a total volume of 10ml 
before tubes were spun for five minutes at 1300RPM.  Excess MACS buffer was poured 
off into virkon before cells were mixed with a biotinylated antibody cocktail that specifically 
recognised non-NK cells within PBMC suspensions (Miltenyi-Biotec, Bergisch Gladbach, 
Germany).  The cocktail was added at a volume of 10µl per 1×107 PBMC per 40µl MACS 
buffer and incubated for 15 minutes at 4°C.  Streptavidin conjugated Macs™ microbeads 
(Miltenyi-Biotec) were subsequently added at a volume of 20µl per 1×107 cells alongside 
an additional 30µl MACS buffer and incubated for 15 minutes at 4°C.  Cells were then 
washed in 10ml MACS buffer and spun for five minutes at 1300 RPM and resuspended in 
500µl MACS buffer.   
Cells were then applied to pre-rinsed (3ml MACS buffer) LS-sized MACS™ depletion 
columns (capacity up to 3 x 107 bound cells) in a magnetic MACS™ separator (Miltenyi-
Biotec).  NK cells that passed through the column were collected in 15ml centrifuge tubes.  
After cells were applied the column, they were flushed through three times with a further 
3ml MACS buffer; each 3ml was allowed to run through completely before further 
application.  MACS buffer was added to the collection tubes to give a total volume of 10 ml 
before cell suspensions were spun for five minutes at 1300 RPM.  Cells were resuspended 
in 10ml cell culture medium and enumerated before being washed again as above and 
resuspended at 1×106 cells ml-1 in culture medium for stimulation with TLR agonists or 
cytokines as described in Section 2.7.1 and 2.7.2. 
2.8.2. CD56+ cell depletion  
CD56 depleted PBMC were either used in add-back assays in conjunction with 
CD56hiCD16- NK cells, the isolation of which is described below in section 2.9.3, or they 
were stimulated directly in antigen-specific ELISpot assays described in section 2.11. 
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CD56+ cell depletion was carried out using a MACS kit (Miltenyi-Biotec).  The procedure 
followed was similar to that described above for NK cell isolation (2.9.1) with some 
amendments.  2×107 PBMC were diluted in 2ml of MACS buffer in 4ml round bottomed 
tubes before being spun for four minutes at 1200 RPM.  Excess buffer was discarded and 
cells were mixed with 20µl MACS™ beads conjugated to anti-CD56 antibodies and 80µl 
MACS buffer and incubated for 15 minutes at 4°C before further washing and 
resuspension in 500µl MACS buffer.   
Cells were then applied to an MS-sized MACS™ column (capacity up to 1 x 107 bound 
cells) attached to a MACS™ separator.  The column was pre-rinsed with 500µl MACS 
buffer before cells were added.  Cells were collected in a 15ml centrifuge tube and the 
column was flushed through three times with 500µl MACS buffer.  The tube was then spun 
for four minutes at 1200 RPM and cells were resuspended in 10ml cell culture medium.  
Cells were enumerated and washed once more and spun for seven minutes at 1500 RPM. 
NK cell-depleted PBMC were resuspended in medium at a concentration of 1×106 cell ml-1, 
for assays where they were recombined with purified NK cell populations, or at 2.5×106 
cells ml-1 for ELISpot assays.   
2.8.3. Isolating CD56hiCD16- NK cells for add-back  
To study the maturation of NK cells it was necessary to firstly remove lineage marker+ 
(including CD3, CD14, CD19) and CD16+ NK cells by negative selection to facilitate the 
isolation of CD56hiCD16- NK cells by positive selection (with anti-CD56).  Enriched 
CD56hiCD16- NK cells were subsequently added back to CD56-depleted PBMC generated 
as described above in Section 2.9.2.  This cell enrichment was performed using the 
CD56+CD16- NK cell isolation kit (Milteyi-Biotec). 
8×107 PBMC were prepared from 80ml of blood (HIV-1 seronegative control donors only), 
washed as described above and resuspended in 400µl MACS buffer in a 15ml centrifuge 
tube.  Cells were then incubated for 10 minutes at 4°C with 100µl of biotin-antibody 
cocktail (Miltenyi-Biotec), which labels all cells within PBMC except for those expressing 
CD56 in the absence of other lineage markers such as CD3, CD14 and CD16.  Cells were 
then washed in 10ml MACS buffer, spun for five minutes at 1300 RPM, resuspended in 
800µl buffer and then incubated for 15 minutes at 4°C with 200µl micro bead cocktail 
(Miltenyi-Biotec).  Washing was repeated and cells were resuspended in 500µl MACS 
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buffer.  Labeled cells were then passed through an LS size MACS column as described in 
section 2.9.1, and the eluent was washed as described and resuspended in 400µl MACS 
buffer in a 15ml centrifuge tube. 
Following initial enrichment of CD56+CD16- NK cells, these were purified further by 
incubation for 15 minutes at 4°C with CD56 Micro Beads (Mitenyi-Biotech).  Cells were 
then washed and resuspended in 500µl prior to being flushed through an MS-sized MACS 
column (described in 2.9.2).  In this positive selection step, the flow-through was 
discarded, the column was then removed from the MACS separator magnet and 
positioned above a 5ml round-bottomed tube, 1ml MACS buffer was added and then the 
column flushed through using a plunger.  Cells were then washed twice in 2ml cell culture 
medium, spun each time for seven minutes at 1500 RPM before being resuspended in 2ml 
culture media. 
CD56+CD16- NK cells were then added to 2×107 CD56 depleted PBMC generated from 
the same sample at a frequency of 1-5%, depending on cell recovery.  The CD56+CD16+ 
depleted PBMC were then spun down once more and resuspended at 1×106 cells ml-1 in 
media. Cells were aliquoted into 5ml polypropylene cell culture tubes (Becton Dickinson) 
and stimulated with cytokines or TLR agonists for maturation assays described in Section 
4.2. 
2.8.4.  CD19+ B-cell depletion 
B-cells were removed for some antigen-specific ELISpot assays in order to determine the 
role played by this cell type in observed results.  CD19 microbeads (Miltenyi-Biotec) were 
used to negatively select for non-CD19+ cells.  2×107 PBMC were prepared as described 
for CD56 depletion in section 2.9.2 and incubated with 20µl CD19 microbeads for 15 
minutes at 4°C.  PBMC were then washed before being passed through an MS-sized 
MACS column (as described in Section 2.9.2) and washed again before being 
resuspended in cell culture medium at 2.5×106 cells ml-1 for ELISpot assays. 
2.8.5.  BDCA-4+ plasmacytoid dendritic cell depletion 
Plasmacytoid dendritic cells were removed for the same ELISpot assays as described in 
2.9.4. BDCA-4 microbeads were used to negatively select non-BDCA-4+ cells.  2×107 
PBMC were prepared as described above in Sections 2.9.2 and 2.9.4 and incubated with 
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20µl of FcR blocking reagent and 20µl of BDCA-4 microbeads and incubated for 15 
minutes at 4°C. PBMC were then washed before being passed through an MS-sized 
MACS column as described in Section 2.9.2 and washed again before being resuspended 
in cell culture medium at 2.5×106 cells ml-1 for ELISpot assays. 
2.9. Enzyme-linked immunosorbent assay (ELISA) assays for c-Kit and 
stem cell factor  
ELISA assays were carried out on stored frozen plasma samples obtained from samples 
at the time of PBMC isolation to quantify c-Kit and stem cell factor (SCF) concentrations.   
2.9.1.  c-Kit ELISA 
c-Kit was quantified according to the manufacturers protocol using a specific ELISA kit 
(R&D Systems, Abingdon, UK).  Capture antibody (R&D Systems) was diluted in PBS 
(Sigma-Aldrich) to 4µg ml-1 and 100µl was added per well to 96-well flat-bottomed ELISA 
plates (Nunc, Roskilde, Denmark).  Plates were then sealed and incubated overnight at 
room temperature.  Following incubation plates were washed three times with wash buffer 
consisting of PBS with 0.05% Tween 20 (Sigma-Aldrich); each well was filled using a wash 
bottle, then the contents discarded.  After the final wash remaining buffer was blotted out 
onto clean paper towels.  Blocking was achieved by adding 300µl reagent diluent, 
consisting of PBS with 1% FCS (Sigma-Aldrich) to each well and incubated at room 
temperature for one hour. 
Whilst plates were being blocked, samples and standards were prepared. Samples were 
thawed and diluted at a ratio of 1:50 in diluent.  Standards were diluted in diluent and a 
seven point serial dilution was carried out starting at 2000pg ml-1. Reagent diluent was 
used as a negative control sample. 
After blocking plates were washed three times as described, before 100µl of sample or 
standards was added to each well.  Samples and standards were added in triplicate.  
Plates were incubated for two hours at room temperature before being washed three 
times.  Streptavidin-HRP was diluted to working concentration in reagent diluent, 100µl 
was added per well, plates were incubated for 20 minutes at room temperature in the dark 
and then washed three times.  Substrate solution was made containing a 1:1 mixture of 
hydrogen peroxide (H2O2) and tetramethylbenzidine (both Becton Dickinson) and 
incubated for approximately 15 minutes at room temperature in the dark.  The plate was 
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checked occasionally and when the lowest standard concentration appeared to have 
changed colour compared to the negative control, 50µl stop solution (2 N Sulphuric acid 
(H2SO4)) was added per well and plates were immediately analysed on a microplate 
reader at 450 nm.  
2.9.2.  SCF ELISA 
SCF was quantified using an ELISA kit (Peprotech) and assays were carried out according 
to manufacturers instructions.  Capture antibody was first dissolved in sterile water to 
100µg ml-1 and then further diluted in PBS to a working concentration of 1µg ml-1.  100µl 
capture antibody was added per well to 96-well flat-bottomed ELISA plates (Nunc) and 
incubated overnight at room temperature.  Plates were then washed four times as 
described in 2.10.1 and 300µl block buffer (as in 2.10.1) was added to each well and 
incubated for one hour at room temperature.   
Whilst plates were being blocked, samples and standards were prepared.  For SCF ELISA 
the samples were diluted at a ratio of 1:3 in diluent (PBS containing 0.1% FCS and 0.05% 
tween-20 – all Sigma-Aldrich).  Standards were reconstituted in sterile water to 1µg ml-1 
before being further diluted in diluent and a seven point serial dilution was carried out 
starting at 2000pg ml-1. Reagent diluent was used as a negative control sample. 
After blocking, plates were washed four times before 100µl of sample or standards was 
added per well.  Samples and standards were added in triplicate.  Plates were incubated 
for two hours at room temperature before being washed four times.  The Avidin-HRP 
conjugate was diluted 1:2000 in diluent and 100µl was added per well, incubated for 30 
minutes and then plates were washed four times.  100µl of ABTS substrate was then 
added to each well and incubated at room temperature while colour change was 
monitored.  When the lowest standard concentration became obviously different to 
negative controls, the plates were analysed immediately at 405nm.  
2.10. IFN-γ  ELISpot assays 
Antigen-specific T-cell responses to specific peptide pools in combination with TLR 
agonists were quantified by ELISpot analysis.  96-well polyvinylidene difluoride-backed 
ELISpot plates (Millipore, Billerica, Massachusetts, USA) were coated with 100µl anti-IFN-
γ antibody diluted in PBS to 10µg ml-1 (Mabtech, Stockholm, Sweden) and incubated 
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overnight at 4°C.  Plates were washed six times with 200µl per well with cell culture media 
before being blocked for one hour at room temperature with PBS containing 10% human 
AB serum (Sigma-Aldrich). 
PBMC were prepared at a concentration of 2.5×106 cells ml-1 in culture medium with 20% 
human AB serum.  Peptide pools, cytokines and TLR agonists were prepared as 
described in Sections 2.7.1, 2.7.2 and 2.7.3 at four times the final concentration required in 
cell culture medium. PHA aliquots were also thawed.  After plates were blocked, the 
blocking buffer was tapped out of the plates and 100µl cells were immediately added per 
well.  50µl of peptide, TLR agonists or cytokines was added to wells as required or 100µl 
PHA was added.  Wells that did not already have 200µl total volume were topped up using 
cell culture medium; all conditions were carried out in duplicate.  Plates were incubated 
overnight at 37°C in 5% CO2.  
After incubation the contents of the plates were shaken off into virkon and the plates 
washed six times with 200µl PBS using a plate washer (Tricontinent, Grass Valley, USA).  
Excess PBS was shaken off and 100µl of 1µg ml-1 biotinylated anti-IFN-γ antibody 
(Mabtech) was then added to each well and the plate incubated for two hours at room 
temperature.  Plates were then washed again as described and 100µl of 1:1000 
streptavidin-alkaline phosphatase (Mabtech) diluted in PBS was added per well and plates 
were incubated for one hour at room temperature.  Plates were washed a final time, 
leaving the last wash in the plate.  Chromogen was prepared using the alkaline 
phosphatase conjugate substrate kit, by mixing development buffer at a 1:25 ratio with 
distilled water and adding 100µl of both chromogen reagents A and B per 10ml (BioRad, 
Hemel Hempstead, UK) and 100µl was added per well.  Plates were then incubated at 
room temperature and the formation of spots was monitored. When clearly defined spots 
were visible in positive control wells and/or peptide-stimulated wells, plates were washed 
thoroughly with tap water three times and left to air-dry before being analysed with a plate-
reading microscope.   
2.11. DNA isolation for HLA tissue-typing 
Cells were frozen at -80°C at 5×106 cells ml-1 in freezing medium containing cell culture 
medium with 20% FCS and 10% DMSO (Sigma-Aldrich).  Cells were initially frozen in a 
‘Mr Frosty’ container (isopropanol coolant), before being transported to normal freezer 
boxes for later processing. 
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DNA isolation was performed using a commercially available kit (Qiagen, Crawley, UK).  
Frozen PBMC samples were thawed in a 37°C heat block, transferred to 15ml centrifuge 
tubes and washed twice in PBS, spun each time for five minutes at 1400 RPM, then 
resuspended in 300µl PBS and transferred to 1.5ml sterile tubes.  900µl of RBC lysis 
solution was added, and the tube was inverted 10 times and incubated for five minutes at 
room temperature.  Tubes were then spun in a microcentrifuge at maximum speed for 20 
seconds and the excess discarded leaving approximately 10µl liquid in tubes, which were 
then vortexed vigorously.  300µl of the cell lysis solution was then added and was drawn 
up and down for 10 seconds using a pipette.  1.5µl RNAse A solution was then added and 
tubes inverted 25 times before incubation for 15 minutes at 37°C.  Sample tubes were 
then placed on ice for one minute after which 100µl protein precipitation solution was 
added and the sample vortexed for 20 seconds.  Samples were spun at maximum speed 
in a microcentrifuge for one minute, the supernatant was then carefully removed, avoiding 
the visible protein pellet and added to 300µl isopropanol prepared in a clean 1.5ml tube.  
The tube was then inverted 50 times until threads or clumps of DNA were visible, the 
sample was then spun at maximum speed for one minute. The supernatant was poured off 
and the remainder was carefully discarded by inverting the tube onto clean tissue.  300µl 
ethanol was then added to the sample and the DNA washed by inverting the tube several 
times before being spun again for one minute at maximum.  Supernatant was then 
discarded and carefully drained by inverting onto tissue before being left to air dry for five 
minutes.  100µl hydration solution was then added and the tube vortexed for five seconds. 
Tubes were then incubated for five minutes at 65°C on a heat block before being left on a 
shaker overnight at room temperature.  DNA yield was determined using a Nanodrop 
(Thermo Scientific, Waltham, USA). A minimum of 2µg DNA at 20µg ml-1 was sent for 
tissue-typing to ProImmune (Oxford, UK). 
2.12. Flow cytometry 
All flow cytometry was carried out using either a FACSCalibur (four colours) or an LSR II 
cytometer (six colours, both Becton Dickinson), which was upgraded during this project to 
include an additional UV laser.  Data was acquired using Cell Quest Pro software (Becton 
Dickinson) for the FACSCalibur and FACSDiva software (Becton Dickinson) for the LSR II.  
All data presented was analysed using FlowJo software (Tree Star, Oregon, USA).  
Example dot plots and gating strategies are presented throughout this thesis.  All samples 
were stored at 4°C and acquired no more than 24 hours after fixation.  
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2.13. Graphs and statistical analysis 
All graphs shown in this thesis have been prepared using GraphPad Prism Software 
(GraphPad Software Inc, California, USA). 
ELISA data were analysed using Microsoft Excel software (Microsoft Corporation, 
Redmond, Washington, USA). 
All other statistical analysis was carried out using GraphPad Prism software using non-
parametric tests; Wilcoxon’s signed rank test was used to analyse differences between 
paired data and the Mann-Whitney U test was used to examine differences between non-
paired data, such as comparison of responses between groups of HIV-1 seropositive and 
seronegative individuals. 
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3. Innate immune responsiveness to TLR agonists during 
chronic HIV-1 infection  
Aim 
In this first results chapter, the impact of chronic HIV-1 infection on innate cell 
responsiveness and activation in response to pathogen-associated molecular patterns 
(PAMP) will be determined.   The effects of chronic HIV-1 infection on responses will be 
explored in an attempt to better understand how this disrupts innate immunity, with the 
goal of identifying non-exhausted immune pathways.  Assays were carried out to identify 
PAMP capable of eliciting and enhancing innate immune responses for potential use in 
both prophylactic and immunotherapeutic settings. 
Introduction 
Chronic HIV-1 infection affects many aspects of both innate and adaptive immunity.  In this 
chapter we have explored innate immune responses in chronic infection with a particular 
focus on NK cell responsiveness.  It has been shown that NK cells interact with TLR-
activated cells such as DC and that these interactions ultimately shape the adaptive 
immune response (Moretta et al., 2008, Gerosa et al., 2002).  It is also known that both NK 
cells and DC are both reduced in numbers and driven toward a dysfunctional state in HIV-
1 infection (Mavilio et al., 2005, Fogli et al., 2004, Donaghy et al., 2003, Mavilio et al., 
2003, Donaghy et al., 2001).  We have therefore investigated which innate TLR-driven NK 
cell functions are preserved during chronic HIV-1 infection. 
PAMP stimulating TLR were compared for their effect on innate immune activation and 
function within CD8+ T-cells and NK cells, and the extent of accessory cell involvement in 
NK cell activation was explored.  NK cell functional subset responsiveness to innate 
stimulation was subsequently examined in chronic HIV-1 infection, and the influence of 
viral suppression under anti-retroviral therapy investigated.  
3.1. Natural killer cells and CD8+ T-cells are sensitive to TLR agonist 
stimulation 
In order to establish the capacity of NK cells and CD8+ T-cells to respond to TLR agonists 
alone, preliminary stimulation assays were carried out to measure activation marker 
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expression in response to LPS and CpG ODN2216.  PBMC from healthy donors were 
isolated from peripheral blood and cultured overnight in the presence of the TLR4 agonist 
LPS (100ng ml-1) and the TLR9 agonist CpG ODN2216 (2.5µM).  The expression of the 
early activation marker CD69 was determined on both CD3+CD8+ T-cells and CD3-CD56+ 
NK cells (see appendix table A.1 for antibody staining panel).  Figure 3.1.1 demonstrates 
the gating strategy used for analysis, including a lymphocyte gate defined by forward and 
side scatter, and examples of CD69 expression in response to LPS and CpG ODN2216 
stimulation of gated CD8+ T-cells and NK cells.  Both NK cells and CD8+ T-cells are 
sensitive to in vitro stimulation with LPS and CpG ODN2216, and showed a clear increase 
in expression of CD69 compared to unstimulated PBMC (left in tissue culture media 
alone). 
 
 
3.2. High frequency of NK cells respond to TLR stimulation; varying 
sensitivity of NK and CD8+ T-cells to different agonists 
The optimum conditions for in vitro stimulation of PBMC were then investigated in order to 
establish the extent to which both NK cells and CD8+ T-cells could be activated by 
representative examples of different human TLR agonists.  A full list of TLR agonists and 
the concentrations used is shown in Table 3.2.1.  PBMC isolated from 12 healthy donors 
Figure 3.1.1 Both NK cells and CD8+ T-cells are sensitive to TLR stimulation. Representative, healthy 
control, flow cytometry dot plots, demonstrating a) NK cell or b) CD8+ T-cell gating strategies from PBMC 
and subsequent expression of the early activation marker CD69 by total NK and CD8+ T-cells following 
overnight culture with or without TLR agonist stimulation in vitro.  
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were cultured overnight in the presence of different TLR agonists at varying concentrations 
(see Table 3.2.1).   
 
Figure 3.2.1 shows histograms for CD69 expression by NK cells and CD8+ T-cells.  The 
graphs reveal variation in the sensitivity of NK and CD8+ T-cells to different TLR agonists.  
The TLR1/2 agonist Pam3CSK4 and the TLR5 agonist flagellin stimulated little CD69 
expression on NK cells except for relatively small increases at high agonist concentrations.  
FSL-1 (a TLR6/2 agonist) did not stimulate significant increases in CD69 expression by NK 
cells compared with unstimulated cells at any of the concentrations tested.  Flagellin and 
FSL-1 were also unable to stimulate significant CD69 expression by CD8+ T-cells at any 
concentration tested.  All other agonists generated significant increases in the frequency of 
CD69 expression by both NK cells and CD8+ T-cells, compared to unstimulated cells.   
The TLR3 agonist Poly(I:C), the TLR4 agonist LPS, the TLR8 agonist ssRNA40 and the 
TLR9 agonist CpG ODN2216 all generated consistently  high frequency CD69 expression 
by NK cells and increased expression by CD8+ T-cells.  Both the TLR2 agonist HKLM and 
the TLR7 agonist Imiquimod R837 generated high frequency CD69 expression by NK cells 
in PBMC from some individuals, however these responses were inconsistent and showed 
great inter-individual variation. 
Table 3.2.1 TLR agonists 
and concentrations used 
for titration experiments. 
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3.3. Lyovec and CpG ODN2006 activate NK and CD8+ T-cells at far lower 
frequency than ssRNA40 and CpG ODN2216 
The HIV-1 derived ssRNA sequence present in the TLR8 agonist ssRNA40 is complexed 
with lyovec, a cationic lipid that protects the ssRNA sequence and enhances cellular 
uptake needed for TLR8 stimulation (InVivoGen, 2012).  ssRNA41 has the same ssRNA 
sequence as ssRNA40, but has uridine molecules in place of adenosine molecules and is 
also complexed to lyovec; this has been shown to not stimulate production of type 1 
interferons and is therefore considered to be a suitable negative control for NK cell and 
CD8+ T-cell activation (InVivoGen, 2012). In order to assess the impact of the lyovec 
component on NK cell and CD8+ T-cell responses, PBMC were stimulated with ssRNA40 
Figure 3.2.1 NK and CD8+ T-cells are stimulated to express CD69 at varying intensities and 
frequencies following in vitro stimulation of PBMC by different TLR agonists. Histogram plots 
from a single representative healthy control individual (n=27) demonstrating CD69 expression by total 
NK cells (left columns) and CD8+ T-cells following overnight stimulation with different TLR agonists at 
different concentrations (see table 1). Dashed lines illustrate positive thresholds and are for illustration 
purposes.   
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in parallel with the negative control agent ssRNA41 and NK cell and CD8+ T-cell activation 
was assessed.  Expression of the early activation marker CD69 and the expression of the 
IL-2Rα chain (CD25) were measured using flow cytometry.  Figure 3.3.1 compares CD69 
and CD25 expression by NK and CD8+ T-cells following overnight stimulation of healthy 
donor PBMC with ssRNA40 and ssRNA41.  ssRNA41 weakly stimulated expression of 
both CD69 and CD25, but does so at a reduced frequency compared to ssRNA40 at the 
same concentration.  
Three different classes of CpG ODN molecules, types A, B and C are recognised by TLR9 
exhibiting distinct stimulatory properties.  Type A CpG ODN molecules, including CpG 
ODN2216, interact with TLR9 on plasmacytoid DC (pDC) and stimulate IFN-α production.  
Type B CpG ODN molecules, such as CpG ODN2006, activate B-cells whilst stimulating 
negligible IFN-α responses.  Type C CpG ODN molecules stimulate both pDC and B-cell 
responses (Marshall et al., 2005, Krug et al., 2001, Krieg et al., 1995).  CpG ODN2216 has 
been used exclusively throughout these studies because it activates pDC and induces 
IFN-α production, a known pathway for NK cell activation.  Type B CpG ODN2006 was 
therefore tested as a negative control for type A CpG ODN stimulated pDC in NK and 
CD8+ T-cell activation.  PBMC from healthy donors were stimulated overnight with either 
CpG ODN2006 or ODN2216 and expression of CD69 and CD25 by NK cells and CD8+ T-
cells was measured by flow cytometry.  Figure 3.3.1 reveals that CpG ODN2006 
stimulated a low frequency of CD69 expression in NK cells, although CpG ODN2216 led to 
a higher frequency of responding NK cells.  CpG ODN2216 induced a low frequency of NK 
cells to express CD25 (8.37%), with little or no induction observed in response to CpG 
ODN2006 (1.1%) (Figure 3.3.1).  CD69 and CD25 expression was induced in CD8+ T-cells 
following in vitro stimulation of PBMC with CpG ODN2216, and both activation markers 
were also expressed following stimulation with CpG ODN2006, albeit at a lower frequency 
(Figure 3.3.1b).  These data indicate that pDC may play an accessory role in the 
responses of NK cells to ODN2216. 
 80 
 
 
3.4. Isolated NK cells remain sensitive to cytokine stimulation, but are 
unresponsive to TLR agonist stimulation 
In order to confirm the requirement of accessory cells for NK cell activation, untouched NK 
cells were purified from four healthy donor PBMC by negative selection on magnetic 
Figure 3.3.1 ssRNA41 and CpG ODN2006 do stimulate NK and CD8+ T cells in vitro, at reduced 
frequency compared to ssRNA40 and CpG ODN2216 respectively.  Dot plots demonstrating the 
induced expression of CD69 and CD25 on a) NK and b) CD8+ T cells from a single healthy control 
individual and are representative of 2 separate experiments following overnight stimulation with the TLR 
agonists shown. Both types of ssRNA were used at 5µg/ml and both types of CpG were used at a 
concentration 2.5µM. 
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beads.  This isolation protocol allowed highly pure NK cell cultures to be generated 
reaching a minimum of 89% purity in all experiments as illustrated in Figure 3.4.1a.   
 
Overlay histograms clearly demonstrate an increased frequency of CD69 expression by 
Figure 3.4.1 NK cells become unresponsive to TLR agonist stimulation in the absence of accessory 
cells.  NK cells were isolated from PBMC using magnetic cell separation and the resulting, negatively 
selected, NK cells were cultured in vitro with TLR agonists in parallel with total PBMC and the resulting 
activation compared by flow cytometry. a) Representative dot plots from a healthy control individual 
demonstrating the efficiency of the negative selection technique.  The top row is plots from total PBMC 
and the bottom row are plots from isolated NK cells. Overlay histograms comparing b) CD69 or c) CD25 
expression by NK cells in response to cytokine or TLR agonist stimulation of PBMC or isolated NK cells 
(filled lines) compared to unstimulated PBMC or isolated NK cells (solid, unfilled line).  Percentages 
displayed are frequency of b) CD69+ or c) CD25+ stimulated CD3-CD56+ NK cells.  Results demonstrated 
are from a single individual and are representative of 4 isolation experiments using PBMC from HIV-1 
seronegative individuals.  These results also show b) CD69 expression is detected on NK cells stimulated 
with all TLR agonists tested here and c) CD25 expression is detected in NK cells following stimulation of 
PBMC with LPS or ssRNA, but very low expression is detected with Poly(I:C) or CpG. 
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NK cells stimulated within unfractionated PBMC in response to TLR ligands or cytokines 
(unfilled lines), compared to unstimulated cultures (filled blue lines) (Figures 3.4.1b&c).  
Furthermore, IL-12 + IL-15, LPS and ssRNA40 stimulated NK cells within PBMC beyond 
early activation to express CD25.  Isolated NK cells cultured with the TLR agonists tested 
did not become activated, demonstrating a clear requirement for accessory cells, either 
through direct contact or through soluble mediators or a combination of both.  Of the 
stimuli, tested only the combination of cytokines IL-12 (1ng ml-1) and IL-15 (20ng ml-1) 
could drive the activation of NK cells in the absence of accessory cells, confirming that the 
cells are intrinsically functionally competent (Figure 3.4.1).   
3.5. Confirmation of DC sensitivity to TLR agonist stimulation 
In view of the lack of activation of purified NK cells in response to TLR agonists, a brief 
study was performed to confirm the relative ability of different TLR agonists to activate 
mDC and pDC.  TLR-activated DC produce pro-inflammatory cytokines, such as IL-12, IL-
18, IL-15 and type I interferons IFN-α and IFN-β, the combination of which depends on the 
subset of DC activated, which is, in turn, dependant on the TLR ligated (Pulendran & 
Ahmed, 2006).  pDC specialise in recognition of intracellular pathogens, viruses and 
intracellular bacteria, which are innately recognised by TLR7 and TLR9 and stimulate high 
levels of type I interferons, which in turn activate Th1 T-cells and lead to the release of 
IFN-γ (Pulendran & Ahmed, 2006).  Alternatively, extracellular pathogens may be 
recognised by different TLR agonists and promote Th2 responses.  These pro-
inflammatory signals are involved in activating other immune cell populations such as NK 
cells; direct cell-to-cell contact has also been implicated in DC-induced NK cell activation.  
The co-stimulatory molecule CD40 is expressed on activated DC and has been shown to 
interact with its ligand CD40L on NK cells, leading to NK cell activation and as such has 
been used as an activation marker for DC in this assay (Carbone et al., 1997). 
Isolated PBMC from healthy donors (n=2) were stimulated for either four hours or 
overnight with the TLR4 agonist LPS (100ng ml-1) or the TLR9 agonist CpG ODN2216 
(2.5µM).  PBMC were then stained for CD123+ pDC or CD11c+ mDC (see Appendix 
Tables A.2 and A.3 for antibody panels).  Activation was analysed by measuring CD40 
expression on Lin-1-HLA-DR+CD123+ pDC or Lin-1-HLA-DR+CD11c+ mDC (see Figure 
3.5.1 for gating strategy).   
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Figure 3.5.1b shows that an increase in expression of CD40 was detected on pDC after 
four hours of stimulation with CpG ODN2216.  After overnight stimulation, upregulation of 
CD40 expression on pDC and also upregulation on mDC is observed.  Reciprocally, the 
TLR4 agonist LPS, induced the expression of CD40 on mDC after four hours of 
stimulation, and both DC subsets express CD40 following overnight stimulation.  
 
 
3.6. Peripheral blood NK and CD8+ T-cells from HIV-1+ individuals are 
refractory to in vitro TLR agonist stimulation 
Once it was established that TLR agonists could activate NK cells and CD8+ T-cells, and 
that the activation was accessory cell dependant, the potential changes in these 
responses were examined in PBMC cultures from HIV-1+ individuals.  Two different 
patient groups were studied, those who were treatment experienced, receiving HAART 
Figure 3.5.1 TLR agonists activate mDC and pDC. PBMC were stimulated for four hours and overnight 
with LPS (100ng/ml) and CpG ODN2216 (2.5µM) before dendritic cell activation was determined by flow 
cytometry.  CD40 expression was used as a marker of activation for both plasmacytoid and myeloid DC.  
a) Representative gating strategy from a healthy control individual.  b) Overlay histograms showing CD40 
expression by unstimulated (filled blue lines) or TLR agonist stimulated (unfilled red line) PBMC.  After 
overnight stimulation CD40 expression by both DC populations is induced. Graphs are representative of 
two healthy control individuals. 
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and controlling virus levels below detectable levels (plasma viral load <50 copies ml-1 
blood), and individuals who were treatment naïve, displaying detectable viraemia.  
Comparison of these two patient groups revealed the effect of active viraemia and the 
effect of treatment on innate responsiveness to TLR agonist stimulation.  All HIV-1+ 
individuals were recruited from clinics at Chelsea and Westminster Hospital, London.  
Assays were also carried out using samples from HIV-1- individuals as ‘healthy control’ 
responses.  Treatment guidelines for HIV-1 patients are constantly changing and it was 
difficult to match patients for age.  The BHIVA guidelines are moving towards treating 
patients earlier in the course of disease progression, while they still have relatively high 
CD4+ T-cell counts (BHIVA, 2012).  The current suggested time to treat when no other 
complications exist is when CD4+ T-cells fall below 350 cells µl-1; clinical guidelines for 
HIV-1 treatment can be found at http://www.bhiva.org/ClinicalGuidelines.aspx.  This early 
treatment strategy is likely to explain why the median age of the group of treatment-naïve 
patients was lower than that of treatment-experienced patients (see patient characteristics 
tables).  The influence median age difference may have on the results obtained are 
considered in the interpretation of data. 
Cultures of patient PBMC were stimulated with a range of TLR agonists at varying 
concentrations as described in section 3.2.  An initial study was carried out in order to 
establish if there are defects in responsiveness to TLR agonist stimulation within the NK 
cell or the CD8+ T-cell population.  Patient characteristics for this study are shown in Table 
3.6.1. 
 
Figure 3.6.1 shows dose response curves for frequency and mean fluorescence intensity 
(MFI) of CD69 expression by total NK cells and total CD8+ T-cells following stimulation 
with TLR agonists as shown.  Appendix Table A.14 summarises the responses to optimal 
TLR agonist concentrations, comparing CD69 frequencies (median and range) by both 
Table 3.6.1 Patient Characteristics. 
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unstimulated cells from the same subject group, and HIV-1+ responses with HIV-1- control 
individuals.   
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Pam3CSK4, flagellin and FSL-1 stimulated very little in vitro response by either NK cells or 
CD8+ T-cells in either HIV-1+ group or HIV-1- control individuals (described in section 3.2 
and shown in Figure 3.6.1).  Data also revealed significantly higher levels of basal 
activation (frequency of CD69 expression) in CD8+ T-cells from PBMC from treatment-
naïve individuals in the absence of in vitro stimulation (Figure 3.6.1c).  Higher levels of 
background CD69 expression were observed, consistent with ongoing immune activation 
in HIV-1+ individuals reported by other groups (Fogli et al., 2004).  These data also 
revealed, however, that despite this higher background, the proportion of CD8+ T-cells 
responding to TLR ligand is significantly higher in HIV-1+ treatment-naïve individuals, but 
not in treatment-experienced individuals, compared to HIV-1- individuals.  No significant 
difference was observed in the MFI for CD69 expression by CD8+ T-cells from HIV-1+ 
treatment-naïve individuals compared to the other subject groups (Figure 3.6.1d).  
Stimulation of PBMC with HKLM activated NK cells and CD8+ T-cells in all subject groups 
tested, particularly at high concentrations (1×108 cells ml-1) (Figure 3.6.1).  NK cell 
activation (frequency of CD69 expression) indicates lower responses (not statistically 
significant) in the treatment-experienced HIV-1+ individuals (Figure 3.6.1a).  These data 
also revealed that responsiveness (as assessed by frequency of CD69 expression) in 
treatment-naïve HIV-1+ individuals is maintained following HKLM stimulation, and tends to 
be greater (although not statistically significant) than in HIV-1- control individuals (Figure 
3.6.1a).  Examination of CD69+ MFI levels or CD8+ T-cell responsiveness in cultures 
stimulated with HKLM revealed no further differences between sample groups other than 
higher CD69 frequencies on CD8+ T-cells as described above (Figure 3.6.1) and a 
significantly higher MFI on CD8+ T-cells from treatment experienced individuals compared 
to healthy controls when stimulated with 108 cells ml-1 HKLM. 
Stimulation of PBMC with Imiquimod R837 activates both NK cells and CD8+ T-cells, 
although a large variation of responsiveness was seen in all sample groups (Figure 3.6.1).  
No significant differences were observed at low agonist concentration in the frequency or 
Figure 3.6.1 Early activation dose response curves. PBMC from HIV-1+, treatment-naïve & 
experienced and HIV-1- control individuals were cultured in vitro overnight with TLR agonists at varying 
concentrations.  Early activation (CD69) of a&b) NK cells and c&d) CD8+ T cells was measured using flow 
cytometry following overnight stimulation.  Data has been log transformed and the mean with 95% 
confidence intervals have been plotted.  Differences are considered significant when error bars do not 
overlap.  Transformed frequency of CD69 expression is shown in a) & c) and the MFI are shown in b) and 
d).  HIV-1- individuals (n=12) are represented by blue lines, HIV-1+ treatment-naïve individuals (n=7) are 
represented by black lines and treatment-experienced individuals (n=6) are represented by red lines.  
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MFI for CD69 expression on NK cells from different sample groups, and the increased 
overall frequency of expression on CD8+ T-cells at low agonist concentrations is likely due 
to higher background activation (Figure 3.6.1).  An increase in CD69 MFI of CD8+ T-cells 
from HIV-1- control individuals compared to treatment-experienced HIV-1+ individuals was 
observed at 2.5µg ml-1 Imiquimod R837 (Figure 3.6.1d). This demonstrates that higher 
quantities of CD69 on a per cell basis are expressed by CD8+ T-cells from HIV-1- control 
individuals (fig 3.6.1d). 
Stimulation of PBMC with Poly(I:C), ssRNA40 or CpG ODN2216 activated NK cells to 
express CD69 at high frequency in vitro.  The frequency of NK cells expressing CD69 was 
significantly greater on NK cells from HIV-1- control individuals compared to treatment-
experienced HIV-1+ individuals for ssRNA40 (at 5µg ml-1) and CpG ODN2216 (at 2.5µM) 
(Figure 3.6.1a).  Conversely, activation of total NK cells from samples was maintained in 
samples from treatment-naïve HIV-1+ individuals relative to HIV-1- control individuals 
(Figure 3.6.1a).  The pattern of NK cell activation was maintained when examining CD69+ 
MFI levels although no significant differences were observed (Figure 3.6.1b).  Stimulation 
with all three TLR agonists activated CD8+ T-cells in vitro, inducing a relatively high 
frequency of CD69 expression in all sample groups (Figure 3.6.1c).  Examination of the 
CD69+ MFI levels for CD8+ T-cells revealed that responses from both treatment-naïve and 
treatment-experienced HIV-1+ individuals were significantly reduced compared to 
seronegative samples stimulated with ssRNA40 and CpG ODN2216, but only compared to 
treatment-experienced when stimulated with Poly(I:C) (fig 3.6.1d).   
Optimal concentrations of TLR agonists were therefore selected for use in future assays 
and, because of low or variable levels of NK cell responsiveness, use of Pam3CSK4, 
HKLM, flagellin, FSL-1 and Imiquimod R837 was discontinued in further assays.  The 
optimal TLR agonist concentrations used in further assays are listed in Table 3.6.2. 
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3.7. Responsiveness to TLR agonist stimulation is maintained in the 
CD56hiCD16- NK cell subset despite chronic HIV-1 infection 
Having determined that NK cell responses in treatment-experienced HIV-1+ individuals 
were refractory to stimulation with some TLR agonists, further studies were performed. 
Samples from newly recruited groups of individuals were examined to elucidate how each 
of the two principal functional NK cell subsets (CD56hiCD16- and CD56loCD16+) were 
affected during chronic HIV-1 infection. CD56hiCD16- NK cells are stimulated to produce 
high levels of cytokines on a per cell basis and are involved in immune modulation by 
interacting with DC and helping to shape the type and magnitude of immune response 
generated (Poli et al., 2009).  CD56loCD16+ NK cells however are associated with 
cytotoxicity through innate recognition of damaged or non-self cells or adaptive recognition 
by ADCC (Caligiuri, 2008).  By examining the responsiveness of these two distinct NK cell 
subsets to TLR agonists in HIV-1 seropositive samples it was possible to interpret how NK 
cell functionality was affected by chronic infection. 
Samples obtained from treatment-naïve and treatment-experienced HIV-1+ individuals 
were again used for this study.  Patient characteristics of the different sample groups are 
shown in Table 3.7.1.  Absolute CD4+ T-cell counts and plasma viral loads are shown, in 
addition to data on the relative frequencies of DC, NK cells and NK cell subsets (Table 
3.7.1).  Consistent with previous studies, the frequency of pDC and NK cells from 
treatment-naïve patient samples were significantly reduced compared to seronegative 
samples and the frequencies of mDC tended to be lower (Donaghy et al., 2001).  There 
was also a trend towards a significant increase in KIR+ NK cells and a reciprocal decrease 
in KIR- NK cells in samples from HIV-1+ treatment-naïve individuals compared to HIV-1- 
controls (Table 3.7.1).  The frequency of peripheral blood DC and NK cells in samples 
from treatment experienced-individuals did not differ significantly to the frequencies seen 
Table 3.6.2 TLR agonists and 
concentrations used for 
titration experiments. 
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in seronegative samples, indicating effective immune cell recovery after antiretroviral 
treatment.  
 
For this study, both CD69 and CD25 were studied as activation markers.  CD25, the IL-
2Rα chain, contributes to the high affinity IL-2 receptor and mediates growth and 
proliferation in T-cells and NK cells (Janeway et al., 2005b).  Expression of CD25 is 
therefore required for optimal proliferation in response to low IL-2 concentrations, and its 
expression demonstrates that a cell is ready to proliferate should the appropriate adaptive 
signals (IL-2) be generated. 
PBMC from HIV-1 seronegative individuals and seropositive individuals, both treatment-
naïve and treatment-experienced, were cultured overnight in the presence of control 
cytokines (IL-12 + IL-15) or TLR agonists Poly(I:C) (5µg ml-1), LPS (200ng ml-1), ssRNA40 
(5µg ml-1) or CpG ODN2216 (2.5µM).  These TLR agonists were selected as they were 
consistently shown to activate both NK cells and CD8+ T-cells (Sections 3.2 and 3.6).  NK 
cell activation was studied by flow cytometry following overnight culture (Methods Section 
Table 3.7.1 Patient Characteristics 
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2.7 and antibody panel in Appendix A.4).  The expression of CD69 and CD25 was first 
examined on total CD3-CD56+ NK cells using the gating strategy shown in Figure 3.1.1.   
3.7.1. Total CD56+ NK cell responses 
Figure 3.7.1a shows the expression of CD69 on NK cells in stimulated PBMC cultures 
from HIV-1 seropositive and seronegative control individuals.  Consistent with previous 
data, NK cells in HIV-1+ individuals were sensitive to cytokine stimulation with little or no 
loss of responsiveness compared to seronegative individuals (Section 3.6).  NK cell 
responses to the TLR agonists tested were lower in HIV-1+ treatment experienced 
individuals compared to HIV-1- controls; the differences did not however reach 
significance when adjustment for multiple testing was applied. With the exception of 
ssRNA40 stimulation the frequency of CD69 was less in treatment-experience individuals 
compared to treatment-naïve individuals (figure 3.7.1a).  
 
 
Stimulation of PBMC with LPS or ssRNA40 induced the expression of CD25 on NK cells 
from HIV-1- control individuals (median, 12.85%, range 5.0-73.6% and median, 56.95%, 
range 16.5-88.4% respectively) although, little or no CD25 expression was, observed 
following stimulation with either Poly(I:C) or CpG (Figure 3.7.1b).  A significant reduction in 
the frequency of CD25+ NK cells was observed within PBMC from HIV-1+ treatment-
Figure 3.7.1 NK cell responsiveness to TLR agonist stimulation in HIV-1 infected versus 
seronegative individuals.  Graphs summarising total CD3-CD56+ NK cell a) CD69+ frequency & b) CD25+ 
frequency to overnight TLR agonist stimulation in PBMC from HIV-1+, treatment-naïve (n=11, grey bars) 
or treatment-experienced (n=13, red bars) or HIV-1- control individuals (n=17, blue bars).  Box plots 
display median, interquartile range and range. Mann-Whitney tests have been carried out with adjustment 
for multiple testing. 
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experienced individuals stimulated with ssRNA40 compared to HIV-1- controls (56.95%, 
16.5-88.4%) (p=0.0072).  
3.7.2. Different effects on CD56hiCD16- and CD56loCD16+ NK cell subset 
responses 
Recent studies have suggested that functional subsets of NK cells are developmentally 
related and that CD56hiCD16- ‘helper’ type NK cells differentiate into mature cytotoxic 
CD56loCD16+ NK cells (Beziat et al., 2011, Yu et al., 2010).  A potential linear relationship 
and differences in the maturity between these subsets raises the possibility that chronic 
viral infection could have a differential impact on their activation and functional capacity.  
In order to test the influence of chronic untreated or treated HIV-1 infection the ability of 
these distinct functional subsets within NK cells to respond to TLR agonists was tested.  
Figure 3.7.2a shows the gating strategy used to identify the different NK cell subsets 
discussed above. 
ssRNA40 stimulation of PBMC from HIV-1+, treatment-naïve individuals, resulted in a 
significantly lower proportion of  CD56loCD16+ NK cells expressing CD69 (77.4%, 42.9-
98.6%) compared to HIV-1- control individuals (91.8%, 73.2-97.4%) (p=0.0252) (Figure 
3.7.2b).  A similar pattern was also observed for ssRNA40 stimulated CD25 expression, 
which is significantly reduced within CD56loCD16+ NK cells from HIV-1+, treatment-naïve 
individuals (14.75%, 1.5-54.9%), compared to HIV-1- controls (43.8%, 7.1-71.2%) 
(p=0.0252) (Figure 3.7.3).  Similar to the responses observed within total NK cells, 
analysis of CD69 expression by the CD56loCD16+ subset stimulated with ssRNA40 
revealed a trend toward refractory NK cell responses in treatment experienced HIV-1+ 
individuals (80.0%, 25.6-99.3%) compared to seronegative samples (91.8%, 73.2-97.4%) 
(Figure 3.7.2b).  
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Figure 3.7.2 Functional NK cell subset responsiveness (CD69) in HIV-1 infected versus 
seronegative individuals following PBMC stimulation with TLR agonists. a) Gating strategy for the 
identification of the CD3-CD56+CD16+ and CD3-CD56+CD16- NK cell subsets from total CD3-CD56+ NK 
cells. b) Graph showing frequency of CD69 expression by CD3-CD56+CD16+ NK cell and CD3-
CD56+CD16- NK cells from PBMC stimulated with TLR agonists in HIV-1+, treatment-naïve (n=11, grey 
bars) or treatment-experienced (n=13, red bars) or HIV-1- control individuals (n=17, blue bars).  Box plots 
display median, interquartile range and range. Mann-Whitney tests have been carried out with adjustment 
for multiple testing. 
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Stimulation of PBMC from treatment-experienced, HIV-1+ individuals with LPS resulted in 
a reduced frequency of CD69 expression on CD56loCD16+ NK cells (34.1%, 5.9-94.1%) 
compared to HIV-1- control individuals (54.3%, 17.8-92.5%) (not significantly different), no 
obvious or significant differences were observed in CD25 expression (Figure 3.7.2b and 
Figure 3.7.3).  There was lower CD69 induction on CD56loCD16+ NK cell responses in 
HIV-1+ treatment-naive individuals stimulated with Poly(I:C) (25.65%, 3.2-76.9%) 
compared to HIV-1- control individuals (51.5%, 7.7-78.5%), also with no effect on CD25 
expression (Figure 3.7.2b and Figure 3.7.3).  No reduction in either CD69 or CD25 
induction in response to LPS or Poly(I:C) was observed in CD56loCD16+ NK cells from 
HIV-1+ treatment-naïve individuals (Figure 3.7.2b and Figure 3.7.3).  
Analysis of the CD56hiCD16- NK cell subset revealed that the frequency of CD56hiCD16- 
NK cells expressing CD69 was similar or higher in both treatment-naïve and treatment-
experienced HIV-1+ individuals compared to HIV-1- control individuals for all agonists 
tested (Figure 3.7.2b).  Remarkably, LPS stimulation of the CD56hiCD16- NK cell subset 
from treatment-naïve HIV-1+ individuals led to a significantly higher frequency of CD69 
expression (median, 59.3%; range, 2.0-93.9%) compared to HIV-1- control individuals 
(median, 27.15%; range, 11.2-84.3%) (p=0.0456) and also HIV-1+ treatment-experienced 
individuals (22.7%,8.4-83.3%) (p=0.048) (Figure 3.7.2b).  The frequency of CD69 
expression was higher on CD56hiCD16lo NK cells from HIV-1+ treatment-naïve individuals 
stimulated with CpG ODN2216 (53.5%, 10.7-84.8%) compared to HIV-1- controls (33.9%, 
14.8-66.5%) (not significantly different) (Figure 3.7.2b).   
TLR-induced expression of CD25 on CD56hiCD16- NK cells was either maintained or 
higher in chronic HIV-1 infection compared to seronegative controls (Figure 3.7.3). 
Differences in CD25 expression following stimulation with the TLR agonists tested here did 
not, however, achieve significance after adjustment for multiple testing was applied. 
These data indicate that the loss of responsiveness to TLR agonists observed in samples 
from HIV-1 seropositive individuals occurs exclusively within the major CD56loCD16+ NK 
Figure 3.7.3 Functional NK cell subset responsiveness (CD25) in HIV-1 infected versus 
seronegative individuals following PBMC stimulation with TLR agonists. Graph showing frequency of 
CD25 expression by CD3-CD56+CD16+ NK cell and CD3-CD56+CD16- NK cells from PBMC stimulated with 
TLR agonists in HIV-1+, treatment-naïve (n=11, grey bars) or treatment-experienced (n=13, red bars) or 
HIV-1- control individuals (n=17, blue bars).  Box plots display median, interquartile range and range. 
Mann-Whitney tests have been carried out with adjustment for multiple testing. 
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cell subset whilst those of the minor CD56hiCD16- NK cell subset are preserved, 
irrespective of treatment status. It is also noteworthy that the maintenance of 
responsiveness in the CD56hiCD16- NK cell subset from treatment-naïve individuals 
persists despite reduced frequencies of plasmacytoid and myeloid DC (Table 3.7.1).  
CD56hiCD16- NK cells do not express inhibitory KIR, which are increased in frequency on 
CD56loCD16+ NK cells from HIV-1 infected individuals, therefore maintenance of 
responsiveness is potentially achieved through lack of inhibition. 
3.8. ssRNA40 induces IFN-γ  production, which is maintained within 
CD56hi, but not CD56lo NK cells from HIV-1 infected individuals 
CD56hiCD16- NK cells are known potent producers of IFN-γ, secreting higher levels of this 
cytokine per cell than their CD56loCD16+ counterparts. IFN-γ production in NK cells was 
therefore measured by intracellular cytokine staining of PBMC following stimulation with 
TLR agonists.  PBMC were stimulated as described in Section 3.7 and NK cell IFN-γ 
production was studied by flow cytometry (Methods Section 2.7 and antibody panel in 
Appendix A.5).  In these experiments NK subsets were gated according to CD56hi or 
CD56lo expression.  Of the TLR agonists studied, only ssRNA40 stimulation was able to 
consistently stimulate IFN-γ production in NK cells from HIV-1- control individuals (median, 
12.2% and range, 23.0-51.8%) (Figure 3.8.1).  IFN-γ production was reduced within total 
NK cells from HIV-1+ treatment-experienced individuals (median, 5.2%, range, 2.4-40.0%) 
compared to HIV-1- controls (not significantly different) (Figure 3.8.1b).  Stimulation with 
cytokines (IL-12 + IL-15) induced low frequency IFN-γ production in NK cells from all 
sample cohorts with no significant differences in the observed responses between these 
groups (Figure 3.8.1b). 
Differences in IFN-γ production within the different NK cell subsets as well as between the 
different cohorts were also determined (Figure 3.8.1c).  ssRNA40 induced IFN-γ 
production in CD56lo NK cells was lower in both treatment-naïve (median, 3.19%, range, 
1.83-39.9%) and treatment-experienced (median, 4.7%, range, 0.8-27.9%) HIV-1+ 
individuals compared to HIV-1- individuals (median, 10.6%, range, 2.1-49.3%) although 
differences did not reach significance when adjusted for multiple testing (Figure 3.8.1c).  
Similar to the expression of CD69 and CD25, IFN-γ production was maintained within the 
CD56hi NK cell subset. Comparable proportions of IFN-γ+ cells were detected in both 
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treatment-naïve and treatment-experienced HIV-1+ individuals compared to HIV-1- 
controls (Figure 3.8.1c). 
 
 
 
3.9. KIR+ NK cells from HIV-1 seropositive individuals maintain early 
activation in vitro, whilst IFN-γ  responses are reduced 
Figure 3.8.1 NK cells produce IFN-γ  following ssRNA stimulation and responsiveness is selectively 
maintained in the CD56+CD16- NK cell population during chronic HIV-1 infection.  ssRNA stimulation 
of PBMC generates production of IFN-γ in NK cells and can also be detected in both CD56+CD16+ and 
CD56+CD16- NK cells in HIV-1- control individuals. a) Flow cytometry dot plots demonstrating IFN-γ 
production in total NK cells and subsets, either cultured overnight in tissue culture medium alone or in the 
presence of ssRNA (example shown is an HIV-1- control individual). b) IFN-γ production is detected in NK 
cells following stimulation with cytokines (IL-12 & IL-15) or ssRNA and is only produced at very low levels 
following stimulation with other TLR agonists. c) Graph displaying frequency of IFN-γ expression by CD3-
CD56+CD16+ NK cell and CD3-CD56+CD16- NK cells NK cells from HIV-1+, treatment-naïve (n=11, grey 
bars) or treatment-experienced (n=13, red bars) or HIV-1- control individuals (n=17, blue bars).  Box plots 
display median, interquartile range and range. Mann-Whitney tests have been carried out with adjustment 
for multiple testing. 
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As CD56loCD16+ NK cells are enriched for various KIR (Jacobs et al., 2001), the 
relationship between KIR expression and TLR agonist responsiveness was examined.  
Expression of KIR has been shown to be important in HIV-1 infection, displaying 
properties that enhance immunological responses against HIV-1 infection in individuals 
expressing specific HLA-B alleles (Alter et al., 2007, Martin et al., 2002).  Increased 
expression of inhibitory KIR has, however, been identified on dysfunctional NK cell 
subsets associated with chronic HIV-1 infection (Mavilio et al., 2005).  Increased KIR 
expression has also been found on CD8+ T-cells in HIV-1 infected individuals and is 
associated with non-responsiveness to TCR-dependant stimulation (Alter et al., 2008).  
Inhibitory KIR expression and interaction with their self HLA ligands is a proposed 
mechanism for NK cell education or ‘licensing’ allowing NK cells to respond to cells not 
expressing MHC molecules (Anfossi et al., 2006, Kim et al., 2005, Kim et al., 2002).  It is 
therefore possible that alteration of KIR expression will have knock on effects on overall 
NK cell responsiveness. 
Results presented demonstrate a trend for higher KIR+ NK cell frequencies in treatment-
naïve HIV-1+ individuals compared to seronegative samples (p=0.072) (Table 3.7.1).  The 
frequency of KIR+ NK cells is increased in treatment-experienced HIV-1+ individuals, 
although not statistically significant, indicating some recovery with HAART (Table 3.7.1).  
Although not examined here, it is likely that the increase in KIR expression on NK cells is 
in part due to the generation of dysfunctional NK cells found in HIV-1 infection, which are 
known to express higher frequencies of inhibitory KIR than CD56+ NK cells (Mavilio et al., 
2005).  
Early activation (CD69) and IFN-γ expression were analysed in KIR+/-CD56+ NK cells in 
response to TLR agonist stimulation, comparing HIV-1 seropositive and seronegative 
samples.  PBMC stimulated with Poly(I:C) and CpG ODN2216 demonstrated significantly 
greater CD69 expression on KIR+ compared to KIR- NK cells from HIV-1 seronegative 
samples. Poly(I:C) KIR- median 20.9% (range 6.8-66.6%) and KIR+ 29.3% (6.6-79.5%) 
(p=0.0057). CpG ODN2216 KIR- 30.3% (11.8-63.4%) and KIR+ 30.9% (15.7-73.9%) 
(p=0.0067) (Figure 3.9.1).  CD69 expression on KIR+ NK cells from HIV-1 seropositive 
individuals stimulated with Poly(I:C) or CpG ODN2216 was not significantly different to 
KIR- NK cells, and no other significant differences were observed between KIR+/- NK cells 
for any stimulation in any of the three sample cohorts.  
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In contrast to early activation, ssRNA40 or IL-12 + IL-15 stimulated a lower frequency of 
IFN-γ production within KIR+ NK cells compared to KIR- NK cells. Stimulation with IL-12 + 
IL-15 induced significantly greater IFN-γ in KIR- compared to KIR+ NK cells in samples 
from HIV-1+ treatment-naïve and treatment-experienced individuals but not in HIV-1- 
controls. Treatment naïve: KIR- 5.7% (1.0-18.7%) and KIR+ 3.4% (1.0-11.4%) (p=0.0137). 
Treatment experienced: KIR- 7.5% (1.3-26.4%) and KIR+ 3.9% (0.8-13%) (p=0.0002).  
Stimulation with ssRNA40 induced significantly greater IFN-γ production in KIR- NK cells in 
all three different sample groups. Seronegative: KIR- 15.8% (3.3-55.0%) and KIR+ 6.7% 
(1.2-40.9%) (p=0.0012). Seropositive treatment-naïve: KIR- 6.4% (2.8-53.3%) and KIR+ 
3.5 (2.0-33.2%) (p=0.0059). Seropositive treatment-experienced: KIR- 11.1% (2.0-38.9%) 
and KIR+ 4.1% (0.8-21.0%)  (p=0.002).   
Figure 3.9.1 KIR+ NK cells maintain early activation (CD69) responses to TLR agonist stimuli, but 
KIR+ NK cells show reduced IFN-γ  production in response to stimuli. Graphs display frequency of a) 
CD69 expression and b) IFN-γ production from KIR+/- NK cells from HIV-1+, treatment-naïve (n= 11, grey 
bars) or treatment-experienced (n=13, red bars) or HIV-1- control individuals (n=17, blue bars).  CD69 
expression by KIR+ cells is equal to or greater than expression by KIR- cells. IFN-γ production in the KIR+ 
NK cell population, where there is a relatively high frequency response, is reduced compared to KIR- NK 
cells. Box plots display median, interquartile range and range. Wilcoxon’s matched pairs test has been 
applied to this data. 
 
 99 
These data indicate that KIR+ NK cells are able to respond to in vitro stimulation with TLR 
leading to CD69 expression and early activation, but are less able to produce IFN-γ than 
KIR- cells.  
3.10. Discussion 
Data presented in this chapter, consistent with other studies (Wesa & Mailliard, 2010, 
Moretta et al., 2008, Iwasaki & Medzhitov, 2004, Moretta, 2002) has shown that NK cells 
and CD8+ T-cells are sensitive to TLR agonist stimulation and that stimulation is, in most 
cases, sufficient to induce early activation responses in these cells.  TLR agonists for 
intracellular TLR (Poly(I:C), Imiquimod R837, ssRNA40 and CpG ODN2216) were 
particularly potent inducers of NK cell and CD8+ T-cell early activation.  This likely reflects 
the requirement for cellular acquired immune response against infections of the kind 
associated with these PAMP.  LPS also induced a strong early activation response 
whereas other agonists (Pam3CSK, HKLM, flagellin and FSL-1) stimulated weaker or no 
activation in NK cells or CD8+ T-cells.   
NK cells have been reported to express functional TLR, notably TLR2, 3, 7, 8 and 9 
(Martinez, Huang & Yang, 2010, Sivori et al., 2010, Hart et al., 2005, Schmidt et al., 2004, 
Sivori et al., 2004).  It is worth noting that, with the exception of TLR3 (which is unusually 
expressed on the cell surface and not associated with lysosomal membranes (Hart et al., 
2005)), none were shown to be functional without accessory cell involvement or prior 
exposure to cytokines such as IL-2, IL-12 or IFN-α, although the data do not conclusively 
rule out the presence of functional TLR on NK cells.  Assays presented here demonstrate 
the inability of TLR agonists to activate isolated NK cell.  Furthermore, isolated NK cells 
are functional and retain the ability to respond to cytokine stimulation.  NK cell activation 
by TLR agonists is therefore reliant on accessory cells and NK cells are activated via 
bystander mechanisms, including the release of soluble agents by DC subsets, including 
IFN-α, IL-12, IL-15 and IL-18, which are potent activators of NK cells (Moretta et al., 2008, 
Fehniger et al., 1999) and also physical cell-to-cell interactions (Nedvetzki et al., 2007, 
Vitale et al., 2004).  Further work is necessary to fully determine whether refractory NK cell 
responses observed in these studies are due to dysfunctional NK cells and/or because of 
reduced numbers and function of dendritic cells in different patient groups.  Dendritic cell 
numbers however appear to have recovered in treatment experienced individuals relative 
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to treatment naïve individuals and therefore parallel DC functional assays would need to 
be carried out to fully solve this issue. 
Chronic innate immune stimulation is thought to occur during HIV-1 infection through 
stimulation of both TLR4 and TLR8 either as a result of HIV-1 induced damage to the gut 
leading to systemic microbial translocation, or through direct recognition of the HIV-1 
genome (Alter et al., 2007a, Brenchley et al., 2006).  Data presented here shows that LPS 
and ssRNA40 are both highly potent NK cell activators inducing not only high CD69 
expression in vitro, but also expression of the IL-2Rα chain, CD25, in HIV-1 seronegative 
individuals. NK cell proliferation was, however, not observed following stimulation with LPS 
or ssRNA alone (data not shown), indicating that TLR stimulation was therefore not 
sufficient to induce IL-2 or growth factor production in NK cells or other lymphocytes in 
vitro.  Nevertheless, the induction of CD25 expression indicates that the cells have 
become potentially more responsive to IL-2 and would therefore be ‘primed’ to proliferate 
under the appropriate conditions, such as those occurring during antigen specific T-cell 
responses.   
The data further demonstrate that chronic HIV-1 infection renders NK cells less responsive 
to TLR activation in vitro.  Interestingly, refractory NK cell responses in HIV-1 infected 
individuals were principally observed against agonists that stimulate intracellular TLR.  
Poly(I:C), ssRNA40 and CpG ODN2216 all stimulated TLR associated with endosomal 
vesicles and all demonstrated significant refractory NK cell activation as measured by 
CD69 expression in HIV-1+ treatment-experienced individuals.  Examination of the 
magnitude of CD69 expression (MFI) on CD8+ T-cells revealed the same pattern as for NK 
cell activation, showing refractory responses in samples from treatment-experienced 
individuals compared to responses in treatment-naïve individuals and seronegative 
healthy control individuals.  This is interesting since treatment-naïve individuals are likely 
to be exposed to chronic stimulation by the HIV ssRNA genome and are, in addition, more 
likely to have virally induced damage to the gut, and thus potentially ongoing microbial 
translocation (Gregson et al., 2009, Alter et al., 2007a, Brenchley et al., 2006).  Higher 
baseline activation of CD8+ T-cells was, however, observed in unstimulated cultures from 
treatment-naïve individuals, which could partially account for the apparent maintenance of 
responsiveness.  The MFI values for TLR-mediated stimulation of CD8+ T-cells revealed 
that although cells from treatment-naïve individuals express a higher frequency of CD69, 
 101 
they do so at a lower magnitude than in healthy control samples and so might have 
impaired functionality on a per cell basis.  
Continued examination of NK cell activation in HIV-1 infection further revealed 
responsiveness to LPS and ssRNA40 as being deficient compared to healthy controls.  NK 
cells from treatment-naïve individuals were refractory to stimulation with ssRNA40, 
displaying refractory responses in both CD69 and CD25 expression.  The lack of 
responsiveness following stimulation with ssRNA40 in these treatment-naïve individuals 
indicates impairment; possibly due to ongoing chronic stimulation of TLR8 by the HIV-1 
viral genome as these individuals have active viraemia.  It must be considered that the 
refractory responsiveness could simply stem from the reduced function and frequency of 
peripheral blood DC populations.  If it is the case that ongoing chronic viraemia reduces 
the ability of innate immune cells to respond to PAMP, it would have implications for the 
immunodeficiency of patients and also, therefore, the potential of using TLR agonists as 
adjuvants in immunotherapies.  
Examination of NK cell subset activation responses demonstrated that the refractory 
responses seen during HIV-1 infection discussed above were found exclusively within the 
CD56loCD16+ NK cell subset and that responsiveness was, by contrast, maintained in the 
CD56hiCD16- subset.  The significant decrease in responsiveness of CD56loCD16- NK 
cells from treatment-naïve individuals following ssRNA40 stimulation indicated that these 
cells had been chronically stimulated prior to in vitro stimulation and that the functional 
capacity of these cells may be impaired.  Preservation of responsiveness in CD56hiCD16- 
NK cells from treatment-naïve individuals was observed despite a reduction in frequency 
of peripheral blood DC populations. This indicates that these NK cells have a lower 
threshold for DC-dependent activation, likely due to the lack of inhibitory KIR expression, 
or that other accessory cells in human peripheral blood are involved.  These possibilities 
were investigated for certain TLR agonists in subsequent chapters 4 and 5, particularly 
section 4.2 (which examines the differentiation of CD56hiCD16- NK cells) and section 5.7 
(which demonstrates a partial requirement of DC in the recovery of recall of antigen 
specific immune responses).  Stimulation with LPS led to greater activation of 
CD56hiCD56- NK cells from treatment-naïve individuals compared to healthy controls.  It 
could be speculated that these cells are already partially activated in vivo by endotoxin as 
a result of microbial translocation and that responses are boosted by further recruitment of 
activated cells in-vitro.   
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The refractory responses occurring in the CD56loCD16+ NK cell subset might also be 
associated with chronic stimulation; it has been suggested that this subset is 
developmentally more mature (this is discussed in the following chapter) and as such is 
more likely to have become exhausted (Beziat et al., 2011, Yu et al., 2010, Freud & 
Caligiuri, 2006).  Activation of the CD56loCD16+ NK cell subset did not recover, even after 
decreases in patient NK cell and DC frequencies were reversed post-therapy. This again 
raises the possibility that a proportion of NK cells remain functionally deficient, or that 
accessory cell populations have not functionally recovered, despite successful treatment 
and recovery of normal cell frequencies.  Anti-retroviral treatment itself may also affect 
responsiveness, which could explain the differences observed between treatment 
experienced and treatment naïve individuals. 
Of the agonists tested, only stimulation of PBMC with ssRNA40 or cytokines was able to 
induce IFN-γ production in NK cells at a high frequency.  This again demonstrated the 
potency of ssRNA as a TLR agonist, and the impact that refractory responses may have 
on NK cell function.   A similar pattern of responsiveness was observed when PBMC from 
HIV-1 seropositive individuals are stimulated with ssRNA40 as has previously been 
described.  Total NK cells from treatment-experienced samples were refractory to 
stimulation, and CD56lo NK cell responses from both treatment-experienced and 
treatment-naïve individuals were refractory.  Refractory IFN-γ production could have 
consequences for the development of a Th1-type acquired immune response, as NK 
derived IFN-γ is known to feedback to DC and promote a cellular immune response 
(Andoniou, Coudert & Degli-Esposti, 2008). Encouragingly the CD56hi NK cell subset from 
HIV-1 samples remained responsive to ssRNA40 stimulation in vitro and produced IFN-γ 
at a higher frequency than CD56lo NK cells. 
KIR expression on CD56loCD16+ NK cells was increased in chronic HIV-1 infection, in 
keeping with previous reports (Mavilio et al., 2005, Alter et al., 2004b, Mavilio et al., 2003), 
with partial recovery observed in treatment-experienced individuals.  Interestingly, early 
activation (CD69 expression) was maintained following TLR agonist stimulation in KIR+ NK 
cells from HIV-1 seropositive individuals, although it has previously been shown that there 
is increased activation of NK cells in HIV-1 infected individuals (Alter et al., 2004b).  
Examination of more functional IFN-γ responses revealed KIR+ NK cells were, however, 
less responsive than KIR- cells.  As discussed above this is unsurprising given that 
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specialist cytokine producing CD56hiCD16- NK cells were found exclusively within the KIR- 
NK subset and that KIR+ NK cells are inhibited in an MHC-I sufficient environment.  There 
did, however, appear to be a knock on effect of HIV-1 infection, as there were higher 
frequencies of inhibitory KIR+ NK cells observed in chronic HIV-1 infection.  Combined with 
the decreased levels of NCR also observed in CD56loCD16+ NK cells, this indicates these 
cells are less responsive and contribute to pathology in HIV-1 infection as previously 
reported (Mavilio et al., 2005).  The frequency and responsiveness CD56-CD16+ NK cells 
was not examined here, but they are also known to have increased levels of inhibitory KIR 
expression and reduced levels of NCR and are unresponsive to stimulation (Mavilio et al., 
2005). 
3.11. Summary 
This chapter has explored innate immune activation in response to TLR agonist 
stimulation, with particular focus on NK cell activation. CD8+ T-cell activation was also 
demonstrated, and the requirement for accessory cells to generate these responses was 
shown. 
Refractory innate cell responses to TLR agonist stimulation in chronic HIV-1 infection were 
observed in NK cells and CD8+ T-cells.  Refractory responses were particularly evident in 
the treatment-experienced HIV-1 seropositive sample group, despite all samples having 
undetectable viraemia and recovering CD4+ T-cell frequencies.  Refractory responses 
observed following LPS and ssRNA40 stimulation were particularly revealing as both have 
been implicated to have a role in chronic immune activation seen in HIV-1 infection (Alter 
et al., 2007a, Brenchley et al., 2006).  Further break down of NK cell responses into the 
two functionally distinct subsets based on CD56 and CD16 expression revealed that 
refractory responses were confined exclusively to the CD56loCD16+ NK cell subset, and 
that responses within the CD56hiCD16- subset were comparable to (or were in some cases 
higher than) those observed in seronegative control samples. 
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4. Effect of chronic HIV-1 infection on natural killer cell 
maturation and cell survival 
Aim 
Data presented in the previous chapter established a normal range for NK cell and CD8+ 
T-cell activation responses to TLR agonist stimulation and the effect of chronic HIV-1 
infection. In this chapter, experiments to investigate the effect of infection on the 
maturational stages of peripheral blood NK cells, and the effect of treatment on these 
subsets are described.  Assays were carried out with the aim of demonstrating how 
chronic HIV-1 infection affected NK cell maturation and survival in vitro.  Furthermore, the 
capacity of PAMP to affect maturation in NK cells from HIV-1 negative healthy control 
individuals was determined through the expression of NK cell maturation markers. 
Comparisons were then made with expression of the same markers in HIV-1 infected 
individuals. 
Introduction 
It is known that dysfunctional NK cells are generated in chronic HIV-1 infection, preventing 
normal activation and full responsiveness to stimuli (Mavilio et al., 2005).  It is also well 
established that CD8+ T-cells are skewed toward more mature and exhausted phenotypes 
in HIV-1 infection (Champagne et al., 2001).  Given the parallels between CD8+ T-cell 
development and NK cell development (Sun & Lanier, 2011), it is likely that NK cells are 
also skewed to a more mature state during chronic HIV-1 infection.   
Current models of differentiation of human blood NK cells suggest that CD56hiCD16- NK 
cells are replenished from the bone marrow from CD56hiCD16-c-
Kit+CD62L+CD94/NKG2A+ precursors (which also lack perforin or KIR expression) initially 
migrating to peripheral lymphoid tissues (Chan et al., 2007, Romagnani et al., 2007, Farag 
& Caligiuri, 2006).  Activation of CD56hiCD16- cells in vitro leads to the loss of c-Kit and the 
acquisition of CD16 and other markers of cytotoxic NK cells (Romagnani et al., 2007, 
Farag & Caligiuri, 2006).  Such a lineage relationship is supported by recent studies 
demonstrating that CD94 defines three peripheral blood NK cell populations with distinct 
functional maturity, with CD94highCD56brightCD16- cells being the least mature, 
CD94lowCD56dimCD16+ the most highly differentiated, and a population of 
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CD94brightCD56dim NK cells showing intermediate expression and functional capacity (Yu et 
al., 2010).  Another recent study by Béziat et al (2011) demonstrated a different 
intermediate NK cell population, defined as CD56brightCD16+, that are capable of producing 
large quantities of cytokine and also demonstrate potent cytotoxic capabilities.  Further 
evidence that CD56dimCD16+ NK cells represent a mature population has been 
demonstrated through their shorter telomere length compared to CD56brightCD16- cells 
(Chan et al., 2007, Romagnani et al., 2007).  
Previous studies have indicated that the CD56loCD16+ NK cell subset is preferentially 
reduced in frequency during chronic HIV-1 infection, leading to the emergence of a 
dysfunctional pre-apoptotic, CD56-CD16+ subset (Mavilio et al., 2005, Mela et al., 2005).  
This raises the possibility that chronic immune activation during HIV-1 infection leads to 
the accelerated differentiation of CD56hiCD16- NK cells into CD56loCD16+ NK cells and 
eventually into the CD56-CD16+ subset.  CD56hiCD16- NK cells can be considered the 
least mature of NK cell subsets within peripheral blood and are likely to be the least 
exposed to chronic activation, being constantly replenished from the bone marrow 
(Romagnani et al., 2007, Farag & Caligiuri, 2006, Ferlazzo et al., 2004).  Such a 
replenishment of CD56hiCD16- NK cells is consistent with the maintenance of the 
activation and cytokine responses to TLR ligands demonstrated in Chapter 3.   
Utilising the phenotypic markers of functional maturation described by Yu et al and Béziat 
et al, the potency of TLR agonists or cytokines for promoting maturation of CD56hiCD16- 
NK cells in vitro was examined here (Beziat et al., 2011, Yu et al., 2010).  The frequency of 
different maturational stages of NK cells was also assessed during HIV-1 infection, and the 
ability of PAMP to further influence maturation or survival in these samples studied.  
Finally, factors involved in cellular maturation were measured in the plasma from control 
and HIV-1 seropositive individuals. 
4.1. Phenotypic analysis of maturational markers on freshly isolated 
and in vitro cultured NK cells 
There is evidence that chronic immune activation likely impacts on NK cell maturation and 
function (discussed in Section 1.6.4), particularly with regard to the generation of the 
dysfunctional CD3-CD56-CD16+ NK cell population (Mavilio et al., 2005, Mela et al., 2005).  
c-Kit, the receptor for stem cell factor, is expressed by CD56hiCD16- NK cells, but is 
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absent on the more cytotoxic CD56loCD16+ subset.  It is therefore postulated that the 
CD56hiCD16- NK subset represents a less mature cell population, potentially giving rise to 
CD56loCD16+ NK cells as they mature (Caligiuri, 2008, Romagnani et al., 2007, Freud et 
al., 2005, Ferlazzo et al., 2004, Carson, Fehniger & Caligiuri, 1997).  CD94, which 
associates with NKG2A, B, C, E and H (whose ligands are self HLA-E molecules) 
(Caligiuri, 2008), represents a further marker useful for NK cell maturation studies (Yu et 
al., 2010).  NK cell maturation was therefore examined ex vivo using a model for human 
NK cell maturation based on the expression of c-Kit on NK cell subsets, defined by CD56 
and CD16 expression.  Data were corroborated using CD94 and CD56 expression to 
define NK cell maturational stages.  These NK cell populations were compared between 
healthy control individuals (n=12) and HIV-1 seropositive individuals from both treatment-
naïve (n=9) and treatment-experienced individuals (n=12).  Patient characteristics for this 
study are shown in Table 4.1.1.  
 
PBMC from healthy donor peripheral blood were stained ex vivo for CD3, CD56, CD16, 
CD94 and c-Kit (CD117) (see Appendix Table A.6 for full details).  For analysis of c-Kit on 
freshly isolated cells, NK cell populations were firstly gated into four subsets based on 
CD56 and CD16 expression within a CD3- gate on lymphocytes (Figure 4.1.1a). 
CD56hiCD16-, CD56hiCD16lo, CD56loCD16+ and CD56-CD16+ subset were included to 
avoid any bias when comparing HIV-1 seronegative with seropositive samples, the latter of 
which is potentially enriched for these NK cells.  c-Kit expression was then examined on 
these subsets using the gating strategy described by Béziat et al. (2011).   
Table 4.1.1 Patient Characteristics 
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Analysis of CD56hiCD16- NK cell frequencies revealed that they were significantly reduced 
in HIV-1+ treatment-naïve (median 2.7%, range 0.4-9.6%, p=0.04) and treatment-
experienced (median 2.5%, range 0.6-19.9%, p=0.02) individuals compared to 
seronegative controls (median 7.8%, range 2.5-17.9%) (Figure 4.1.1b).  This finding was 
likely influenced by the fact that the analysis included the dysfunctional CD56-CD16+ NK 
Figure 4.1.1 NK cell maturation – c-Kit expression. a) Gating strategy demonstrating the four NK cell 
populations based on CD56 and CD16 expression within CD3- lymphocytes; CD56hiCD16-, CD56hiCD16lo, 
CD56loCD16+ and CD56-CD16+ and the c-Kit expression within each subset. b) Graph displaying the 
frequency of NK cell subsets as a proportion of total NK cells in HIV-1- control and HIV-1+ individuals, 
both treatment-experienced and naive. c) Graph displaying frequency of c-Kit expression as a percentage 
of the NK cell subsets shown in in HIV-1- control and HIV-1+ individuals, both treatment-experienced and 
naïve. HIV-1- control (HC, n=12, blue bars), HIV-1+ treatment-naïve (TN, n=9, grey bars) and experienced 
(TD, n=12, red bars) individuals. Box plots display median, interquartile range and range. Mann-Whitney 
tests have been carried out. 
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cell population, the frequency of which was significantly less in HIV-1- controls (median 
13.0%, range 4.4-24.6%) compared with HIV-1+ treatment-naïve (median 29.7%, range 
12.0-46.5%, p=0.004) and treatment-experienced individuals (median 16.6%, range 8.9-
56.4% p=0.039) in (Figure 4.1.1b).  There was no significant difference in frequency 
between sample groups for either the CD56hiCD16lo or the CD56loCD16+ subsets although 
a reduction in the median percentage was observed for the latter in treatment-naïve HIV-
1+ individuals (not significant), consistent with previously published data (healthy controls: 
median 76.2%, range 59.3-89.0%; treatment-naive: median 68.9%, range 47.1-86.6%) 
(Mavilio et al., 2003). 
c-Kit expression was analysed on each of the four NK cell subsets defined above (Figure 
4.1.1c).  For analysis of this data, isotype control staining using a phycoerythrin-
conjugated mouse IgG1k antibody was subtracted from the values for c-Kit.  In addition to 
observing a lower frequency of CD56hiCD16- NK cells in HIV-1+ individuals, it was found 
that there was a significantly lower frequency of c-Kit expressed by this subset both in HIV-
1+ treatment-naïve (median 56.2%, range37.7-76.7%) and treatment-experienced (median 
56.9%, range 19.8-78.7%, p=0.039) individuals compared to HIV-1- control individuals 
(median 74.5%, range 53.7-89.5%, p=0.0098).  Lower frequencies of c-Kit+ cells were 
observed within the CD56hiCD16lo NK cell subset in all three groups of individuals, 
compared to that observed within CD56hiCD16- NK cells, consistent with a loss of this 
marker on maturation (HIV-1- controls: median 32.4%, range 7.3-57.4%; HIV-1+ 
treatment-naïve: median 22.0%, range 8.0-40.8%; treatment-experienced: median 24.0%, 
range 5.8-64.5%).  Although the HIV-1 seropositive patient groups had a lower median 
proportion of c-Kit expressing cells within CD56hiCD16lo cells, there was no significant 
difference in the frequency of c-Kit expression between groups of individuals, consistent 
with this being an intermediary subset that is replenished from the CD56hiCD16- subset.   It 
is clear from this data that neither CD56loCD16+ NK cells nor CD56-CD16+ NK cells 
expressed any significant level of c-Kit, consistent with the relative maturity of these 
subsets.  
Figure 4.1.2a shows the gating strategy used to examine NK cell maturation in three 
subsets defined by CD94 expression (Yu et al., 2010): CD56hiCD94+, CD56loCD94+ and 
CD56loCD94- (although Yu et al describe these subsets as CD94highCD56bright, 
CD94highCD56dim and CD94lowCD56dim respectively).  Yu et al. (2010) describe the 
CD56loCD94+ subset as an intermediary subset with the ability to produce high levels of 
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cytokine in response to stimuli and also to carry out cytotoxic effector functions.  No 
significant differences were found between groups of individuals in any of the three CD94-
defined subsets. However, consistent with the data for c-Kit expression, a reduction in the 
median proportion of NK cells within the CD56hiCD94+ subset and a reciprocal increase in 
the median proportion of cells in the CD56loCD94- subset was observed in HIV-1 
seropositive treatment-experienced individuals whilst the frequency of CD56loCD94+ varied 
little between groups (Figure 4.1.2b). 
c-Kit and CD94 expression are both useful determinants of NK cell maturation and were 
used to determine changes in maturation brought about by TLR agonist stimulation 
discussed in the following sections.  
 
 
4.2. CD56hiCD16- NK cells lose expression of CD94 and c-Kit when 
stimulated in vitro with cytokines and TLR agonists. 
Figure 4.1.2 NK cell maturation – CD94 
expression.  a) Gating strategy demonstrating NK 
cell populations based on CD56 and CD94 
expression within CD3-CD56+ NK cells; 
CD56hiCD94+, CD56loCD94+, CD56loCD94-. b) 
Graph displaying the frequency of the three NK 
cell subsets shown as a proportion of total NK 
cells in HIV-1- control and HIV-1+ individuals, 
both treatment-experienced and naive. HIV-1- 
control (HC, n=12, blue bars), HIV-1+ treatment-
naïve (TN, n=9, grey bars) and experienced (TD, 
n=12, red bars) individuals. Box plots display median, 
interquartile range and range. Mann-Whitney tests 
have been carried out. 
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In order to determine whether CD56+CD16- NK cells could progress toward CD56loCD16+ 
cells, NK cells were depleted from healthy donor PBMC (n=2) and then reconstituted for 
culture with autologous isolated CD56hiCD16- NK cells as described in Sections 2.9.2 and 
2.9.3.  Figure 4.2.1 demonstrates the different steps in the procedure, showing the 
phenotype of PBMC before (upper panels) and after (middle panels) NK cell depletion and 
reconstitution with CD3-CD56hiCD16- NK cells (lower panels).  Cells were then cultured for 
six days in medium alone or with the cytokines IL-12 (1ng ml-1) and IL-15 (20ng ml-1) or the 
TLR agonists LPS (200ng ml-1) or ssRNA40 (5µg ml-1).  Figure 4.2.2 shows the results 
from a single representative individual of two tested.  When cultured in medium alone 
90.4% of reconstituted NK cells remain CD56hiCD16- (for the individual shown) compared 
to 88.6% in the equivalent freshly reconstituted (day 0) sample and 90.3% of NK cells 
remain CD56hiCD94+ compared to 91% in the freshly reconstituted sample.  Interestingly, 
the frequency of c-Kit+ NK cells increased from 42.7% compared to 74.2% in the ex vivo 
reconstituted sample shown after overnight culture in medium alone (Figure 4.2.2, centre 
panels).  
In the example shown, stimulation of cells with cytokines or with the TLR agonists LPS or 
ssRNA40 reduced the frequency of CD56hiCD16- NK cells.  Conversely, an increase in the 
frequency of CD56loCD16+ cells was observed in the presence of cytokines, LPS or 
ssRNA40, consistent with a redistribution of NK cell subsets towards a more mature 
phenotype (Figure 4.2.2). 
A reduction in the frequencies of c-Kit+ and CD56hiCD94+ NK cells was observed when 
stimulated with cytokines (IL-12 and IL-15) and the TLR agonists LPS and ssRNA40.  A 
reciprocal rise was observed in the frequency of the most mature CD56loCD94- subset 
after stimulation, again consistent with progressive differentiation (Figure 4.2.2 and Tables 
4.2.1 and 4.2.2).  
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Figure 4.2.1 NK cell depletion and CD56hiCD16- NK cell reconstitution. Dot plots demonstrating the 
various stages for removing CD56loCD16+ NK cells. Total NK cells were removed from PBMC and in 
parallel CD56hiCD16- cells were isolated and then added back into NK depleted PBMC. 
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A full summary of data from two individuals is shown in Tables 4.2.1 and 4.2.2.  Data from 
sample one clearly demonstrated NK cell maturation in response to stimulation and is 
Figure 4.2.2 CD56hiCD16- NK cells lose CD56hi, CD94 and c-Kit expression and gain CD16 
expression following TLR agonist stimulation.   CD56loCD16+ NK cell depleted PBMC were cultured in 
the presence of different TLR agonists and cytokines for 6 days and the resulting changes in differentiation 
markers was measured by flow cytometry.  Dot plots demonstrating that some CD56hiCD16- NK cells, 
which express both CD94 and c-Kit become CD56loCD16+ NK cells and that those NK cells lose CD94 
expression.  Furthermore c-Kit expression is being lost from all NK cells following stimulation. Dot plot from 
a single healthy control individual and representative of 2 separate individuals. 
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described above.  Sample two followed a similar pattern to sample 1, but data were 
skewed for cytokine and ssRNA40 stimulation where a higher intensity stain for CD56 was 
observed.  c-Kit frequency was, however, reduced in stimulated cultures for sample two 
and LPS stimulation did not appear to affect CD56 expression, demonstrating that NK 
cells were induced to mature as was seen in sample one.  A small increase in the 
proportion of CD16+ cells was observed in both individuals tested after stimulation of 
reconstituted cultures with cytokines, LPS or ssRNA40, although this did not account for 
the observed loss in CD56hic-Kit+ cells.  It is likely however that the six-day assays did not 
permit sufficient time for full differentiation and for CD16 expression to occur.  Others have 
demonstrated induced CD16 expression after stimulation for longer periods of 10 or 14 
days  (Beziat et al., 2011, Chan et al., 2007).  However, a reduction was observed in both 
individuals in the proportion of CD56hiCD94+ cells with reciprocal increases in the 
proportions of CD56loCD94+ and CD56loCD94- cells, indicating that an early progression of 
differentiation may be occurring.  Assays such as this serve as a useful model to examine 
how chronic stimulation with PAMP such as endotoxin and viral RNA affects NK cell 
maturation in vivo in HIV-1 infection. 
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Table 4.2.1 Frequencies of NK cell 
differentiation groups from freshly isolated 
PBMC and NK cell depleted CD56hiCD16- NK cell 
reconstituted PBMC. 
 
Table 4.2.2 Frequencies of NK cell 
differentiation groups from PBMC and NK cell 
depleted CD56hiCD16- NK cell reconstituted 
PBMC cultured for 6 days in the conditions 
shown. 
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4.3. Reduced frequencies of CD94+ and c-Kit+ NK cells are maintained 
in PBMC cultures from HIV-1 infected individuals. 
In order to establish the impact of chronic HIV-1 infection on NK cell maturation, in vitro 
culture assays using PBMC were carried out.  PBMC from HIV-1 seropositive individuals 
who were treatment-naïve and viraemic, or treatment-experienced with undetectable 
viraemia, were cultured for six days in culture medium. The frequencies of the different 
maturational groups were examined and compared to the frequencies of the same 
populations in HIV-1 seronegative individuals.  Patient characteristics for this study were 
shown previously in Table 4.1.1.  As it was demonstrated in Section 4.1.1 that c-Kit is only 
expressed on CD56hi NK cells, CD56hic-Kit+ cells were compared with CD56loc-Kit- NK 
cells in this analysis.  A lower frequency of total CD56hic-Kit+ cells was observed in 
treatment-naïve (median 3.2%, range 0.5-12.0%) and treatment-experienced (median 
1.9%, range 0.5-7.3%) HIV-1+ individuals compared to HIV-1 seronegative controls 
(median 5.0%, range 2.1-14.2%), although this did not reach significance (Figure 4.3.1). 
After six days in vitro culture in medium alone, ex vivo differences persisted, becoming 
statistically significant in samples from both treatment-experienced and treatment-naïve 
HIV-1 seropositive compared to seronegative individuals.  There was a significantly higher 
frequency of c-Kit+ NK cells from seronegative samples after six days (median 7.1%, range 
3.6-39.6%) compared to both treatment-naïve (3.7%; 0.4-10.3%) and treatment-
experienced (3.5%; 0.2-13.4%) seropositive samples (p=0.0251 and p=0.0209 
respectively) (see Figure 4.3.1).  Correspondingly, there was a significantly greater 
frequency of c-Kit negative NK cells in both treatment-naïve (93.6%; 82.8-98.5%) and 
treatment-experienced (94.3%; 78.5-99.2%) compared to seronegative (76.4%; 43.7-
93.0%) samples (p=0.006 and p=0.004 respectively) (see Figure 4.3.1).  The differences 
observed appeared to be as a result of a spontaneous enrichment of CD56hic-Kit+ NK cells 
in healthy control individuals.  This observation was consistent with data presented in 
Section 4.2 where a spontaneous rise in CD56hic-Kit+ was also observed.  The mechanism 
driving this phenomenon is not clear, but it is possible that loss of mature cells was seen 
as an enrichment of this less mature subset.  Alternatively, there is a possibility that the 
CD56hic-Kit+ NK cells were proliferating and this could account for the increased frequency 
of this population.    
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Similar changes were observed in the expression of CD94 on NK cells during in vitro 
culture (Figure 4.3.2).  A reduction in the median frequency of CD56hiCD94+ cells was also 
observed within NK cells from treatment-experienced HIV-1+ individuals compared to 
seronegative controls and HIV-1+ treatment-naïve individuals, although this difference did 
not reach significance (Figure 4.3.2 and see Table 4.3.1 for medians and ranges).  A 
reciprocal increase in the median frequency of CD56loCD94- NK cells was observed in 
HIV-1+ treatment-experienced individuals compared to HIV-1 seronegative and HIV-1+ 
treatment-naïve individuals.  The median frequency of CD56loCD94+ NK cells remained 
Figure 4.3.1 Spontaneous increase in c-Kit- NK cells from HIV-1+ individuals following 6 days 
unstimulated culture of PBMC and stimulation with cytokines or TLR agonists does not further reduce 
c-Kit+ NK cell frequencies in HIV-1+ patient groups. PBMC cultured in the presence of cytokines and TLR 
agonists for 6 days does not lead to further decreases in CD56hic-Kit+ NK cell frequency expression as those 
observed after culture in medium alone.  Blue bars (HC-Healthy Control, n=12) – HIV-1- control; grey bars 
(TN, n=9) – HIV-1+, treatment-naïve; red bars (TD, n=12) – HIV-1+, treatment-experienced individuals. Box 
plots display median, interquartile range and range. Mann-Whitney tests have been carried out. 
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consistent between groups (Figure 4.3.2 and see Table 4.3.1 for medians and ranges).  
Similar to the effects observed on c-Kit+ NK cells, leaving cells unstimulated for six days in 
vitro culture resulted in significant differences between sample groups.  The frequency of 
CD56hiCD94+ NK cells in HIV-1+ treatment-naïve and treatment-experienced individuals 
was significantly less than in HIV-1- controls (p=0.0086 and p=0.0185 respectively) (Figure 
4.3.2 and Table 4.3.1).  No significant difference was observed between sample groups for 
the intermediate CD56loCD94+ NK cell group in either freshly isolated PBMC or after six 
days culture across the different sample groups.  A significantly higher frequency of 
CD56loCD94- NK cells were observed in samples from treatment-experienced HIV-1+ 
individuals after six days in vitro culture compared to seronegative controls (p=0.0062) 
(Figure 4.3.2).  Data for spontaneous change in frequency of CD94 populations is shown 
in full in Table 4.3.1. 
This data either indicates a shift from CD56hic-Kit+ to CD56loc-Kit- NK cells and a shift from 
CD56hiCD94+ to CD56loCD94- NK cells or preferential survival or proliferation of the 
CD56hic-Kit+ and CD56hiCD94+ populations or the loss of CD56loc-Kit- and CD56loCD94- 
NK cells with no apparent influence on the intermediate, CD56loCD94+ population.  
 
Table 4.3.1 Median frequencies and ranges (%) of CD56hiC94+, CD56loC94+ and CD56loC94- NK 
cells from total CD3-CD56+ NK cell populations on freshly isolated PBMC and on PBMC 
cultured for six days without stimulation. 
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4.4. Cytokine and TLR agonist stimulation does not further reduce low 
c-Kit frequencies observed in HIV-1 sample groups 
In Addition to establishing that frequencies of NK cells from HIV-1 infected individuals were 
spontaneously changing in vitro, the effects of stimulation with the cytokines IL-12 (1ng ml-
1) and IL-15 (20ng ml-1) and the TLR agonists LPS (200ng ml-1) and ssRNA40 (5µg ml-1) 
were also examined.  Appendix Table A.15 shows a full summary of the median 
frequencies and ranges of CD56hic-Kit+ and CD56loc-Kit- NK cell populations following 
stimulation. 
Figure 4.3.2 Spontaneous decrease in frequency of CD94+ NK cells and corresponding increase 
in CD94- NK cells from HIV-1+ individuals following 6 days unstimulated culture of PBMC and 
Stimulation with cytokines and LPS further reduces CD94 frequencies in HIV-1+ individuals. 
Stimulation with cytokines and LPS further reduces CD94 frequencies in HIV-1+ individuals.  PBMC 
cultured in the presence of cytokines or LPS for 6 days leads to further decreases in CD94 expression 
as those observed after culture in medium alone and the pattern is maintained with ssRNA stimulation. 
Blue bars (HC-Healthy Control, n=12) – HIV-1- control; grey bars (TN, n=9) – HIV-1+, treatment-naïve; 
red bars (TD, n=12) – HIV-1+, treatment-experienced individuals. Box plots display median, 
interquartile range and range. Mann-Whitney tests have been carried out. Day 0 graph repeated from 
figure 4.1.2b. 
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There was a significantly lower frequency of CD56hic-Kit+ NK cells after six days culture 
with IL-12 and IL-15 in PBMC from treatment-experienced individuals compared to 
seronegative individuals (p=0.0012) (Figure 4.3.1), however no such difference is 
observed for treatment-naïve individuals.  A significantly greater frequency of CD56loc-Kit- 
NK cells was observed in HIV-1+ treatment-experienced individuals compared to 
seronegative controls (p=0.0004), but samples from treatment-naïve individuals were not 
significantly different to seronegative controls, but did have a significantly lower frequency 
of CD56loc-Kit- NK cells than treatment-experienced individuals (p=0.0037) (Figure 4.3.1). 
Interestingly, stimulation with LPS revealed no significant differences in frequency of 
CD56hic-Kit+ NK cells across the different sample groups.  The same pattern of 
significantly higher frequencies of CD56loc-Kit- NK cells in both treatment-naïve and 
treatment-experienced HIV-1+ individuals compared to HIV-1- controls (p=0.0268 and 
p=0.0205 respectively) (Figure 4.3.1) was observed as was seen for spontaneous 
changes observed in unstimulated cultures seen in Section 4.3.  Stimulation of PBMC with 
ssRNA40 for six days did not induce changes in c-Kit expression that were significantly 
different between sample groups in either the CD56hic-Kit+ or CD56loc-Kit- NK cells subsets 
(Figure 4.3.1). 
4.5. CD56hiCD94+ NK cell populations are higher or preserved in HIV-1- 
and HIV-1+ treatment-naïve individuals when stimulated with 
cytokines and LPS 
Continuing from section 4.4, frequencies of NK cell maturation populations based on CD56 
and CD94 expression in response to six day in vitro stimulation with the cytokines IL-12 
and IL-15 and the TLR agonists LPS and ssRNA40 was studied.   
Stimulation with cytokines led to an increased frequency of CD56hiCD94+ NK cells in 
samples from HIV-1 seronegative individuals such that the frequency was significantly 
greater than in either treatment-naïve (p=0.0037) or treatment-experienced (p=0.0003) 
HIV-1+ individuals (Figure 4.3.2).  The Frequency of this population in HIV-1+ treatment 
naïve individuals has also increased such that it is significantly higher than in treatment-
experienced individuals (P=0.0021) (Figure 4.3.2). A significantly higher frequency of 
CD56loCD94- NK cells from seropositive treatment-experienced individuals compared to 
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both seronegative and seropositive treatment-naïve individuals was also observed 
(p=0.0003 and p=0.0012 respectively) (Figure 4.3.2). 
The cause of the change in frequency is unclear, however increased intensity of CD56 
staining has previously been observed with prolonged cytokine stimulation.  It is however 
interesting that the phenomenon occurs to a lesser degree in samples obtained from HIV-
1+ individuals suggesting either proliferation of the subset or the loss of other populations 
such that the frequency of this population is increased.  Appendix Table A.16 shows a full 
summary of the median frequencies and ranges of CD56hiCD94+, CD56loCD94+ and 
CD56loCD94- NK cell populations following stimulation.  
A similar pattern of expression was found for LPS stimulation except significant differences 
did not arise between the two HIV-1 seropositive sample groups.  Furthermore, the 
changes observed in the presence of LPS or ssRNA40 mirrored those observed in 
cultures left in medium alone for six days, although differences between groups achieved 
greater statistical significance (Figure 4.3.2). 
A significantly higher frequency of CD56hiCD94+ NK cells was observed in LPS stimulated 
HIV-1- individuals compared to seropositive treatment-naïve and treatment-experienced 
individuals (p=0.0037 and p=0.0025 respectively) (Figure 4.3.2).  A significantly higher 
frequency of CD56loCD94- NK cells was present within NK cells from treatment-
experienced seropositive compared to seronegative samples (p=0.0002) (Figure 4.3.2).  
No differences in frequency between CD56hiCD94+ NK cells between sample groups were 
observed in ssRNA40 stimulated cultures, a greater frequency of mature CD56loCD94- NK 
cells was, however, observed in samples from HIV-1+ treatment-experienced individuals 
compared to HIV-1- controls (p=0.0252) (Figure 4.3.2). 
These data and the data presented in Section 4.4 provide evidence that LPS and 
ssRNA40 stimulation resulted in the preservation of, or increase in, NK cell populations 
with a less mature phenotype in HIV-1- individuals compared with HIV-1+ individuals.  
Without determining the extent of cell proliferation and apoptosis, within each subset, it is 
difficult to fully interpret this data. 
4.6. Spontaneous and stimulation induced changes in HIV-1 infected 
individuals 
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Data re-analysis was carried out to compare the change in maturational subsets, in the 
same individuals, between freshly isolated PBMC and PBMC cultured for six days with and 
without TLR agonist stimulation.  The CD94+/- NK cell subsets were used for this analysis 
and paired tests were used to compare changes (Figure 4.6.1). 
HIV-1 seronegative PBMC cultured in medium alone showed no significant differences in 
either CD56hiCD94+ or CD56loCD94- NK cell expression when comparing the frequencies 
at day 0 and day 6, although a significant decrease in frequency was observed in the 
intermediate CD56loCD94+ subset (p=0.0205).  Samples from HIV-1+ treatment-naïve 
individuals cultured in medium alone did not show any significant frequency difference in 
either the CD56loCD94+ or CD56loCD94- subsets, but there was a spontaneous and 
significant decrease in frequency of the CD56hiCD94+ subset over six days (p=0.0156).  
Samples from HIV-1+ treatment-experienced individuals showed no difference in 
CD56hiCD94+ NK cell frequency after six days in vitro culture, but a significantly higher 
frequency of CD56loCD94+ NK cells was observed after six days and a corresponding 
reduction in the CD56loCD94- subset was also found (p=0.0391 and p=0.0195 
respectively) (Figure 4.6.1).  
No significant changes in frequency occurred between the NK cell subsets discussed 
above in samples from either HIV-1- or HIV-1+ treatment-naïve individuals when 
stimulated for six days with either LPS or ssRNA40.  The same pattern of decreasing 
CD56loCD94+ and reciprocal increasing CD56loCD94- frequency that was observed in 
medium alone cultures in samples from HIV-1 seropositive treatment-experienced 
individuals was maintained in LPS (p=0.0195 and p=0.0195 respectively) and ssRNA40 
(p=0.0273 and p=0.0273 respectively) stimulated cultures (Figure 4.6.1). 
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Data presented here confirms that NK cells from HIV-1 seropositive individuals have a 
more mature phenotype prior to in vitro culture and that this is exacerbated in NK cells 
cultured in vitro without further stimulation.  This phenomenon is particularly evident in 
samples from treatment-experienced individuals, where the increase in CD56loCD94- cells 
occurs with a corresponding decrease in CD56loCD94+ NK cells.  This undoubtedly has an 
Figure 4.6.1 Side by side comparison of NK cell CD94 expression on freshly isolated PBMC or 
following 6 days in culture with TLR agonists. There is a spontaneous increase in CD94- NK cells at 
the expense of CD56loCD94+ NK cells in PBMC from HIV-1+ treatment-experienced individuals (red bars) 
and this pattern is maintained when PBMC are stimulated with both LPS and ssRNA. Blue bars (HC-
Healthy Control, n=12) – HIV-1- control; grey bars (TN, n=9) – HIV-1+, treatment-naïve; red bars (TD, 
n=12) – HIV-1+, treatment-experienced individuals. Box plots display median, interquartile range and 
range. Wilcoxon’s matched pairs tests have been carried out. 
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impact on the function of these cells, as CD94 is part of the CD94/NKG2A inhibitory 
receptor complex (Borrego et al., 2006) and CD56loCD94- cells have also been shown to 
be NKG2A- (Yu et al., 2010), therefore these cells are considered less responsive to 
stimuli.  It is probable that the HIV-1+ treatment-experienced individuals enrolled in studies 
presented throughout this thesis have been infected for longer than treatment-naïve 
individuals, leading to greater terminal differentiation and exhaustion within the NK cell 
compartment; this will be discussed further in discussion at the end of this chapter (Section 
4.8) and the final discussion (Section 6.1). 
4.7. Reduced levels of soluble c-Kit and its ligand stem cell factor are 
detected in plasma of HIV-1 seropositive samples 
ELISA assays were carried out on plasma samples collected at the time of PBMC isolation 
and stored at -80°C.  This assay was carried out to assess whether plasma levels of c-Kit 
(and its ligand stem cell factor (SCF)) reflected the changes observed in NK cells.  It could 
be expected that, if ongoing maturation from CD56hic-Kit+ to CD56loc-Kit- NK cells is 
occurring in vivo, there would be a higher concentration of c-Kit in plasma from HIV-1 
seropositive samples as NK cells shed c-Kit.  There was, however, a significantly reduced 
concentration of soluble c-Kit in plasma from both HIV-1+ treatment-naïve and treatment-
experienced individuals compared to HIV-1 seronegative controls (p=0.0098 and p=0.0012 
respectively) (Figure 4.7.1).  Furthermore, a lower concentration of SCF was observed in 
plasma samples from treatment-naïve HIV-1+ individuals compared to HIV-1- control 
individuals (p=0.0474).  Appendix Table A.17 summarises the quantities of both c-Kit and 
SCF detected in plasma samples from the different groups.   
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Figure 4.7.1 c-Kit and its ligand, stem cell factor, are detected in plasma and are reduced in HIV-1 
seropositive individuals.  ELISA were carried out on stored plasma samples to quantify the levels of c-
Kit and SCF. Blue bars (HC-Healthy Control, n=12) – HIV-1- control; grey bars (TN, n=9) – HIV-1+, 
treatment-naïve; red bars (TD, n=12) – HIV-1+, treatment-experienced individuals. Box plots display 
median, interquartile range and range. Mann-Whitney tests have been carried out. 
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4.8. Discussion 
Analysis of NK cell maturation was performed using two established phenotypic strategies 
(Beziat et al., 2011, Yu et al., 2010).  Data presented, consistent with previous studies 
(Beziat et al., 2011, Carson, Fehniger & Caligiuri, 1997), showed that c-Kit+ NK cells are 
almost exclusively CD56hi NK cells and that c-Kit- NK cells are CD56lo.  We have also 
confirmed the presence of the minor, intermediate, CD56hiCD16lo NK cell subset described 
by Béziat et al. (2011). 
Examination of CD56 versus CD94 expression on NK cells, in agreement with Yu et al. 
(2010), revealed three distinct NK cell populations; CD56hiCD94+, CD56loCD94+ and 
CD56loCD94-.  Recently it has been shown that the CD56loCD94+ NK cell subset has 
functional properties attributed to both CD56hiCD16- and CD56loCD16+ NK cells, namely 
that they are capable of cytokine secretion and of cytotoxicity (Yu et al., 2010). Using 
these models of NK cell maturation, a skewed population of NK cells was demonstrated in 
chronic HIV-1 infection.  A lower frequency of CD56hiCD16- NK cells was observed in both 
treatment-naïve and treatment-experienced HIV-1 seropositive individuals compared to 
seronegative when the dysfunctional CD56-CD16+ NK cell subset previously described in 
HIV-1 seropositive individuals by Mavilio et al. (2005) was also included in the analysis.  
This finding further demonstrated that NK cells in chronic infection are driven towards a 
dysfunctional population and that less mature cell populations that are still capable of 
responding potently to stimuli, are reduced in frequency. 
Assays were carried out to determine if CD56hiCD16- NK cells expressing c-Kit and CD94 
could be driven to mature towards CD56loCD16+ cells on in vitro stimulation.  Isolated 
CD56hiCD16- NK cells were added back to PBMC depleted of NK cells and stimulated with 
cytokines or TLR agonists.  The results demonstrated that CD56hiCD16- NK cells 
expressed both c-Kit and CD94 and that after six days in vitro culture with either LPS or 
ssRNA40, the phenotype of these cells shifted towards more mature phenotypes.  CD56 
expression declined and some cells began to express CD16; furthermore c-Kit expression 
was largely lost and there was an increase in frequency of CD94- NK cells.  Interestingly 
CD56loCD94+ ‘intermediate’ NK cells were also induced by TLR agonist stimulation.  The 
observed shift in maturational phenotype of NK cells in the presence of LPS and ssRNA40 
may have relevance for HIV-1 infection, as these stimuli are systemically elevated during 
chronic infection as a result of bacterial translocation or viral replication respectively 
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(Brenchly et al. 2006, Gregson et al. 2009 and Alter et al. 2007).  This assay is therefore a 
useful model, demonstrating the ability of these ligands to drive NK cell maturation, which 
has important implications for chronic HIV-1 infection pathology and the generation of 
exhausted and dysfunctional NK cells.  
A surprising apparent increase in c-Kit expression was observed after in vitro culture of 
PBMC from HIV-1 seronegative control individuals without stimulation for six days (and 
also after overnight culture, data not shown).  It is possible, although unlikely, that c-Kit 
expression would increase in these cultures, however such an effect may be due to result 
from an uncharacterised inhibitory effect of the PBMC isolation procedure, seemingly 
preventing effective staining of c-Kit on freshly isolated PBMC and which is subsequently 
reversed during culture.  Alternatively a selective loss of cells with a more mature 
phenotype could account for the apparent rise in frequency of c-Kit expressing cells or that 
these cells are proliferating.  This phenomenon aside, it was clear that PBMC from healthy 
control individuals, cultured without stimulation did not alter in their expression of 
maturation markers, and after six days culture showed no reduction in CD94 or CD56 
expression or any increase in CD16 expression. 
In order to determine the effect of chronic HIV-1 infection on the frequencies of NK cell 
populations according to maturation markers, assays were carried out on samples from 
both treatment-naïve and treatment-experienced HIV-1 infected individuals and compared 
to responses from seronegative individuals.  Significant differences were observed in c-Kit 
expression on freshly isolated cells that were consistent with models for continued 
turnover and replenishment of NK cells, loss of cells with a mature phenotype or 
proliferation of less mature cells. Similar trends were observed using CD94-based 
differentiation staging.   
After six days in vitro culture, peripheral blood NK cells from both HIV-1+ patient groups 
clearly showed a greater frequency of mature subsets and lower frequencies of less 
mature subsets. This spontaneous effect was seen in both patient groups and therefore it 
is possible that elevated LPS levels, previously observed in patient plasma from both 
viraemic and aviraemic individuals (Gregson et al., 2009, Brenchley et al., 2006), could 
play a significant a role in driving the changes in proportion of the populations seen here.  
Viral ssRNA, only being present in very low/undetectable levels in treatment-experienced 
individuals, is less likely to contribute to the changes observed. The possibility that low 
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copy recrudescence of viral replication in the presence of anti-retroviral therapy contribute 
to accelerated immune maturation in HIV-1 infected individuals receiving anti-retroviral 
therapy cannot be excluded. Data on changes in maturational phenotype in the presence 
of the positive control (stimulation with IL-12 and IL-15) proved difficult to interpret as these 
cytokines induced additional confounding changes in NK cell markers, these changes 
could be attributed to selective proliferation or loss of specific populations.  Previous 
reports have demonstrated that CD56lo NK cells stimulated with cytokines become 
transiently CD56hi (Loza & Perussia, 2004), but these cells are functionally distinct from 
CD56hiCD16- NK cells and instead represent highly activated NK cells.  Data presented 
here also shows that cells from HIV-1 seronegative and seropositive treatment-naïve 
samples stimulated with cytokines had an increased frequency of CD56hiCD94+ NK cells, 
indicating that a proportion of the CD56lo NK cells that become CD56hi are excluded in the 
analysis for the intermediate CD56loCD94+ NK cell population.  CD56lo NK cells from 
treatment-experienced samples did not show the same pattern, implying that either 
cytokine responsiveness is compromised in these patients, or that the observed cells are 
derived from more mature CD56loCD94- NK cells which, on activation, become 
CD56hiCD94- NK cells. The frequency of such activated CD56hiCD94- cells was not 
included in our analysis.  
Changes in the maturation phenotype of NK cells was partially induced in ssRNA40 
stimulated HIV-1 seronegative individuals, and the differences in the proportions of 
different maturational stages between these and HIV-1 seropositive individuals became 
less pronounced. This indicates that in vitro stimulation of samples from seronegative 
individuals achieves a similar phenotype to the spontaneous maturation observed in 
seropositive individuals.   
Interestingly, there were no significant differences in frequency of ‘immature’ CD56hic-Kit+ 
NK cells between sample groups after stimulation.  This indicates that in vitro stimulation 
of NK cells from HIV-1 seronegative control individuals resulted in similar changes in 
phenotype of NK cells similar to that observed spontaneously for HIV-1 seropositive.  
Perhaps unsurprisingly, it appears that in vitro stimulation with LPS was insufficient to 
drive phenotypic changes seronegative samples to the same degree as that resulting from 
HIV-1 infection, there being significantly more CD56loc-Kit- NK cells in both groups of 
seropositive samples after culture.  In contrast, ssRNA40 stimulation resulted in higher 
frequencies of mature populations of NK cells in seronegative control individuals to a 
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similar level the same level to that observed for HIV-1 infected individuals, indicating a 
hierarchy of potency for different innate signals.  Differences in the patterns of 
maturational stages observed according to CD94 expression corroborated the above 
findings.  ssRNA40 was more potent than LPS at lowering the frequency of CD56hiCD94- 
cells in HIV-1 seronegative control individuals and significant spontaneous changes were 
observed in NK cells from HIV-1 seropositive treatment-experienced individuals.  It is likely 
that, prior to treatment, NK cells from HIV-1 seropositive individuals have been chronically 
exposed to both ssRNA and systemic LPS and have therefore undergone continuous 
activation affecting the changes in phenotype observed. 
Analysis of HIV-1 seropositive NK cell subsets following in vitro culture provided further 
evidence for a shift in maturation phenotype.  A spontaneous decrease in the proportion of 
CD56hiCD94+ NK cells was observed in treatment-naïve samples and, although not 
significant, there was both a reduction in CD56loCD94+ and an increase in CD56loCD94- 
NK cell frequencies in unstimulated and stimulated cultures.  Examination of results from 
treatment-experienced samples revealed significant reductions in the frequency of 
CD56loCD94+ NK cells and a corresponding increase in CD56loCD94- NK cells in 
stimulated and unstimulated cultures. 
Quantification of soluble c-Kit and SCF concentrations in plasma samples revealed lower 
levels of both in HIV-1 seropositive compared to seronegative control individuals.  This 
assay, however, was not capable of distinguishing the origins of soluble c-Kit, and it is 
likely that it derived from multiple cells and not only NK cells.  It is also a possibility that 
lower amounts of c-Kit protein is synthesised and released during chronic HIV-1 infection, 
or that c-Kit simply has a shorter half-life and is degraded more quickly in HIV-1 
seropositive individuals.  This data does not support a model whereby NK cells in HIV-1 
seropositive individuals are continually maturating due to chronic stimulation with either 
LPS or viral ssRNA. 
Assays presented in this chapter are unable to determine the mechanisms driving the 
changes in frequency of the different populations studied.  In order to better determine 
whether maturation is occurring or if populations are expanding or being lost, assays, such 
as fate mapping, with the capability of identifying how cells have changed need to be 
carried out.  The survival and proliferative potential of the different populations should be 
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examined and use of proliferation markers such as CFSE should be utilised and changes 
in absolute cell numbers should also be examined. 
Data presented here contrast with the early activation studies presented in Chapter 3, 
which demonstrated NK cells from HIV-1 seronegative individuals responded more 
vigorously to stimulation than the same cells in HIV-1 seropositive samples, albeit within a 
shorter time frame (overnight).  It is likely that low-level stimulation, which occurs in chronic 
infection, drives exhaustion and therefore weaker activation responses, whilst maturation 
toward senescent or dysfunctional populations is ongoing.  This seems likely given that the 
activation data demonstrated that refractory responses were confined to the more mature 
CD56loCD16+ NK cell subset, which would have been exposed to either viral ssRNA or 
LPS stimulation for longer, leading to exhaustion and therefore a lower capacity to 
respond to further stimulation.  Conversely, the data presented here also provided support 
for the hypothesis that CD56hiCD16- NK cells are less mature and as such have had a 
lower exposure to stimulatory signals, permitting more robust activation responses.  It is 
also interesting that samples from HIV-1 seropositive, treatment-experienced individuals 
undergo spontaneous frequency changes in maturation phenotypes to a greater extent 
than samples from treatment-naïve individuals despite successful anti-retroviral treatment 
and undetectable viral loads.  This indicates that extremely low levels of viral ssRNA, 
below current diagnostic detection limits, are potentially capable of chronically stimulating 
through TLR pathways, or that elevated microbial translocation and raised LPS 
concentrations are more important in driving the in vitro population changes observed.  
Furthermore, treatment-experienced individuals are likely to have been exposed to chronic 
infection for longer periods than those within the treatment-naïve group. Treatment-
experienced patients will have commenced therapy as a result of diagnosis of AIDS-
defining symptoms, high plasma viral loads or low levels of CD4+ T-cells (current 
guidelines are for treatment to begin at counts below 350 cells ul-1 blood (BHIVA, 2012)). 
Longer duration of infection before effective viral suppression will likely result in increased 
immune exposure to stimuli promoting chronic immune activation and exhaustion. 
4.9. Summary 
In this chapter it has been demonstrated that both c-Kit and CD94 are useful NK cell 
maturation markers when used in combination with CD56.  CD56hiCD16loc-Kit+ and 
CD56loCD94+ populations are particularly useful for the identification of intermediate 
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transitional NK maturation states.  Additionally, increased expression of CD16, coincident 
with the loss of c-Kit and CD94 provided further evidence of progressive maturation ex 
vivo and in vitro. 
Examination of NK cell maturation markers in HIV-1 seropositive samples revealed that 
different NK cell populations spontaneously change in vitro without additional stimulation.  
This was the case in both treatment-naïve individuals with detectable viraemia and 
treatment-experienced individuals with undetectable viraemia.  It was also shown that 
further stimulation with TLR agonists did not cause further changes in HIV-1 seropositive 
individuals, but population changes were observed in NK cells from seronegative 
individuals, similar to those observed spontaneously in patients, when stimulated with 
ssRNA40 or LPS.  These data provide evidence that ongoing innate stimulation in chronic 
HIV-1 infection affects the different maturation states of NK cell populations, such that 
higher frequencies of mature NK cells dominate in vitro. 
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5. Enhancement of antigen specific T-cell responses using 
TLR agonist adjuvants 
Aim 
The previous chapter focused on innate NK cell activation and maturation, and the impact 
of TLR driven changes in HIV-1 seronegative and chronically infected HIV-1 seropositive 
individuals. This chapter will focus on how different TLR agonists influence innate and 
antigen-specific T-cell activation and maturation and the potential influence of different 
accessory cell populations, including NK cells.  
Introduction 
It has been shown that TLR agonist stimulated DC activation leads to reciprocal NK cell 
interactions and that these interactions have been shown to modulate the type and 
magnitude of adaptive immune response generated (Gerosa et al., 2005, 2002, Moretta, 
2002).  There is also evidence that NK cells are involved in triggering antigen-specific 
effector CD8+ T-cell responses and enhancement of antigen presentation to memory T-
cells (Jennings & Yuan, 2009, Krebs et al., 2009).  HIV-1 infection, as discussed in 
Chapter 1, has been shown to interfere with the normal generation of adaptive immune 
responses in many different ways, leading to ineffective or unnecessary immune activity.  
Chronic immune activation is observed during ongoing HIV-1 infection, leading to T-cell 
exhaustion and an accumulation of HIV-1 specific CD8+ T-cells that are skewed towards a 
pre-terminally differentiated phenotype and have been shown to be dysfunctional (Alter et 
al., 2008, Champagne et al., 2001).  Additionally HIV-1 preferentially infects HIV-1-specific 
CD4+ T-cells, rendering them targets for CTL; this is the fundamental mechanism for the 
loss of CD4+ T-cells that defines HIV disease (Appay & Sauce, 2008, Douek et al., 2002). 
Understanding how different adjuvants activate and prime T-cells prior to the generation of 
adaptive responses is therefore important for the design of vaccines and therapeutic 
strategies that aim to overcome the evasion and exhaustion of antigen-specific immunity 
characteristic of acute and chronic HIV-1 infection, respectively. 
Building on data presented in Chapter 3, innate activation of CD4+, CD8+ and γδ+ T-cells in 
response to TLR agonist stimulation was evaluated and assessed further by examination 
of innate responses within different memory T-cell subsets.  Data from innate stimulation 
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studies was used to inform the selection of TLR ligands for use in assays to determine 
their potential for enhancement of antigen-specific immune responses to peptides 
representing HIV-1 antigens. 
5.1. TLR agonist stimulated innate T-cell activation 
An initial study was carried out to determine the ability of the TLR agonists Poly(I:C) and 
CpG ODN2216 to stimulate activation in different T cell subsets, namely CD8+, CD4+ and 
γδ+ T-cells.  Responses from HIV-1 seronegative control subjects were compared to 
treatment-experienced and treatment-naïve HIV-1+ individuals.  Early activation (CD69 
expression) was examined in stimulated PBMC cultures after one and four days (see 
Appendix Section A.7 for antibody panel).   
Figure 5.1.1 demonstrates the gating strategy used to analyse activation responses of the 
three T-cell subsets after stimulation.  γδ+ T-cells, despite only accounting for a small 
fraction of T-cells overall, were highly sensitive to Poly(I:C) and CpG ODN2216 driven 
activation, responding with high frequency of CD69 expression in the individual shown.  
Early activation was also observed in CD4+ and CD8+ T-cell cultures stimulated with TLR 
agonists.  
Table 5.1.1 shows the patient characteristics for the samples used and Figure 5.1.2 
summarises the findings.  The graphs show that there was a relatively high frequency of 
background CD69 expression in γδ+ T-cells in all sample groups.  This was particularly 
evident in cells from HIV-1+ treatment-naïve individuals and was significantly higher in this 
cohort compared to HIV-1- controls after overnight culture in medium alone (p=0.0098).  
Stimulation for four days with IL-12 and IL-15 resulted in a significantly higher frequency of 
CD69 on γδ+ T-cells from treatment-naïve compared with seronegative individuals 
(p=0.0072). Conversely, a significantly lower frequency of CD69 expression was observed 
within γδ+ T-cells from treatment-experienced compared to seronegative individuals 
(p=0.0063).  After four days of cytokine stimulation, significantly higher frequencies of 
CD69 were observed in CD4+ and CD8+ T-cells in HIV-1+ treatment-naïve individuals 
compared to seronegative individuals, possibly due to differences in response kinetics 
(p=0.0234 and p=0.0037 respectively).   
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Figure 5.1.1 T cells are activated in PBMC cultures stimulated with TLR agonists. PBMC were 
cultured in the presence of TLR agonists and the expression of CD69 and HLA-DR on γδTCR+, CD4+ and 
CD8+ T cells was measured by flow cytometry. Dot plots show gating strategy for different T cell groups 
and expression of CD69 following overnight culture. Representative HIV-1- control individual shown. 
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No differences in early activation were observed in γδ+ T-cells between patient groups after 
Poly(I:C) or CpG ODN2216 treatment, despite the higher levels of background CD69 
expression in HIV-1+ individuals.  A significantly higher frequency of CD69 expression was 
observed within CD4+ T-cells from HIV-1- controls compared to both HIV-1+ treatment-
naïve and treatment-experienced individuals stimulated with Poly(I:C) after one day 
Figure 5.1.2 T-cell responsiveness after 1 or 4 days of culture with TLR agonists.  γδTCR+ T cells are 
the principal T-cell group responding to TLR agonist stimulation.  A high frequency of CD69 expression on 
γδTCR+ T cells from HIV-1+, treatment-naïve, individuals is observed particularly following stimulation with 
cytokines and is significantly greater than expression on HIV-1- control individuals, however background 
expression is also greater and stimulation with TLR agonists reveals a deficit in the magnitude of 
activation. Blue bars (HC-Healthy Control, n=12) – HIV-1- control; grey bars (TN, n=5) – HIV-1+, 
treatment-naïve; red bars (TD, n=6) – HIV-1+, treatment-experienced individuals. Box plots display 
median, interquartile range and range. Wilcoxon’s matched pairs tests have been carried out. 
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(p=0.0037 and p=0.0032 respectively) and four days (p=0.0451 and p=0.0044 
respectively).  Similar responses were observed for CD4+ T cells after stimulation with 
CpG ODN2216: HIV-1- control individuals had a significantly higher frequency of CD69 
expression than HIV-1+ treatment-naïve or treatment-experienced individuals after one 
day (p=0.0052 and p=0.0017, respectively) and a significantly higher frequency than 
treatment-experienced individuals after four days of culture (p=0.0044).   A significantly 
higher frequency of CD69+CD8+ T-cells was observed in HIV-1- control individuals 
compared to HIV-1+ treatment-experienced individuals stimulated with Poly(I:C) for one 
day (p=0.0072), however no differences were observed after four days.  A significantly 
higher frequency of CD69+CD8+ T-cells was observed in HIV-1- controls compared to both 
HIV-1+ treatment-naïve and treatment-experienced individuals after one day of stimulation 
with CpG ODN2216 (p=0.0234 and p=0.0218 respectively) and a significantly higher 
frequency was observed for treatment-naïve patients after four days (p=0.0445). 
 
5.2. Impact of TLR agonist stimulation on distinct CD8+ T cell 
maturation stages 
Chronic HIV-1 infection results in the polarisation of CD8+ T cells towards a senescent pre-
terminally differentiated effector memory cell functional phenotype (TEM), with a 
consequent loss of cells from within the central memory pool (TCM) (Alter et al., 2008, 
Appay & Sauce, 2008, Champagne et al., 2001).  Early activation of total CD8+ T-cells has 
previously been demonstrated in response to TLR agonist stimulation (Chapter 3).  In 
depth analysis of CD8+ T-cell memory subset activation was therefore performed to 
establish which CD8+ T-cell subsets could be potentially recruited into the effector T-cell 
response by TLR agonists.  Figure 5.2.1 displays the gating strategy used to identify the 
four different, naïve (CD8+CCR7+CD45RA+CD62L+), TCM (CD8+CCR7+CD45RA-CD62L+), 
Table 5.1.1 Patient Characteristics 
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TEM (CD8+CCR7-CD45RA-CD62L-) and terminally differentiated effector memory RA+ 
(TEMRA) (CD8+CCR7-CD45RA+CD62L-) subsets based on protocols by Champagne et al. 
(2001) and Wherry et al. (2003) (see Appendix Section A.8 for antibody panel). 
 
PBMC from healthy controls (n=17) were cultured overnight without stimulation, with the 
cytokines IL-12 and IL-15 or with the TLR agonists Poly(I:C), LPS, ssRNA40 and CpG 
ODN.  CD69 expression was measured on distinct memory CD8+ T-cell subsets and the 
results are presented in Figure 5.2.2 and Table 5.2.1.  Naïve and TCM CD8+ T-cells 
displayed high frequencies of CD69+ expression without stimulation compared with the 
more mature TEM and TEMRA (see table 5.2.1 for values).   
Figure 5.2.1 Gating strategy for CD8+ T-cell memory subsets. Dot plots from a single HIV-1- control 
individual demonstrating the gating strategy to identify the four memory subsets: naïve, central memory 
(TCM), effector memory (TEM) and terminally differentiated effector memory CD45RA+ (TEMRA) CD8+ T-
cells. 
 
 137 
Naïve  TCM 
TEM TEMRA 
!
"#
$
%
#
&
'(
)*
+)
,
-
.
/
0
),
#
11
2)
 
Stimulation with cytokines induced robust increases in CD69 expression within both TEM 
and TEMRA CD8+ T-cells with lower increases seen in the less mature naïve and TCM 
subsets, particularly in naïve cells stimulated with cytokines (Figure 5.2.2 and Table 5.2.1). 
A similar pattern was seen following stimulation with different TLR agonists, where the 
more mature TEM and TEMRA CD8+ T-cells demonstrated a greater increase in CD69 
frequency above background compared to naïve and TCM cells (Figure 5.2.2 and Table 
Figure 5.2.2 Memory CD8+ T-cell early activation responses to TLR agonist stimulation. PBMC from 
17 HIV-1- control individuals were cultured overnight with cytokines or TLR agonists as shown and the 
CD69 expression on the four memory CD8+ T-cell subsets was measured by flow cytometry.  Graphs 
show the frequency of CD69+ cells with and without the stimuli shown.  Box plots display median, 
interquartile range and range. Wilcoxon’s matched pairs test has been applied to this data. 
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5.2.1).  Interestingly, neither IL-12 & IL-15 nor poly(I:C) induced significantly higher CD69 
frequency on naïve CD8+ T-cells compared to unstimulated cells (Table 5.2.1). 
Stimulation with LPS, ssRNA40 and CpG ODN2216 induced activation in all CD8+ T cell 
subsets, with mature TCM and TEMRA achieving higher overall CD69 expression than 
observed in either naïve or TEM subsets when stimulated with ssRNA40 and CpG 
ODN2216 (Figure 5.2.2 and Table 5.2.1).  These data demonstrate that innate TLR 
agonist stimulation preferentially promotes activation in mature CD8+ T-cell subsets.   
 
Naïve Central Memory Effector Memory TEMRA 
Stimuli 
Median 
CD69+ 
(%) 
Range 
P-Value 
(Vs 
medium 
alone) 
Median 
CD69+ 
(%) 
Range 
P-Value 
(Vs 
medium 
alone) 
Median 
CD69+ 
(%) 
Range 
P-Value 
(Vs 
medium 
alone) 
Median 
CD69+ 
(%) 
Range 
P-Value 
(Vs 
medium 
alone) 
Medium 
Alone 
21.6 0.7-75.4 -- 28.9 1.5 – 72.0 8.7 1.6-31.4 - 4.9 1.3-30.6 - 
IL12+IL15 23.8 1.9-79 0.2184 49.7 11.8-87.7 0.0003* 84.0 62.3-98.7 0.0003* 85.3 10.9-99.0 0.0003* 
Poly(I:C) 29.3 3.3-69.1 0.2763 40.1 5.4-72.6 0.0138* 44.0 11.0-92.0 0.0003* 38.2 3.6-67.4 0.0009* 
LPS 28.4 0.7-68.4 0.0465* 41.3 3.5-70.9 0.0027* 40.7 4.7-86.7 0.0005* 21.7 3.0-51.1 0.0005* 
ssRNA40 46.2 8.1-76.1 0.0012* 52.3 25.4-88.4 0.0003* 71.2 45.1-95.6 <0.0001* 66.2 18.2-89.9 <0.0001* 
CpG 
ODN2216 
36.1 4.8-83.0 0.0005* 39.7 5.7-83.8 0.0005* 56.9 31.4-89.2 0.0003* 57.2 17.4-87.2 0.0003* 
 
5.3. Innate activation responses of CD8+ T-cells are reduced within 
mature cell populations in HIV-1+ individuals 
Having determined responses to innate stimulation of different memory CD8+ T-cell 
subsets in HIV-1- controls, assays were undertaken to identify the subsets impacted 
during chronic HIV-1 infection.  PBMC from HIV-1 seropositive treatment-naïve and 
treatment-experienced samples were stimulated as described in Section 5.2, and CD69 
expression from different memory CD8+ T-cell subsets were compared to responses from 
seronegative samples.  Patient characteristics for this study are shown in Table 5.3.1. 
 
Table 5.2.1 HIV-1- control individuals CD8+ T-cell memory early activation responses to cytokine or 
TLR agonist stimulated PBMC culture. 
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No significant differences in background unstimulated CD69 expression were observed 
between different sample populations for the different CD8+ T-cell memory subsets (Figure 
5.3.1).  Stimulation of cells with IL-12 and IL-15 induced significantly higher frequencies of 
CD69 expression by HIV-1 seronegative TEM and TEMRA CD8+ T-cells compared to 
seropositive treatment-experienced samples (p=0.021 and p=0.0439 respectively) (Figure 
5.3.1 and Tables 5.3.1 and 5.3.2).  Interestingly, no differences were observed in the 
activation of naïve and TCM subsets between groups.  Naïve and TCM CD8+ T-cells from 
HIV-1 infected individuals, similar to seronegative samples, showed no significant increase 
in CD69 frequency after stimulation with IL-12 & IL-15 (Table 5.3.2).  
 
 
Table 5.3.1 Patient Characteristics. 
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Stimulation with any of the TLR agonists tested revealed no significant differences in 
CD69 expression by either the naïve or TCM CD8+ T-cell subsets between different 
sample groups, although HIV-1- controls tended to have a higher frequency of expression 
Figure 5.3.1 Memory CD8+ T-cell early activation responses to TLR agonist stimulation in HIV-1 
seronegative and seropositive individuals. Graphs show CD69 frequency on memory CD8+ T-cells 
after PBMC were cultured overnight with cytokines or TLR agonists as shown. Blue bars (Healthy Control, 
n=17) – HIV-1- control; grey bars (n=11) – HIV-1+, treatment-naïve; red bars (n=13) – HIV-1+, treatment-
experienced individuals. Box plots display median, interquartile range and range. Mann-Whitney tests 
have been carried out. 
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(Figure 5.3.1).  In contrast, significant differences occurred in the more mature TEM and 
TEMRA subsets.  A significantly lower frequency of CD69 was induced on TEMRA cells 
from HIV-1+ treatment-naïve individuals compared to HIV-1- control individuals stimulated 
with ssRNA40 (p=0.0426).  There was a significantly lower frequency of CD69+ TEM cells 
from HIV-1+ treatment-experienced individuals compared with HIV-1- control individuals 
after stimulation with Poly(I:C) (p=0.0007), LPS (p=0.0076), ssRNA40 (p=0.0426) and 
CpG ODN2216 (p=0.0080) (Figure 5.3.1).  With the exception of Poly(I:C) stimulation 
(p=0.0363), the frequency of CD69 expression within TEM cells from HIV-1+ treatment-
naïve individuals was not significantly lower than observed in HIV-1- controls.  
CD8+ T-cell subsets with a more advanced maturational status were therefore observed to 
be more readily activated than naïve or memory subsets using innate TLR stimulation 
alone.  These assays also revealed substantial defects in responsiveness of effector 
memory and terminally differentiated effector memory CD8+ T-cell subsets during chronic 
HIV-1 infection, particularly in individuals receiving successful anti-retroviral treatment.  
 
Table 5.3.2 HIV-1+ treatment-naïve individuals, CD8+ T-cell memory early activation responses to 
cytokine or TLR agonist stimulated PBMC culture. 
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5.4. KIR+ CD8+ T-cells are sensitive to innate stimulation despite a 
higher frequency observed in HIV-1 infection 
An increased frequency of KIR expression on CD8+ T-cells during chronic HIV-1 infection 
has been shown to correlate with plasma viral load (Alter et al., 2008).  This study also 
demonstrated that such KIR+CD8+ T-cells are unresponsive to antigen-specific stimulation 
but remain responsive to TCR independent stimuli, raising the possibility of recovery of 
functional competence. In view of the reduced responsiveness of TEM and TEMRA CD8+ 
T-cells to TLR ligands, assays were performed to determine whether KIR expression also 
influences TLR ligand-induced activation.   
Consistent with previously published data (Alter et al., 2008) a significantly higher 
frequency of KIR+CD8+ T-cells was detected in HIV-1+ treatment-naïve individuals with 
detectable viraemia compared to HIV-1- controls (p=0.0165) (Table 5.3.1).  Interestingly, 
samples from treatment-experienced individuals without detectable viraemia showed no 
significant difference in frequency of KIR+CD8+ T-cells compared to seronegative controls, 
indicating a reversion to normal levels. 
In order to assess the responsiveness of KIR+CD8+ and KIR-CD8+ T-cells to TLR agonists, 
PBMC were stimulated in vitro as described previously (Section 3.7).  Frequencies of 
CD69 and IFN-γ producing cells were then quantified using flow cytometry (Figure 5.4.1).  
Table 5.3.3 Table 5.3.3. HIV-1+ treatment-experienced individuals, CD8+ T-cell memory early 
activation responses to cytokine or TLR agonist stimulated PBMC culture. 
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KIR+CD8+ T-cells were clearly responsive to TLR agonist stimulation, and exhibited a 
higher frequency of both CD69 and IFN-γ expression than KIR- cells.  This trend was 
maintained across all three different patient groups (Figure 5.4.1).  It is noteworthy that a 
statistically significantly higher frequency of CD69 and IFN-γ expression was observed on 
KIR+CD8+ T-cells following overnight in vitro culture without stimulation.  This indicates that 
these cells were already partially activated.  Also, TLR-mediated stimulation did not 
significantly influence the frequency of KIR+CD8+ T-cells (data not shown).  TLR agonist 
stimulation alone was therefore unable to induce KIR expression on CD8+ T-cells in vitro 
over the time period studied. 
KIR expression on CD8+ T-cells is confined to memory subsets, particularly TEM (Alter et 
al., 2008, Anfossi et al., 2004).  It is therefore not surprising that KIR+CD8+ T-cells 
demonstrated a higher degree of responsiveness to TLR agonist stimulation (Figure 5.4.1) 
and showed higher frequencies of mature TEM and TEMRA cells that were responsive to 
innate stimulation (Section 5.2 and 5.3).  In addition to a higher frequency of KIR+CD8+ T 
cells observed during chronic HIV-1 infection, responses specific for HIV-1 antigens were 
found to be deficient in this subset (Alter et al., 2008).  The ability of KIR+CD8+ T-cells to 
respond to innate signals, including TLR ligands, indicates that appropriate adjuvanting 
systems could potentially be used to recover antigen-specific function in this subset. 
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5.5. Effect of TLR agonist co-stimulation on antigen specific T-cell 
responses 
Chronic stimulation in HIV-1 infection results in the generation of senescent, exhausted 
antigen specific CD8+ T-cells.  This has been attributed to either chronic activation leading 
to irreversible loss of function in these cells (Appay & Sauce, 2008, Brenchley et al., 2003) 
or reversible exhaustion of CD8+ T-cell expressing the programmed death-1 (PD-1) 
receptor (Sauce et al., 2007).  Furthermore, PD-1 expression and CD38 upregulation are 
associated with cellular activation, and are seen on HIV-1 specific CD8+ T-cells and are 
reduced with HAART, implying functional recovery (Appay & Sauce, 2008, Sauce et al., 
2007).  Having demonstrated the ability of TLR agonists to preferentially stimulate memory 
CD8+ T-cell responses, co-stimulation assays were performed to assess whether TLR 
agonists could enhance antigen-specific recall responses in CD4+ and CD8+ T-cells.  
Preliminary experiments were performed using the FEC peptide pool (described in Section 
2.6.3 and Appendix Table A.11) to stimulate PBMC from healthy donors (n=4; Table 
Figure 5.4.1 KIR+ CD8+ T cells maintain responsiveness to TLR agonist stimuli. Graphs display 
frequency of a) CD69 expression and b) IFN-γ production from KIR+/- CD8+ T cells from. Blue bars (n=17) 
– HIV-1- control; grey bars (n=11) – HIV-1+, treatment-naïve; red bars (n=13) – HIV-1+, treatment-
experienced individuals. Box plots display median, interquartile range and range. Wilcoxon’s matched 
pairs tests have been carried out. 
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5.5.1), either with or without TLR agonists in IFN-γ ELISpot assays (for details see Section 
2.10).  Co-stimulations were carried out using Poly(I:C), LPS, ssRNA40 and CpG 
ODN2216, which were titrated at the concentrations shown in Table 5.5.2.  TLR agonists 
were titrated in these assays to determine whether very low concentrations, such as might 
be observed in vivo, would have any effect on antigen-specific responses.  IFN-γ ELISpot 
assays were employed in this study as they are highly sensitive and enable accurate 
determination of antigen-specific T-cell frequency.  
 
Figure 5.5.1 shows the number of IFN-γ spot forming cells (SFC) per million PBMC 
cultured.  The black dotted line at 50 SFC per million cells represents the chosen threshold 
of responsiveness; responses below this level are considered as background.  Data is 
presented as background subtracted and for TLR agonist co-stimulated co-cultures, TLR 
agonist alone responses are also subtracted so that any responses observed are above 
those, which would be achieved by simply adding the responses to peptide and TLR 
ligand stimuli alone.  Background subtracted values shown to be below 0 SFC were 
rounded to 0 for analysis.  Background values where cultures were stimulated with TLR 
agonists alone are not presented here or for the following sections (5.6 and 5.7) as they 
were zero in the vast majority of cases and only rarely induced a response.  Additionally, 
when a response was observed it was only seen in a very low number of cells, and the 
highest recorded value was 84 SFC per million PBMC. 
FEC stimulation resulted in responses in all samples above background levels, albeit with 
varying frequency, with one individual responding more vigorously than the others.  Both 
Poly(I:C) and ssRNA40 co-stimulation had little effect on responses, except at very low 
concentrations (1ng ml-1) of Poly(I:C), when all four samples showed reduced 
Table 5.5.1 Patient Characteristics 
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responsiveness compared to FEC stimulation alone, reducing the mean SFC per million to 
383 (range 66-1212) from 425 (76-1248).   
Co-stimulation with FEC peptides and LPS also revealed an overall reduction in 
responsiveness, particularly at a concentration of 10ng ml-1, when the mean SFC per 
million cells was reduced in three out of four samples tested, from 425 (76-1248) 
stimulated with FEC alone to 274 (86-770) (Figure 5.5.1).  Both samples co-stimulated 
with 100ng ml-1 LPS, showed decreased responses below the 50 SFC per million 
threshold, from 130 to 36 and 76 to 26 respectively.  Reduction of responsiveness to 
antigen-specific stimulation may have relevance for HIV-1 infection where it is known that 
plasma LPS levels are elevated (Gregson et al., 2009, Brenchley et al., 2006).  This will be 
explored further in the next section (5.6). 
Co-stimulation of FEC peptide responses with higher concentrations of CpG ODN2216 
(10nM) caused a reduction in overall responsiveness in all four samples tested, reducing 
the mean SFC per million cells to 362.5 (24-1122) compared to 425 (76-1248) with FEC 
alone, and reducing one sample to below cut-off threshold levels.  Although this reduction 
is not as dramatic as that observed in LPS co-stimulation, it does suggest that, at higher 
concentrations, TLR agonist co-stimulation can have a negative effect on antigen-specific 
responses.  However, in contrast to these findings, co-stimulation of PBMC with FEC and 
lower concentrations (1nM) of CpG ODN2216 resulted in enhanced IFN-γ production in 
three out of four samples tested, increasing the mean SFC per million cells for these 
individuals from 425 (76-1248) for FEC alone to 474 (94-1412) for FEC plus CpG 
ODN2216.  Of all the combinations tested, CpG ODN2216 at a concentration of 1nM was 
the only one that enhanced responses, providing evidence that antigen-specific responses 
may, in some circumstances, be boosted using TLR agonists.  
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Figure 5.5.1 IFN-γ  ELISpot responses of PBMC from HIV-1- control individuals in response to a FEC 
peptide pool in combination with TLR agonists. PBMC were cultured in the presence of a mixed 
peptide pool containing peptides from Influenza, EBV and CMV alone or in the presence of TLR agonists.  
Each line represents a single individual; dotted lines were used to compare between FEC alone and FEC 
with the lowest TLR agonist concentration used for each individual.  Dotted line at 50 spots per million 
cells represents the threshold considered responsive to peptide. All peptide + TLR agonist points have had 
TLR agonist alone responses subtracted. Wilcoxons matched pairs analysis has been carried out on all 
samples where FEC alone responses were above 50 spots per million cells and p values are only shown 
where they are <0.05 (none of the changes in response were significant for these assays). 
Table 5.5.2 TLR agonist concentrations used in 
titration co-stimulation assays. 
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5.6. Effect of TLR agonist co-stimulation on HIV-1 antigen specific T-
cell responses 
Further to experiments described above in section 5.5, similar assays were undertaken 
using samples from both treatment-naïve (n=13) and treatment-experienced (n=13) HIV-
1+ individuals.  Patient characteristics for this study are displayed in Table 5.5.1.  Two 
concentrations of each TLR agonist were used in these assays (based on results from 
seronegative studies in Section 5.5) and results are shown in Figures 5.6.1, 5.6.2 and 
5.6.3. For this study three different peptide pools were used to stimulate PBMC for the 
IFN-γ ELISpot assays: the control FEC peptide pool used above, and two different HIV-1 
gag peptide pools referred to as the 20mer and the 9mer pools (Section 2.6.3 and 
Appendices Tables A.11, A.12 and A.13).  In the 20mer peptide pool, peptides overlap by 
10 amino acids, encompassing the possibility of stimulating both CD4+ and CD8+ T-cells.  
The latter pool contained different 9mer peptides with varying sequence overlaps that 
have previously been demonstrated to be immunogenic for the majority of HIV-1+ 
individuals, stimulating antigen-specific CD8+ T-cell responses.  A value below 50 SFC per 
million PBMC in cultures stimulated with peptide alone, was considered below the 
threshold of a specific response.  Individuals unresponsive to the peptide pools were 
excluded from analysis of TLR co-stimulatory effects. 
5.6.1. TLR agonist co-stimulation of T cell responses to FEC peptides 
in HIV-1 infected individuals 
Figure 5.6.1 summarises in vitro co-stimulation responses of HIV-1 seropositive PBMC 
responses using the FEC peptide pool.  The majority of individuals made responses to 
FEC peptide pool alone above threshold levels; only one HIV-1+ treatment-naïve 
individual displayed a response below threshold.  
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Figure 5.6.1 IFN-γ  ELISpot responses of PBMC from HIV-1+ individuals in response to a FEC 
peptide pool in combination with TLR agonists. PBMC from HIV-1+ individuals, either treatment-naïve 
(black lines) or treatment-experienced (red lines) were cultured in the presence of FEC.  Each line 
represents a single individual. Dotted line at 50 spots per million cells represents the threshold considered 
responsive to peptide. All peptide + TLR agonist points have had TLR agonist alone responses subtracted.  
Wilcoxons matched pairs analysis has been carried out on all samples where FEC alone responses were 
above 50 spots per million cells and p values are only shown where they are <0.05 
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Co-stimulation with Poly(I:C) revealed some minor changes in responsiveness compared 
to FEC alone.  There was a modest increase in mean SFC per million using low 
concentrations of Poly(I:C) (1ng ml-1) compared to peptide alone in four out of six 
treatment-naïve individuals tested.  Four out of ten treatment-experienced individuals also 
demonstrated an increase in the mean frequency of IFN-γ producing cells in response to 
FEC in the presence of Poly(I:C) (1ng ml-1), with the mean SFC per million increasing from 
558.1 (range 61-1336) to 583 (range 68-1282) for the entire group.  Less consistent 
results were obtained using the higher concentration of Poly(I:C) (100ng ml-1).  An 
increase in SFC was observed in three out of six treatment-naïve individuals, with no 
difference in the mean for the group, and only three out of ten treatment-experienced 
individuals demonstrated an increase in IFN-γ SFC. 
LPS co-stimulation showed a clear change in response compared to FEC alone.  Cells co-
stimulated with LPS and antigen consistently showed decreased IFN-γ production in both 
treatment groups at different LPS concentrations (1 and 10ng ml-1) (Figure 5.6.1).  
Treatment-naïve individuals displayed a significant reduction in mean SFC per million with 
LPS co-stimulated cultures, from 631 (210-1376) in FEC alone to 494.2 (136-1232) (1ng 
ml-1 LPS) and 481.3 (154-1158) (10ng ml-1 LPS) (p=0.0195 and p=0.0039 respectively).  
Seven out of nine (1ng ml-1) and nine out of nine (10ng ml-1) LPS co-stimulated cultures 
from treatment-naïve individuals had a lower frequency of IFN-γ stimulated cells compared 
to cultures stimulated with FEC alone.  Cells from treatment-experienced individuals 
followed a similar reduction on co-stimulation of FEC responses with increasing 
concentrations of LPS: 9/12 and 11/12 individuals showed a reduction with 1ng ml-1 and 
10ng ml-1 LPS, respectively.  The mean SFC per million was reduced from 785.9 (61-2088) 
with FEC alone to 720.8 (52-2034) (1ng ml-1 LPS; not significant) and significantly reduced 
to 643.7 (42-1824) (10ng ml-1 LPS; p=0.0309).  Variable responses were observed in 
cultures from HIV-1 seropositive samples co-stimulated with FEC and ssRNA40.  No 
difference in mean IFN-γ production was observed following ssRNA40 (1ng ml-1) co-
stimulation in treatment-naïve individuals compared to cultures stimulated with FEC alone 
(FEC alone mean 547, range 210-1106; FEC + ssRNA40 mean 549.3, range 252-1050), 
with 3/6 individuals showing increased IFN-γ production.  Similarly, cells from treatment-
experienced individuals co-stimulated with FEC and ssRNA40 (1ng ml-1) had a similar 
frequency of IFN-γ producing cells (mean 570.4, range 50-1244) compared to FEC alone 
(mean 558.1, range 61-1336), with 4/10 individuals showing increases in IFN-γ production.  
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Co-stimulation with 100ng ml-1 ssRNA40 generated a modest increase in the frequency of 
IFN-γ production in treatment-naïve samples (mean 575.3, range 240-1202) compared to 
cultures stimulated with FEC alone (mean 547, range 210-1106), with four out of six 
individuals increasing IFN-γ production.  Samples from treatment-experienced individuals, 
however generated a lower frequency of IFN-γ spots when co-stimulated with ssRNA40 
(100ng ml-1) (mean 501.7, range 71-1222) compared to cultures stimulated with FEC 
alone (558.1, range 61-1336), although five out of ten individual samples showed 
increased in IFN-γ production.   
Interestingly, CpG ODN2216 co-stimulation with FEC generated lower or stable production 
of IFN-γ in HIV-1+ seropositive samples in contrast to the observed enhancement of IFN-γ 
production in HIV-1- control individuals (Section 5.5).  PBMC from treatment-naïve 
individuals had a reduced frequency of IFN-γ SFC when co-stimulated with the lower 
concentration (1nM) of CpG ODN2216 (mean 582.9, range 4-1290) compared to cultures 
stimulated with FEC alone (mean 631, range 210-1376) (Figure 5.6.1).  This was reduced 
further, and significantly, at the higher concentration (100nM mean 537.3, range 216-
1206) (p=0.0421).  Six out of nine treatment-naïve individuals had lower SFC per million 
counts compared to FEC stimulated cultures at both concentrations of CpG ODN2216.  
Co-stimulation of PBMC from treatment-experienced individuals with lower concentrations 
of CpG ODN2216 (1nM) had no effect on the frequency of IFN-γ SFC, (FEC alone mean 
785.9, range 61-2088; FEC + ODN2216 mean 784.2, range 88-2086), but was reduced at 
the higher concentration of 100nM (mean 743.6, range 52-1904).  The frequency of IFN-γ 
SFC was reduced in 6/12 HIV-1+ treatment-experienced individuals in the presence of 
CpG ODN2216 at both concentrations compared to cultures stimulated with FEC alone.  
5.6.2. TLR agonist co-stimulation of the HIV-1 gag 20mer peptide 
responses 
HIV-1+ individuals are known to better maintain antigen-specific T-cell responses to 
viruses other than HIV-1 itself (Komanduri et al., 2001, Villacres et al., 2001).  In particular, 
a high frequency of IFN-γ producing, CMV-specific effector memory CD8+ T-cells can be 
found during HIV infection.  It is therefore perhaps unsurprising that such responses 
proved difficult to enhance further in the presence of TLR agonists. The potential of TLR 
agonists to influence T-cell responses to HIV-1 derived antigen was therefore tested in 
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vitro to establish whether such responses could be recovered from the partial anergy 
caused by chronic stimulation in vitro.  PBMC from treatment-naïve and treatment-
experienced individuals were stimulated with peptides derived from HIV-1 and co-
stimulated with the range of TLR agonists described above.   
Responses to the 20mer peptide pool alone were not as vigorous as those observed in 
response to the FEC peptide pool with five out of seven from the treatment-naïve and 6/11 
from the treatment-experienced group responding above the threshold level of 50 SFC per 
million cells.  Data from this experiment is presented in Figure 5.6.2. 
Co-stimulation of gag 20mer responses with Poly(I:C) were variable.  Co-stimulation of 
PBMC from treatment-naïve individuals with 1ng ml-1 Poly(I:C) had no effect on the mean 
frequency of IFN-γ SFC compared to stimulation with peptide alone (mean peptide + 
Poly(I:C) 246.8, range 130-368;  mean peptide only 245.2,  range 124-310) and this was 
reduced when PBMC were co-stimulated with 100ng ml-1 Poly(I:C) to 213.6 (2-350).  The 
frequency of IFN-γ SFC increased in two out of five HIV-1+ treatment-naive individuals 
when co-stimulated with 1ng ml-1 and in one out of five increased with 100ng ml-1 
Poly(I:C).  By contrast, co-stimulation of PBMC from HIV-1+ treatment-experienced 
individuals reduced the frequency of SFC when co-stimulated with both 1ng ml-1 (mean 
236.4, range 24-538) and 100ng ml-1 (mean 242, range 14-572) Poly(I:C) compared to 
stimulation with peptide alone (mean 262, range 68-508). 
Co-stimulation of 20mer peptides with LPS displayed a similar reduction in the frequency 
of IFN-γ SFC.  In treatment-naïve samples, mean IFN-γ SFC per million PBMC were 
reduced from 245.2 (range 124-310) to 116.4 (range 0-218) for 1ng ml-1 and 160.8 (range 
60-272) for 100ng ml-1 LPS.  Five out of five and four out of five individuals had reduced 
SFC frequencies respectively.  Treatment-experienced individuals had a reduced mean 
IFN-γ SFC per million PBMC of 198.4 (0-530) for 1ng ml-1 and 175.6 for 100ng ml-1 LPS 
compared to 262 SFC per million PBMC for cultures stimulated with 20mer peptides alone.  
Four out of five and five out of five individuals had reduced SFC per million PBMC, 
respectively compared to peptide alone. 
ssRNA40 had little impact on the responses to HIV-1 Gag 20mer peptides in HIV-1+ 
treatment-naïve individuals.  Co-stimulation with 1ng ml-1 ssRNA40 increased mean IFN-γ 
SFC from 245.2 (peptide alone) in four out of five individuals to 258.8 (range 166-292), but 
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decreased the mean SFC at 100ng ml-1 to 225.2 (range 142-280).  Four out of five and two 
out of five individuals had increased SFC per million PBMC, respectively, compared to 
peptide alone. 
In contrast, a marked decrease in the mean IFN-γ SFC per million PBMC was observed in 
treatment-experienced individuals when co-stimulated with 100ng ml-1 ssRNA40 (mean 
166.8, range 40-472) compared to PBMC stimulated with peptide alone (262, range 68-
508).  Little change, however, was observed at lower concentration (1ng ml-1) (mean 246, 
range 0-610).  The frequency of SFC per million PBMC was reduced in five out of five 
(100ng ml-1 ssRN40) and three out of five individuals (1ng ml-1 ssRNA40) respectively.  
Co-stimulation of PBMC with HIV-1 gag 20mer peptides and CpG ODN2216 showed 
stable or reduced antigen-specific responses.  The mean SFC per million cells reduced 
from 245.2 when treatment-naïve samples were stimulated with 20mer alone to 209.6 
(range 118-306) when co-stimulated with 1nM CpG ODN2216, but remained relatively 
stable (mean 242.8, range 148-290) when co-stimulated with 100nM.  One out of five and 
two out of five individual treatment-naïve samples had increased IFN-γ SFC frequencies 
when co-stimulated with 1nM and 100nM CpG ODN2216 respectively. Co-stimulation of 
PBMC from treatment-experienced individuals with 20mer and CpG ODN2216 reduced the 
mean IFN-γ SFC per million cells from 262 with peptide alone to 238.4 (range 12-516) with 
1nM and 235.2 (range 16-524) with 100nM.  
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Figure 5.6.2 IFN-γ  ELISpot responses of PBMC from HIV-1+ individuals in response to an HIV-1 gag 
20mer peptide pool in combination with TLR agonists. PBMC from HIV-1+ individuals, either 
treatment-naïve (black lines) or treatment-experienced (red lines) were cultured in the presence of an HIV-
1 gag 20mer peptide pool.  Each line represents a single individual. Dotted line at 50 spots per million cells 
represents the threshold considered responsive to peptide. All peptide + TLR agonist points have had TLR 
agonist alone responses subtracted. Wilcoxons matched pairs analysis has been carried out on all 
samples where 20mer alone responses were above 50 spots per million cells and p values are only shown 
where they are <0.05 (none of the changes in response were significant for these assays). 
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5.6.3. TLR agonist co-stimulation using the HIV-1 gag 9mer peptide 
pool 
MHC class I-restricted HIV-1 gag 9mer pooled peptides were also used in co-stimulation 
assays with TLR agonists.  CD8+ T-cells and PBMC from HIV-1+ treatment-naïve 
individuals responded more frequently to the 9mer peptides alone, with 9/12 responding 
compared to 6/13 treatment-experienced individuals.  The data for these assays is shown 
in Figure 5.6.3.  
Co-stimulation of PBMC from HIV-1+ samples with Poly(I:C) led to modest increases in 
IFN-γ SFC per million cells in both treatment-naïve and treatment-experienced samples at 
1 and 100ng ml-1.  Co-stimulation of treatment-naïve samples increased the mean SFC 
per million cells from 175.2 (96-336) when stimulated with peptide alone to 195.5 (96-366) 
with 1ng ml-1 and 188.5 (104-352) with 100ng ml-1 Poly(I:C).  Two out of four individuals 
increased the frequency of SFC at both concentrations.  A similar pattern was observed in 
PBMC from treatment-experienced individuals, where the mean IFN-γ SFC per million 
cells was 233.5 (range 58-558) when stimulated with peptide alone, 261.5 (range 26-624) 
with 1ng ml-1 Poly(:IC), and 247 (36-644) with 100ng ml-1 Poly(:IC), with three out of four 
and two out of four individuals showing an increase in SFC respectively.  
Surprisingly, low concentrations of LPS (1ng ml-1) increased the frequency of IFN-γ 
producing cells in treatment-naïve samples when combined with 9mer peptides.  The 
mean IFN-γ SFC per million was raised from 419.6 (range 96-1880) when stimulated with 
peptide alone to 466.4 (range 26-2236) when co-stimulated with 1ng ml-1 LPS.  Increases 
were observed in six out of nine individuals.  Conversely, the mean SFC per million PBMC 
dropped to 359.1 (range 38-1618) at higher (100ng ml-1) LPS concentration, with 
increases observed in only three out of nine individuals respectively.  Reduced 
frequencies of IFN-γ SFC were observed from treatment-experienced individuals in 
response to gag 9mer peptides when co-stimulated with LPS (peptide alone mean 230, 
range 58-558; peptide + LPS 1ng ml-1 mean 166.7, range 0-484; peptide + LPS 10ng ml-1 
mean 182, range 18-470).  An increased frequency of IFN-γ SFC was only observed in a 
single individual at both concentrations of LPS.   
Co-stimulation with ssRNA40 increased the mean frequency of IFN-γ SFC in PBMC from 
treatment-naïve individuals from 175.2 (range 96-336) when stimulated with peptide alone, 
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to 220 (range 54-538) with 1ng ml-1, and to 192 (range 160-368) with 100ng ml-1 
ssRNA40.  The frequency increased in two out of four and three out of four individuals.  
Modest increases were also observed on co-stimulation of cells from treatment-
experienced individuals, where the mean SFC per million cells increased from 233.5 
(range 58-558) when stimulated with peptide alone, to 261 (range 30-634) with 1ng ml-1, 
and to 247 (range 10-562) with 100ng ml-1 ssRNA40, with increases observed in two out of 
four and three out of four individuals respectively. 
CpG ODN2216 co-stimulation of gag 9mer responses demonstrated a consistent increase 
in responsiveness in treatment-naïve individuals at low concentrations (1nM), with six out 
of nine individual samples increasing the number of IFN-γ SFC.  The mean number of SFC 
per million cells increased from 419.6 (range 96-1880) with peptide alone to 478.9 (range 
62-2146) with 1nM CpG ODN2216.  At higher concentration (100nM) CpG ODN2216 
reduced the mean SFC per million to 397.8 (82-1796); increases were observed in only 
two out of nine individuals.  Co-stimulation of PBMC from treatment-experienced 
individuals with CpG ODN2216 and 9mer peptides in combination did not substantially 
alter IFN-γ production compared to that observed with peptide alone.  IFN-γ SFC per 
million PBMC, after co-stimulation with peptides and 1nM CpG ODN2216, was 238.3 
(range 28-616) compared to 230 (range 58-558) with peptide alone and 226.7 (30-632) 
when co-stimulated with 100nM CpG ODN 2216.  
Data presented for co-stimulation of antigen-specific responses using different peptides 
and TLR agonists has revealed consistent inhibitory effects with certain TLR ligands 
whereas others, when used at an appropriate concentration, enhance peptide-stimulated 
responses.  LPS consistently decreased IFN-γ responses compared to peptide alone in 
both treatment-naïve and treatment-experienced HIV-1 infected individuals at low and high 
concentrations, and with all three different peptide pools studied.  Exceptionally, IFN-γ 
responses to gag 9mer were enhanced within PBMC from HIV-1+ treatment-naïve 
individuals when co-stimulated 1ng ml-1 LPS.   
The most consistent enhancement of IFN-γ responses was observed when co-stimulating 
peptide induced responses with CpG ODN2216.  This was the case both for PBMC from 
HIV-1- control individuals stimulated with FEC peptides and from HIV-1+ treatment-naïve 
individuals stimulated with HIV-1 gag 9mer in combination with CpG ODN2216 at low 
concentration (1nM).  
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Figure 5.6.3 IFN-γ  ELISpot responses of PBMC from HIV-1+ individuals in response to an HIV-1 gag 
9mer peptide pool in combination with TLR agonists. PBMC from HIV-1+ individuals, either treatment-
naïve (black lines) or treatment-experienced (red lines) were cultured in the presence of an HIV-1 gag 
9mer peptide pool.  Each line represents a single individual. Dotted line at 50 spots per million cells 
represents the threshold considered responsive to peptide. All peptide + TLR agonist points have had TLR 
agonist alone responses subtracted. Wilcoxons matched pairs analysis has been carried out on all 
samples where 9mer alone responses were above 50 spots per million cells and p values are only shown 
where they are <0.05 (none of the changes in response were significant for these assays). 
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5.7. NK cell and BDCA4+ DC depletion reduces IFN-γ  production in 
response to antigen-specific stimulation 
In order to establish which cell populations provide accessory help for antigen-specific 
stimulation of IFN-γ production in PBMC, a small experiment was carried out using PBMC 
depleted of specific cell types and stimulated with the FEC peptide pool.  For these assays 
three HIV-1- control samples were depleted of B-cells, NK cells and BDCA4+ pDC (pDC as 
described by Dzionek et al. (2000)), using magnetic cell depletion as described in Section 
2.8, before being stimulated overnight with FEC in IFN-γ ELISpot assays.  Table 5.7.1 
shows the efficiency of the different depletions for the three samples.  The frequency of 
pDC is displayed as frequency of CD123+ cells in the gated lineage cocktail- (Lin-1-) HLA-
DR+ population.  NK cells and B-cells were efficiently depleted beyond 75% for all three 
samples.  Depletion of pDC was less complete with sample two only depleted by 37% of 
the total lineage-HLA-DR+ pDC population (see Figure 3.5.1 for pDC gating strategy). 
Table 5.7.2 summarises the ELISpot data for the depletion assays.  All three individuals 
had strong responses to FEC peptide alone, with responses above the 50 SFC per million 
PBMC threshold of activation.  The SFC per million cells for the depleted samples is listed 
and the proportion compared to total PBMC is shown.  Depletion of B-cells only reduced 
IFN-γ production in one of the individuals by 16%, and actually increased production in the 
other two individuals.  The increase in IFN-γ seen in samples 1 and 3 is potentially caused 
by the slightly higher frequency of IFN-γ producing cells that would be present without B-
Table 5.7.1 Frequency of NK cells, B-Cells and pDC before and after 
magnetic cell separation from total PBMC from 3 HIV-1- control 
individuals.  BDCA-4 was used as a marker to remove pDC from PBMC. 
 
NB. Frequency of pDC is frequency of Lin-HLA-DR+ cells. 
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cells.  From this data, it appeared that B-cells did not contribute to antigen-specific IFN-γ 
production. 
 
 
Depletion of NK cells led to a modest reduction of stimulated IFN-γ production in the three 
samples (16%, 24% and 30%, respectively).  This reduction indicates that NK cells might 
produce IFN-γ in response to antigen-specific stimuli, however further studies are needed 
to confirm this.  This is examined further in section 5.8.3. 
Depletion of pDC led to a larger decrease (38%, 48% and 32% respectively) in stimulated 
IFN-γ production than B-cells or NK cells, despite the less efficient depletion.  This is not 
surprising as DC are specialist antigen presenting cells that express high levels of MHC 
class I and II, and therefore reduced DC frequencies will lead to less peptide presentation 
and less T-cell stimulation.  This experiment confirmed a requirement for pDC to generate 
optimal responses to antigen-specific stimulation in vitro.  In addition, a potential 
contribution of NK cells in promoting optimal antigen-specific recall responses is indicated. 
The interaction of NK cells with DC is well established (Moretta et al., 2008, Gerosa et al., 
2005) and it is possible that without NK cell feedback, DC are unable to fully stimulate T-
cell activation.  It is unclear however whether adjuvant systems such as TLR agonist 
stimulation are further stimulating antigen-specific T-cells or rather providing a mechanism 
to enhance bystander, non-specific T-cell responses. 
Table 5.7.2 IFN-γ  ELISpot Responses to FEC peptide pool of NK cell, B-cell and pDC depleted 
PBMC from 3 HIV-1- control individuals. Spot forming cells per million (SFC) shown for 3 individuals in 
response to a FEC peptide pool cultured overnight with PBMC or PBMC depleted of CD19+, CD56+, or 
BDCA-4+ cells by magnetic cell separation.  Proportion of SFC per million cells from depleted versus total 
PBMC also shown. 
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5.8. CpG ODN2216 enhancement of T-cell responses is not restricted to 
antigen-specific T-cells 
Preliminary assays were carried out in an attempt to identify which cell populations were 
responsible for the enhanced IFN-γ production observed in ELISpot assays presented in 
Section 5.6.  In order to identify antigen-specific T-cell populations, MHC class I pentamer 
staining was used to identify antigen-specific CD8+ T-cells and activation (CD69) and 
degranulation (CD107a) responses were measured.  Pentamer staining allows the 
identification of very small populations of antigen-specific CD8+ T-cells in flow cytometric 
assays, and was employed here to establish the levels of activation and degranulation of 
cells recognising particular CMV and HIV-1 gag epitopes (CMV and HIV-1 gag epitopes 
are listed in Appendix Table A.10) (HIV-1 gag epitope pentamers are referred to as HIV-1 
gag pentamer (1) or pentamer (2)).  Degranulation was assessed using CD107a 
expression as described previously by Betts et al (2003) and by Alter et al (2004a).  
Methods for pentamer staining and degranulation are described in Section 2.7.4.  The 
preliminary nature of these assays combined with the technical difficulties involved with 
evaluating very low numbers of pentamer stained cells and the low numbers of individuals 
tested mean that conclusions are more based on qualitative descriptions and firm 
conclusions could not be made.  
In order to identify antigen-specific cells, the HLA-A and HLA-B profiles of responding 
individuals were established in order to use appropriate HLA-specific pentamers.  DNA 
was isolated from stored cell samples (see Section 2.11 for method) and HLA-typed 
(ProImmune, Oxford, UK).  Individuals were selected for testing if co-stimulation of CpG 
ODN2216 and the HIV-1 gag 9mer peptide pool had enhanced their cells’ IFN-γ production 
in ELISpot assays (Section 5.6).  Experiments focused on the treatment-naïve sample 
group, as this is where the most consistent (seven out of nine samples) enhancement of 
antigen-specific responses was observed.  Of seven individuals showing enhanced 
responses, samples from six were tissue-typed, the results of which are shown in Table 
5.8.1.  Of these, five were found to have HLA-A*02:01 (highlighted in Table 5.8.1).  
Pentamers specific for this allele were therefore selected (see Appendix Table A.10).  
From the five suitable individuals it was possible to obtain a fresh peripheral blood sample 
from three individuals when they were visiting clinics for routine appointments.  The patient 
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characteristics of these individuals are presented in Table 5.8.2.  A single HIV-1- control 
individual was also used in this study (Table 5.8.2).  
 
Table 5.8.1 HLA typing results for 6 HIV-1+ individuals selected on the basis they showed 
increased IFN-γ  SFC per million when cultured with HIV-1 peptide + CpG ODN2216 compared to 
peptide alone.  Samples marked between * were used in used in assays described in this section. 
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PBMC were cultured overnight either in medium alone or in the presence of IL-12 (1ng ml-
1) and IL-15 (20ng ml-1), PHA (10µg ml-1), FEC peptides (5µg ml-1) or HIV-1 gag 9mer 
peptides (5µg ml-1) with or without CpG ODN2216 (1nM).  An appropriate volume of cells 
was removed for intracellular cytokine staining assays before degranulation and pentamer 
and cell surface marker immunostaining was carried out, all as described in Section 2.7.  
Antibody panels and pentamer details for these assays can be seen in Appendix tables 
A.9 and A.10.  Example dot plots and the gating strategy for these assays are shown in 
Figure 5.8.1 and 5.8.2.  These demonstrate the large number of events that were acquired 
(106 cells within the lymphocyte gate), as is necessary for examination of responses within 
the minor CD8+pentamer+ subset of cells.  Responses within the total CD8+ T-cell 
population and within maturational subsets were also examined (Figures 5.8.1 and 5.8.2).  
IFN-γ could not be examined in parallel with pentamer staining, for technical reasons, but 
was examined on NK cells (gating not shown, see Sections 3.7 and 3.8 for NK gating) and 
is included in analysis shown in Table 5.8.3.  The dot plots demonstrated in Figure 5.8.1 
and 5.8.2 represent results from a single individual of three tested, and demonstrate 
stimulation with HIV-1 9mer peptides with and without CpG ODN2216 co-stimulation, or for 
CMV pentamer staining after stimulation with the FEC peptide pool.  Gating of 
pentamer+CD8+ T-cells was set according to negative pentamer staining for each 
individual.  Results from this individual indicate increased CD69 expression and CD107a 
expression within total CD8+ T-cells when co-stimulated with CpG ODN2216 compared to 
9mer alone (Figure 5.8.1).  Furthermore, the increase is more pronounced in the more 
mature TEM and TEMRA subsets (Figure 5.8.2).  Surprisingly, a decrease was observed 
in IFN-γ production in total CD8+ T-cells as well as a decrease in degranulation within the 
pentamer+ subset.  Conversely, a small increase in CD69 expression was observed within 
this subset.  Data from these assays is displayed in full in Tables 5.8.3, 5.8.4 and 5.8.5. 
Table 5.8.2 Individual patient characteristics 
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Figure 5.8.1 TLR agonist co-stimulation of antigen-specific T-cells. Gating strategy demonstrating the 
CD69 (activation) expression or CD107a (degranulation) expression by a) total CD8+ T-cells (IFN-γ 
expression is also shown on total CD8+ T-cells), b) negative control pentamer+ CD8+ T-cells, c) CMV 
pentamer+ CD8+ T-cells and d) HIV-1 gag pentamer+ in response to overnight stimulation of PBMC with 
either the HIV-1 gag 9mer peptide pool alone or in combination with 1nM CpG ODN2216 or in the case of 
CMV pentamer staining to the FEC peptide pool. 
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5.8.1. Early activation 
Early activation responses (CD69 expression) were examined within total CD8+ T-cells 
and CD8+ T-cell memory subsets as well as antigen-specific cells (Table 5.8.3).  As 
mentioned above, analysis of this data is qualitative and statistics have not been carried 
out.  Overnight stimulation of PBMC from the HIV-1- control individual with IL-12 and IL-15 
increased CD69 expression only on TCM and TEMRA cells.  All three HIV-1+ individuals 
Figure 5.8.2 TLR agonist co-stimulation of memory T-cells. Gating strategy demonstrating 
responsiveness of the 4 different memory CD8+ T-cell subsets in response to either HIV-1 gag 9mer 
peptide stimulation alone or in combination with 1nM CpG ODN2216. Early activation (CD69) and 
degranulation (CD107a) expression are shown for all cell types and IFN-γ was only measurable in this 
assay on total CD8+ T-cells. 
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had increased responses within CMV pentamer+CD8+ T-cells, two out of three had 
increased responses in TEM cells, one out of three had increased responses in naïve and 
TEMRA cells, and all three individuals had reduced responses in total CD8+ T-cells, TCM 
cells and in both HIV-1 gag pentamer+CD8+ T-cells subset cells. 
Overnight stimulation with PHA decreased CD69 expression on all subsets except TEMRA 
cells in the HIV-1- control individual compared to unstimulated cultures.  All three HIV-1+ 
individuals had increased CD69 expression in response to PHA in CMV pentamer+CD8+ T-
cells.  Two out of three individuals had increased expression in both HIV-1 gag 
pentamer+CD8+ T-cells and in naïve, TCM and TEMRA cells.  Only one out of three of the 
individuals increased CD69 expression in total CD8+ T-cells and in TEM cells. 
CD69 expression in the HIV-1- control individual in response to overnight FEC peptide 
stimulation compared to unstimulated cultures was reduced in all cell subsets except 
TEMRA cells.  All three HIV-1+ individuals had reduced CD69 expression in total CD8+ T-
cells, naïve, TCM and TEMRA cells and only one out of three individuals had an increase 
in CD69 expression in TEM cells.  All three individuals, however, had increased 
expression in CMV pentamer+CD8+ T-cells. 
Two out of three HIV-1+ individuals had reduced expression of CD69 when stimulated with 
the HIV-1 gag 9mer peptides compared to unstimulated cultures in all subsets except 
naïve CD8+ T-cells, where all three individuals had reduced expression.  Although the 
same pattern is largely seen in CpG ODN2216 co-stimulated cultures compared to 
unstimulated cells, improvements were seen compared to cultures stimulated with 9mer 
alone.  All three samples had higher CD69 expression in total CD8+ T-cells and in the 
naïve, TEM and TEMRA subsets, and two out of three samples had higher expression in 
both the HIV-1 pentamer+CD8+ T-cell subsets and in TCM cells.   
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Table 5.8.3 Early activation (CD69) responses of total CD8+ T-cells, pentamer+ CD8+ T-cells and 
memory subset CD8+T-cell subsets from different individuals to the stimulations shown. 
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5.8.2. Degranulation 
Expression of CD107a was used as an indicator of degranulation (Table 5.8.4).  It was 
possible to measure the degranulation response in pentamer stained CD8+ T-cells and in 
the four maturational subsets.  As mentioned above, analysis of this data is qualitative and 
statistics have not been carried out.  The degranulation response to cytokine stimulation in 
the HIV-1- control individual was reduced in total CD8+ T-cells, naïve, TCM and TEM T-cell 
subsets, but was increased in CMV pentamer+CD8+ T-cells and TEMRA cells compared to 
unstimulated cultures.  The response to cytokines in HIV-1+ individuals showed that all 
three had increased degranulation in the CMV pentamer+ population. Two out of three 
samples showed increased degranulation responses in total CD8+ T-cells, HIV-1 gag 
pentamer+ (1) CD8+ T-cells and within all maturational subsets when stimulated with 
cytokines.  Two out of three individuals had decreased degranulation responses in the 
HIV-1 gag pentamer+ (2) cell subset when stimulated with cytokines.  
Stimulation of HIV-1 seropositive samples and the seronegative sample with PHA 
increased CD107a frequency in all cell subsets measured, with two exceptions.  
Degranulation was reduced in TCM cells in the HIV-1- control sample and in HIV-1 gag 
pentamer+ (1) cells from the first HIV-1+ individual, although this is likely due to the high 
background degranulation observed in this cell subset in this individual.  Peptide 
stimulation of the HIV-1- individual with the FEC peptide pool showed an increase or no 
change in degranulation in all cell subsets except TCM cells, which were reduced.  All 
three HIV-1+ individuals had increased degranulation responses in total CD8+ T-cells, 
CMV pentamer+ cells, TEM and TEMRA cells when stimulated with FEC peptides.  Two 
out of three individuals had increased degranulation in naïve cells and two out of three 
individuals had reduced responses in TCM. 
All three HIV-1+ individuals had increased degranulation responses in total CD8+ T-cells, 
TCM and TEM cells in response to the HIV-1 gag 9mer peptide pool alone compared to 
unstimulated cells.  Two out of three individuals had decreased degranulation in both HIV-
1 gag pentamer+CD8+ T-cell subsets and in TEMRA cells, and all three individuals had a 
decreased degranulation response in naïve CD8+ T-cells.  CpG ODN2216 co-stimulation 
enhanced degranulation responses in some cell subsets in HIV-1+ individuals also 
stimulated with HIV-1 gag 9mer peptides.  All three individuals had an increased CD107a 
frequency in total CD8+ T-cells, and interestingly in naïve, TEM and TEMRA cells 
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compared to stimulation with 9mer alone, but none of the individuals had an increased 
response in TCM cells.  One out of three and two out of three individuals had increased 
degranulation responses in HIV-1 gag pentamer+ (1) and (2) CD8+ T-cells respectively.  
These data indicate that non-specific T-cells are recruited and or that cells maintain 
functional for longer when co-stimulated with CpG ODN2216, as responses above 
background were observed in co-stimulated cultures even though they were not in cultures 
stimulated with peptide alone. These findings are similar to the early activation data 
presented above, in that it appears that co-stimulation with CpG ODN2216 might help 
sustain responses for longer and, as discussed in the next section, the chosen time point 
may miss peak responses. 
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Table 5.8.4 Degranulation (CD107a) responses of total CD8+ T-cells, pentamer+ CD8+ T-cells and 
memory subset CD8+T-cell subsets from different individuals to the stimulations shown. 
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5.8.3. IFN-γ  production 
Table 5.8.5 describes the observed frequencies of IFN-γ production and as before the low 
numbers of individuals examined dictates the qualitative nature of analysis and the lack of 
statistics applied.  Stimulation of HIV-1- PBMC with cytokines increased IFN-γ frequency in 
NK cells, but reduced the frequency in CD8+ T-cells.  In HIV-1+ individuals, IFN-γ 
frequency was reduced in both CD8+ T-cells and NK cells when PBMC were stimulated 
with cytokines compared to unstimulated PBMC.  The second positive control, PHA, also 
revealed reduced responses across both CD8+ T-cells and NK cells in HIV-1+ individuals.  
This is unusual and contradicts the ELISpot data, which showed very strong IFN-γ 
responses to mitogen.  It is possible that the overnight time point for stimulation was too 
long and that peak IFN-γ production had passed and therefore would not have been 
detected by this assay.  The situation seen in the HIV-1- control individual was less clear 
with small increases observed in total NK cells and CD56loCD16+, but decreases in 
CD56hiCD16- NK cells or CD8+ T-cells.   
Stimulation with FEC increased IFN-γ frequency in CD8+ T-cells, total NK cells and both 
NK subsets in the HIV-1- control individual tested compared to unstimulated cultures.  
More varied results were seen in the HIV-1+ individuals, where one out of three samples 
had an increased IFN-γ frequency in total CD8+ T-cells and CD56hiCD16- NK cells.  All 
three individuals had a reduced IFN-γ frequency in total NK cells, and the frequency was 
either the same or reduced in CD56loCD16+ NK cells stimulated with the FEC peptide pool. 
IFN-γ responses to HIV-1 gag 9mer peptides were examined in HIV-1+ individuals (Figure 
5.8.1 and Table 5.8.5).  IFN-γ frequency was reduced in two out of three individuals 
stimulated with 9mer peptides alone compared to unstimulated cultures in CD8+ T-cells, 
and CD56loCD16+ NK cells, but was increased in two out of three total NK cell populations 
and in CD56hiCD16- NK cells was increased in all three individuals.  Co-stimulation with 
CpG ODN2216 increased the IFN-γ frequency in CD8+ T-cells in two out of three 
individuals compared to cells stimulated with peptide alone.  Two out three of the samples 
also had reduced IFN-γ frequency in total NK and both NK subsets compared to 
stimulation with peptide alone. 
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Table 5.8.5 IFN-γ  responses of total CD8+ T-cells, total NK cells and NK cell subsets from different 
individuals to the stimulations shown. 
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5.9. Discussion 
Chapters 3 and 4 explored innate immune responses to TLR agonists, focusing particular 
attention on NK cell activation and maturation.  TLR agonist stimulation of DC and NK cell 
responsiveness affects adaptive immune responses, effectively shaping the type of 
response generated and the magnitude of that response.  Experiments have been carried 
out in this chapter to quantify the innate responsiveness of various T-cell populations, 
specifically CD8+ T-cell memory subsets, and to investigate how responsiveness is 
affected by chronic HIV-1 infection.  From this point, further studies were carried out to 
assess the in vitro effects of a range of TLR agonists on antigen-specific T-cell responses 
in both HIV-1 seronegative and seropositive individuals.  
Initial assays were carried out looking at the activation of CD4+ T-cells, CD8+ T-cell and γδ+ 
T-cells in response to Poly(I:C) and CpG ODN2216 stimulation.  These assays revealed 
γδ+ T-cells to be the primary responsive subset activated by innate immune stimulation.  It 
was also clear from these assays that early activation in the form of CD69 expression 
could easily be observed on CD8+ T-cells and γδ+ T-cells. 
Bystander T-cell responses were also examined in HIV-1+ individuals and these assays, in 
agreement with NK cell data, revealed that bystander T-cell responses were refractory 
compared to seronegative control responses.  Both treatment-naïve and treatment-
experienced individuals displayed significantly reduced responsiveness, despite treatment-
experienced individuals having received successful anti-retroviral therapy.  Interestingly 
there was an exception to this trend: T-cells from treatment-naïve individuals responded at 
a higher frequency compared to those from seronegative control individuals.  This is likely 
due to the ongoing viraemia and therefore chronic immune stimulation these individuals 
are experiencing, which was indicated by the higher background activation of T-cells, 
particularly γδ+ T-cells, observed. 
In order to better understand which T-cell memory subsets were activated by innate 
stimulation, activation (as measured by CD69 expression) of these subsets was examined. 
These assays demonstrated that, despite having a higher background level of activation, 
unsurprisingly naïve and TCM cells did not respond to stimulation as vigorously as the 
more mature TEM and TEMRA subsets.  Although not necessarily reaching as high a 
frequency of expression as naïve and TCM cells when stimulated with Poly(I:C) or LPS, 
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TEM and TEMRA cells had a higher relative increase in expression.  It therefore appears 
that TLR agonist stimulation preferentially stimulates the more mature TEM and TEMRA 
subsets.  It is also noteworthy that Poly(I:C) was unable to significantly increase activation 
in naïve cells, and LPS only managed to activate these cells by a relatively small amount, 
which contraindicates their potential use as adjuvants. 
The same responses were then compared in cells from HIV-1 seropositive individuals, and 
revealed that the refractory responses previously observed in total CD8+ T-cells were 
confined to the more mature and most responsive TEM and TEMRA subsets.  This is 
perhaps unsurprising as these cells are more mature and, as such, are likely to have been 
subjected to chronic stimulation and the associated fatigue. Furthermore, it is known that 
these cells are increased in frequency and are dysfunctional in chronic HIV-1 infection 
(Champagne et al., 2001).  A further interesting observation was that responses in 
treatment-naïve individuals trended to be lower than seronegative ones, although none 
were individually significantly reduced.   
The expression of KIR on CD8+ T-cells was determined on HIV-1 seronegative and 
seropositive individuals.  In agreement with findings by Alter et al. (2008), it was shown 
that there was a significantly higher frequency of KIR+CD8+ T-cells in HIV-1+ treatment-
naïve individuals, but not so in treatment-experienced samples indicating recovery with 
treatment.  The responsiveness of the KIR+CD8+ T-cells was then examined in response 
to TLR agonist stimulation and they were found to be more sensitive to stimulation, 
expressing higher levels of CD69 and IFN-γ than KIR- cells.  This situation was maintained 
across all the sample groups.  No change in KIR expression in response to TLR agonist 
stimulation was found after overnight stimulation (data not shown). 
Having established the characteristics of innate immune activation of CD8+ T-cells, 
attention was shifted to antigen-specific immune responses and the effects of TLR agonist 
stimulation on them.  Much lower concentrations of TLR agonist were used in this assay to 
better represent potential in vivo scenarios, and also as the primary stimulants in these 
assays were antigen-specific peptide pools.   
Initial IFN-γ ELISpot assays were conducted using samples from HIV-1- control individuals 
and the FEC peptide pool as a stimulant, in order to accurately establish IFN-γ production 
on a per cell basis over a prolonged period.  This was a small study conducted for 
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optimisation of conditions for studies using samples obtained from HIV-1+ individuals.  
This study revealed neither Poly(I:C) nor ssRNA40 co-stimulation consistently altered IFN-
γ production either positively or negatively.  LPS was found to have a consistent negative 
effect on IFN-γ production, and there was an indication that CpG ODN2216 provided some 
enhancement of IFN-γ production at low concentrations in three out of four samples tested.  
These data provided evidence that antigen-specific responses could be enhanced using 
some TLR agonists, but also revealed potential negative or inhibitory effects of other TLR 
agonists on IFN-γ production using LPS.  The potential for negative effects of adjuvants 
emphasises the need for studies such as these with the ability to determine the functional 
consequences of using such systems. 
Further IFN-γ ELISpot assays were carried out using samples from HIV-1 seropositive 
individuals to determine if there was any potential for TLR agonists to enhance antigen-
specific responses in chronically infected individuals.  These assays were also able to 
reveal negative factors that inhibited maximum IFN-γ production.  For these assays HIV-1 
specific peptide pools were used, specifically gag 20mer and 9mer peptides (as these had 
previously been used within our group and were known to elicit high frequency IFN-γ 
responses; data not shown) as well as the FEC peptide pool.  Responses to the different 
peptide pools alone varied: consistent IFN-γ responses were observed against FEC 
peptides but there were less individual responders to both 20mer and 9mer gag peptides 
in treatment-naïve samples and even less responders in treatment-experienced samples.   
As seen for seronegative samples co-stimulation of antigen-specific responses with 
Poly(I:C) did not induce any consistent changes in IFN-γ production in seropositive 
samples for any of the peptide pools tested.  ssRNA40 co-stimulation did not noticeably 
affect FEC or 9mer stimulated cultures, but proved to have some modulating effects with 
20mer stimulation.  A small but consistent enhancement of IFN-γ production was seen in 
treatment-naïve samples co-stimulated with low concentrations (1ng ml-1) of ssRNA40.  A 
substantial drop in IFN-γ production was, however, observed when treatment-experienced 
cultures were co-stimulated with higher concentrations (100ng ml-1) of ssRNA40.   
The co-stimulation effects of LPS were the most consistent of responses observed, 
demonstrating substantially reduced IFN-γ production in the majority of samples across all 
combinations of peptide and LPS concentration.  One exception to this was observed in 
cells from treatment-naïve individuals co-stimulated with HIV-1 gag 9mer peptides and low 
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LPS concentrations, which demonstrated increases in IFN-γ production in six out of nine 
samples.  This finding demonstrates further the potentially damaging pathology brought 
about by HIV-1 infection, which has been associated with elevated bacterial endotoxin 
levels, which have been shown to persist despite successful treatment (Gregson et al., 
2009, Brenchley et al., 2006). 
Finally, co-stimulation with CpG ODN2216 provided interesting, but mixed results.  The 
effects of CpG ODN2216 co-stimulation on PBMC from treatment-experienced individuals 
demonstrated even responses with no substantial or consistent changes in IFN-γ 
production.  Co-stimulation of cells from treatment-naïve individuals with both FEC and 
HIV-1 gag 20mer peptides led to stable or slightly reduced IFN-γ responses, as did co-
stimulation with 9mer peptides and a higher concentration of CpG ODN2216.  Co-
stimulation of treatment-naïve samples with 9mer peptides and the lower CpG ODN2216 
concentration (1nM) revealed a consistent and substantial, but not statistically significant, 
increase in IFN-γ production, indicating enhancement of antigen-specific responses is 
possible given the right conditions. 
A brief experiment was conducted to confirm the roles of different accessory cells in 
antigen-specific responses where IFN-γ was produced.  Depletion ELISpot assays 
confirmed that B-cells were not involved and NK cells played a minor role in stimulating an 
antigen-specific IFN-γ response.  Removal of BDCA4+ pDC revealed the biggest defect, 
confirming pDC as the major accessory cell type required for the generation of IFN-γ in an 
antigen-specific immune response. 
The final study undertaken attempted to identify which specific cell types were involved in 
antigen-specific immune responses and furthermore whether CpG co-stimulation was 
simply enhancing antigen-specific CD8+ T-cell responses, or if other non-specific cells 
were being recruited.  Flow cytometry assays utilising TCR-specific pentamer staining and 
degranulation staining were carried out to achieve this.  It must be stressed that these 
assays were preliminary in nature and due to the low numbers tested statistical tests could 
not be applied and the data presented were qualitative in nature. 
Because of the technical difficulties involved, intracellular IFN-γ staining was carried out 
separately to pentamer staining of cells.  IFN-γ could not, therefore, be looked at directly 
on antigen-specific cells.  Unlike ELISpot or ELISA assays, intracellular cytokine staining is 
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unable to determine total IFN-γ produced, and will only reveal cells that have produced 
IFN-γ within the final four hour time frame that brefeldin A was applied to cultures.  It was 
therefore difficult to accurately measure total IFN-γ production in some of these assays, as 
it is likely that peak production may have been rapid and therefore have been missed in 
some of the conditions tested after an overnight stimulation.  This also seems likely given 
the fact that a number of responses, such as those against the PHA positive control, were 
lower than those observed in unstimulated cultures suggesting that IFN-γ production had 
been down regulated.  It is also likely that, due to ongoing viraemia and bacterial 
translocation, T-cells in HIV-1 samples were already activated and therefore unstimulated 
cultures were not truly unstimulated.  In this assay it was also surprising that cytokine 
stimulation with IL-12 and IL-15 was unable to stimulate IFN-γ production in CD8+ T-cells 
as would be expected. 
Examination of the degranulation responses did provide some interesting data despite 
suffering a similar problem to IFN-γ staining whereby peak expression could have been 
missed.  An increase in degranulation was observed in the mature TEM and TEMRA CD8+ 
T-cell subsets when stimulated with FEC peptides, but the same results were not observed 
in cultures stimulated with HIV-1 gag 9mer peptides alone.  Co-stimulation with CpG 
ODN2216 demonstrated improved responses over stimulation with peptide alone, not only 
in total CD8+ T-cells, TEM and TEMRA cell, but interestingly also in the naïve cell subset, 
indicating recruitment of non-specific cells compared to stimulation with HIV-1 gag 9mer 
peptide alone.   
The final measure of responsiveness examined was CD69 expression.  In the HIV-1 
seronegative individual tested, mostly negative responses were observed in response to 
all stimuli, which indicates that peak expression of CD69 might have been missed.  
Interestingly, however, in the HIV-1- control sample tested there was an increase in CD69 
expression in the TEMRA subset, a phenomenon also observed in degranulation 
responses, indicating that TEMRA cells in HIV-1- individuals remain activated and 
functional for longer than less mature cells.  Responses in HIV-1+ individuals also 
indicated that peak expression of CD69 had been missed, as the majority of responses in 
the various subsets were consistently reduced following stimulation.  There was, however, 
one exception: CMV pentamer+CD8+ T-cell activation remained high regardless of the 
stimulation.  Despite CD69 expression being lower than unstimulated cultures, CpG 
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ODN2216 co-stimulated cultures revealed higher CD69 frequencies than cultures 
stimulated with peptide alone. This indicates that, rather than simply boosting antigen-
specific responses, co-stimulation might be stimulating functional responses such that they 
are maintained for longer.  
Further assays exploring the potential of TLR agonists to disrupt or improve antigen 
specific T-cell responses are required and the mechanisms involved in such scenarios 
would need to be elucidated if such materials were to be used as adjuvants in an HIV 
vaccine or immunotherapeutic treatment. 
5.10. Summary 
This chapter has examined bystander immune responses within T-cell populations and 
then progressed to examine the effect of TLR-agonist stimulation on antigen-specific 
immune responses.  γδ+ T-cells were shown to be the primary innate responsive T-cells 
activated to high frequencies after stimulation.  It was demonstrated that TLR agonists 
were only capable of stimulating early activation in T-cells.  It was then shown that, 
similarly to NK cells, T-cell activation in response to TLR-agonist stimulation was refractory 
in chronic HIV-1 infection.  Activation within different maturational CD8+ T-cell subsets was 
then explored, and it was demonstrated that mature TEM and TEMRA cells were most 
sensitive to TLR agonist stimulation and that it was responses within these subsets that 
were refractory in HIV-1 seropositive samples. 
Investigations focusing on the effects of TLR agonist co-stimulation on antigen-specific T-
cell responses revealed their ability to modulate IFN-γ production.  LPS was shown to 
consistently down regulate IFN-γ production, which may have implications for HIV-1 
pathology.  Enhancement of antigen-specific IFN-γ production was seen with CpG 
ODN2216 under certain circumstances. This provides at least some evidence of the 
potential to enhance responses in a manner that would be of benefit in both prophylactic 
vaccinations and immunotherapeutic strategies.  Assays designed to identify the cell types 
affected by TLR agonists yielded some interesting results and demonstrated that a range 
of non-antigen-specific T-cells were potentially recruited.  Further work is however needed 
to fully establish which cells are involved and the mechanisms by which they are 
operating.  
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6. Discussion 
6.1. Final Discussion 
The work presented in this thesis investigated innate NK cell and T-cell immunity during 
chronic HIV-1 infection and specifically characterised innate immune responsiveness 
toward TLR agonist stimulation.  The potential properties of TLR agonists as model 
adjuvants in antigen-specific immune responses were also investigated. 
NK cell and CD8+ T-cell immune responses were demonstrated at relatively low 
concentrations of TLR agonist.  These responses were largely accessory cell dependent, 
in contrast to other studies, which have found direct NK cell stimulation in the absence of 
accessory cellular support (Sivori et al., 2010, Marcenaro et al., 2008, Hart et al., 2005, 
Chalifour et al., 2004, Sivori et al., 2004).   
Sivori et al. (2004) demonstrated NK cell responsiveness to both CpG ODN (type A and B) 
(5µg ml-1) and Poly(I:C) (50µg ml-1), but only in the presence of cytokines (IL-2, IL-12 or IL-
8) and state that no responses were observed in the absence of cytokines.  The presence 
of TLR3 and TLR9 mRNA in NK cells, but not protein, was also demonstrated.  A further 
study by Sivori and colleagues demonstrated TLR9 protein in endosomal NK 
compartments through co-localisation assays.  Furthermore trafficking of CpG molecules 
was demonstrated to occur via interaction with and internalisation of KIR3DL2, but again 
IL-12 was required for this interaction to occur (Sivori et al., 2010).  Hart and colleagues 
demonstrated TLR3, TLR7 and TLR8 expression on NK cell lines, but not in freshly 
isolated NK cells.  NK cell activation in response to TLR agonists (Poly(I:C) (10µg ml-1) or 
R848 (3µg ml-1)) was demonstrated, but described as accessory cell dependant, as 
activation was inhibited by anti-IL-12 antibodies (Hart et al., 2005).  Chalifour and 
colleagues demonstrated NK responsiveness to the TLR2 and TLR5 agonists KpOmpA 
(membrane protein A of Klebsiella pneumoniae) and flagellin, both at a range of 
concentrations, but only found substantial IFN-γ production when co-stimulated with 
cytokines (Chalifour et al., 2004).  Finally, Marcenaro and colleagues demonstrated NK 
cell activation in response to BCG (at a 1:1 ratio of bacterial particles to NK cells) via 
TLR2, which they showed was expressed at low levels on the surface of NK cell.  This 
study also demonstrated that responses were enhanced by IL-12, but were not reliant on 
its presence (Marcenaro et al., 2008). 
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These studies, however, use either high concentrations of agonists and/or co-stimulate NK 
cells with cytokines (Sivori et al., 2010, Marcenaro et al., 2008, Hart et al., 2005, Chalifour 
et al., 2004, Sivori et al., 2004).  It is also noteworthy that these studies used different TLR 
agonists to those presented in this thesis.  Assays presented here, therefore, cannot rule 
out functional expression of TLR on NK cells, although it is shown that TLR agonists used 
at the stated concentrations were not directly stimulatory.  It is also likely that resting NK 
cells do not express functional TLR. However, it would be interesting to explore TLR 
expression by NK cells in the context of chronic HIV-1 viraemia as HIV-1 genomic ssRNA 
has been shown to stimulate TLR7 and TLR8, and these receptors have been found to be 
expressed in NK cell lines (Alter et al., 2007a, Hart et al., 2005).  
NK cells and CD8+ T-cells from HIV-1 infected individuals were shown to be refractory to 
TLR agonist-mediated stimulation.  Particularly interesting was the finding that treatment-
experienced individuals demonstrated refractory responses more frequently than did 
treatment-naïve individuals.  It should be noted, however, that individuals in the treatment-
naïve cohort were generally younger than individuals in the treatment-experienced cohort 
(as illustrated by patient characteristics tables throughout).  Therefore, a generalised 
impact of ageing on immune competence in treatment-experienced individuals compared 
to treatment-naïve individuals studied must be considered a possibility.  Additionally, 
although precise information regarding time since diagnosis and initiation of treatment was 
not available, it is possible that consistent refractory responses in treatment-experienced 
individuals may reflect a longer period of infection in this group, leading to greater overall 
burden of concomitant infection and immune exhaustion, as compared to the treatment-
naïve group, who are likely to be more recently infected.  Alternatively, the impact of 
periodic viral recrudescence, low virus copy number (<50 copies ml-1 of blood) and 
previous treatment failures cannot be ruled out in treatment-experienced individuals. 
Innate responsiveness to TLR agonist stimulation within CD56hiCD16- NK cells was 
entirely maintained and refractory responsiveness was observed only in CD56loCD16+ NK 
cells.  This is interesting data, as CD56hiCD16- NK cells are known to produce cytokines 
involved in the generation of adaptive immune response and indicates that these cells 
might have an important role in potential anti-HIV-1 immunotherapeutic approaches.  It 
should be noted, however, that the frequency of CD56hiCD16- NK cells are reduced in 
peripheral blood from chronically infected patients (Mavilio et al., 2003).  Therefore 
approaches seeking to utilise the cytokine-producing potential of these cells might also 
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need to seek to induce their proliferation and enhance their survival.  Interestingly, clinical 
trials with ultra-low dose IL-2 in combination with SCF have demonstrated recovery of 
CD56hiCD16- NK cell subsets, but also stimulate the growth of immunosuppressive 
regulatory T-cells, which in turn might suppress HIV-1 specific immunity (Goodier & 
Coleman, 2009, Shah et al., 2006).  
The study of NK cell maturational subsets in Chapter 4 further investigated the ability of 
CD56hiCD16- NK cells from HIV-1 infected individuals to mature into effector NK cells in 
the presence or absence of TLR ligands. Specifically, the variable expression of c-Kit, 
CD94, CD16 and CD56, used previously by other groups as markers of human NK cell 
maturation, provided useful information (Beziat et al., 2011, Yu et al., 2010). In vitro 
stimulation assays clearly demonstrated a shift in frequencies of the different NK cell 
subsets, reducing CD56hiCD16- cells and increasing CD56loCD16+ cells, potentially 
indicating a linear progression for innately stimulated NK cells.  Our data did not exclude 
other models for NK cell maturation and we did observe, as others have an, increase in 
CD56 expression, especially in longer term cultures stimulated with IL-12 and IL-15, 
although this was not seen in cultures stimulated with TLR agonists (Loza & Perussia, 
2004).  It could be that this represented an alternative maturation pathway, however it 
seems that only robust in vitro cytokine stimulation, over a prolonged time period, induced 
this phenotype indicating that it perhaps represents a hyper-activated state, not 
representative of normal maturation. 
Alternatively the data could demonstrate proliferation or loss of specific cell populations 
during in vitro culture as well as preferential survival.  Fate mapping and proliferation 
assays need to be carried out in order to fully appreciate the mechanisms causing the shift 
in populations observed.  Further work using assays such as the CD56+CD16- NK cell 
reconstitution assay would also prove useful to further study how NK cells mature during 
HIV-1 infection. 
After demonstrating that CD56hiCD16- NK cells cultured in vitro matured upon stimulation 
with TLR agonists, maturation of NK cells cultured within whole PBMC populations from 
healthy and HIV-1 seropositive individuals in the presence or absence of TLR agonist 
stimulation, was investigated.  NK cells from HIV-1 seropositive individuals that were 
cultured within whole PBMC in the absence of stimulation showed signs of spontaneous 
changes in the frequency of maturation phenotypes above that seen in healthy controls.  
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This suggests that chronic stimulation in HIV-1 infection is sufficient to drive NK cell 
changes when the cells are cultured ex vivo, it is likely that cell loss due to apoptosis is 
also a possibility here and this possibility should also be further examined.  It is interesting 
to note that this was also significant in treatment-experienced individuals with suppressed 
viraemia, indicating that multiple factors are involved in driving chronic immune stimulation 
and that detectable HIV-1 viraemia alone is not wholly responsible.  TLR agonist 
stimulation of PBMC from healthy individuals revealed similar phenotypic changes 
observed in HIV-1 seropositive individuals.  This raises the possibility that TLR agonist 
stimulation is a driver of ongoing NK cell maturation in chronic HIV-1 infection. 
The exact mechanisms driving changes have not been determined.  Assays used to study 
human NK cell maturation directly ex vivo do, however, require longer periods of cell 
culture, which may limit the availability of the required accessory cells for TLR stimulation. 
The in vitro assays used here thus have technical limitations in this respect.  Addition of 
exogenous factors, including cytokines, to substitute for accessory cell-dependence may 
overcome these limitations, but this in itself is likely to skew NK cell maturation in vitro, as 
observed after IL-12 and IL-15 stimulation.  
T-cell responses to TLR agonist stimulation were transient and declined after four days of 
stimulation (Chapter 5). The γδ-T-cell subset was highly sensitive to innate stimulation, 
indicating that adjuvant studies should also monitor their activation and function, although 
further investigation of this was beyond the scope of this thesis.  Activation in response to 
TLR agonist stimulation was skewed towards mature memory CD8+ T-cell phenotypes in 
healthy control individuals.  Stimulation of PBMC from HIV-1 infected individuals revealed 
that refractory responses were confined mostly to the mature TEM subset, consistent with 
skewed maturation of HIV-1 specific T-cells towards this subset demonstrated by 
Champagne et al. (2001).  This indicates that HIV-1-specific CD8+ effector memory T-cells 
are exhausted, accounting for their poor responsiveness.  Again, treatment-experienced 
individuals show the biggest reduction compared to healthy control responses and, given 
that these individuals are likely to have been exposed to infection for longer than 
treatment-naïve individuals this further supports the notion that their TEM cells are 
exhausted.  Detailed longitudinal studies examining changes in responsiveness of memory 
CD8+ T-cell subsets might better define loss of function in these cells, for example, by 
looking at the relationship between the acquisition of inhibitory molecules (such as CTLA-
4, PD-1 and TIM-3) and TLR ligand-mediated activation.   
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It was also shown that KIR+CD8+ T-cells, which are expanded in chronic HIV-1 infection 
and are an indicator of reduced HIV-1-specific activation, maintained innate 
responsiveness compared to KIR-CD8+ T-cells in the same individuals and expressed the 
activation marker CD69 at a higher frequency than KIR- cells.  This analysis did not 
examine responsiveness between HIV-1 infected and healthy control cohorts, but it is 
likely that KIR+CD8+ T-cells represent more mature memory subsets given the higher 
frequency of CD69 observed and that antigen-specific KIR+CD8+ T-cells have been shown 
to be unresponsive (Alter et al. 2008).  Data presented here demonstrated that KIR+CD8+ 
T-cells responded to TLR agonist stimulation as potently as KIR-CD8+ T-cells in HIV-1 
infected individuals (both treatment-experienced and treatment-naïve) indicating that 
although these cells may be unresponsive to TCR engagement, they are not exhausted 
(Alter et al., 2008). 
Studies were undertaken with the aim of investigating the potential of TLR agonist 
stimulation to modulate antigen-specific CD8+ T-cell responses.  Interestingly LPS was 
shown to have a negative effect on antigen-specific IFN-γ production in healthy individuals 
in response to the FEC peptide pool and this trend was also seen in HIV-1 infected 
individuals in response to FEC and HIV-1 peptide pools.  The mechanism leading to this 
observation is unclear, but increased LPS levels are seen in HIV-1 infection, particularly 
acute infection, and not only add to immunopathology but also have implications for the 
generation of acquired immune responses (Brenchley et al., 2006, Mehandru et al., 2004).    
By contrast, co-stimulation with CpG ODN2216 was shown to have a positive effect, 
though not statistically significant, on antigen-specific IFN-γ production, particularly in HIV-
1 seropositive treatment-naïve individuals.  The mechanism involved here is also unclear, 
but TLR9 stimulation is known to stimulate pDC to produce high levels of IFN-α and 
potently activates other immune cells.  TLR9 and TLR7 are both expressed by pDC, TLR7, 
however, has been implicated in the recognition of the HIV-1 ssRNA genome and is likely 
to contribute to chronic stimulation and exhaustion. Therefore TLR9 agonists might prove 
a more attractive target as an adjuvant, as it is not involved in chronic stimulation during 
HIV-1 infection.  The exact parameters that led to enhanced responses need to be more 
fully established, however, as certain combinations of CpG ODN2216 and peptide led to 
downregulation of IFN-γ production, and this also raises the possibility that other agonists, 
either those tested here or others, might also have beneficial effects when used in the 
appropriate combination. 
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An attempt was made to further characterise antigen-specific co-stimulation responses 
using flow cytometry assays to monitor activation and functional responses of memory 
CD8+ T-cells and antigen specific CD8+ T-cells.  The results of these assays were however 
difficult to interpret, and it is likely that peak CD8+ T-cell activation, IFN-γ production and 
degranulation responses occurred early following peptide stimulation and were therefore 
missed after overnight culture.  Detailed time course studies would help to identify optimal 
conditions.  Ideally this study would need to be extended to larger numbers of individuals, 
and encompassing different MHC class I haplotypes would achieve more robust data that 
may lead to clearer elucidation of events. 
Although the responses observed in these assays did not convincingly demonstrate 
enhanced responses using CpG ODN2216 above those seen for negative control 
individuals, they were consistently higher than responses observed for cultures stimulated 
with peptide alone.  It is possible that CpG ODN2216 stimulation might have enhanced 
responses by maintaining them longer than stimulation with peptide alone.  A time course 
assay would, again, address this hypothesis. 
Evidence presented in this thesis has demonstrated the importance of innate 
responsiveness in chronic HIV-1 infection.  The principle focus of the early chapters was 
on NK cell activity, and it was demonstrated that although NK cells have been shown to be 
dysfunctional in chronic HIV-1 infection, some subsets, particularly the immature 
immunoregulatory CD56hiCD16- NK cells, remain functional.  Recent work by others has 
further illustrated NK cell immune-modulating abilities in chronic viral infection, still further 
demonstrating that immunotherapies for HIV-1 infection should seek to promote healthy 
NK cell activity (Waggoner et al., 2011).  Furthermore, work presented in this thesis 
described how the use of TLR agonists used as adjuvants in model stimulations could 
boost antigen-specific immune responses in HIV-1 infection, demonstrating that innate 
immune responses should be more thoughtfully considered when designing both vaccines 
and immunotherapies. 
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6.2. Future work 
Although this thesis has demonstrated much in terms of the basic functional properties 
associated with innate agonist stimulation of ‘helper’ type NK cell function, larger scale 
studies are warranted to determine how knowledge found here could be applied to clinical 
use in the future.  
Parallel longitudinal studies following responsiveness of individuals to the various 
stimulants beginning at acute infection would greatly aid the understanding of the 
progression of the generation of dysfunctional responses. Such studies would reveal the 
kinetics of dysfunction and would provide further insight into the effects of treatment 
regimes to control immune disruption.  A limitation in designing such studies is, however, 
the difficulty in identifying and recruiting individuals in the early acute phase of HIV 
infection. 
Animal models of the effects of chronic viral infection on NK cell maturation are needed to 
fully explain data presented within this thesis.  As HIV does not infect mice, other models 
of chronic viral infections such as murine CMV (MCMV) or lymphocytic choriomeningitis 
(LCMV) have been used to demonstrate the long-term effects of chronic infection on NK 
cells (Waggoner et al., 2011).  Studies such as these provide very useful data, but 
interpretation from mouse to human, particularly within NK cell compartments, must be 
cautious as, despite the genetic similarities between species, many major differences still 
persist.  Mouse models, however, provide data that can be obtained under controlled 
conditions that cannot be investigated in human systems.   
Similar investigations to those presented in this thesis using tissue samples instead, where 
the dominant NK cell population is CD56hiCD16lo, would provide information regarding 
responsiveness of cell populations in the context of where the interactions being 
investigated would likely be occurring in vivo.  Either tonsillar tissue or gut biopsy tissue 
samples could be obtained from clinical settings for use in such studies. 
Clinical investigations or trials should be the ultimate goal of any such research in order to 
provide better adjuvant systems for vaccines or immunotherapeutic treatments. It is 
becoming ever more clear that modulation of adaptive immune responses through innate 
immune manipulation is capable of efficiently priming appropriate immune responses and 
immune memory.  
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Appendices 
Antibody panels used for Flow Cytometry Assays  
A.1 Total NK and CD8+ T-cell activation panel 
Basic innate NK & CD8+ T-cell activation panel  
Marker Fluorochrome 
Clone & 
Isotype 
Volume per test 
(µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 FITC B9.11, IgG1 κ 2.5 BC - A07756 
CD56 APC N901, IgG1 κ 5 BC - IM2474 
CD69 PE FN50, IgG1 κ 10 BD - 555531 
 
A.2 Plasmacytoid DC activation panel 
pDC activation panel    
Marker Fluorochrome 
Clone & 
Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
Lin-1 FITC Various* 2.5 BD - 340546 
CD123 PE 9F5, IgG1 κ 5 BD - 555644 
HLA-DR PerCP TÜ36, IgG2b κ 2.5 BD - 555561 
CD40 APC 5C3, IgG1 κ 10 BD - 555591 
 
*Lin-1 markers & Clones  
CD3 - SK7 
CD16 - 3G8 
CD19 - SJ25C1 
CD20 - L27 
IgG1 κ 
CD14 - MϕP9 
CD56 - NCAM16.2 
IgG2b 
κ 
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A.3 Myeloid DC activation panel 
mDC activation panel    
Marker Fluorochrome 
Clone & 
Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
Lin-1 FITC Various* 2.5 BD - 340546 
CD11c PE B-ly6, IgG1 κ 5 BD - 555644 
HLA-DR PerCP TÜ36, IgG2b κ 2.5 BD - 555561 
CD40 APC 5C3, IgG1 κ 10 BD - 555591 
 
A.4 NK cell subset activation panel 
NK subset panel    
Marker Fluorochrome Clone & Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 APC-H7 SK1, IgG1 κ 1.25 BD - 560179 
CD56 APC N901, IgG1 κ 5 BC - IM2474 
CD16 FITC LNK16, IgG1 κ 10 MCA1193F 
CD69 PE FN50, IgG1 κ 10 BD - 555531 
CD25 PE-Cy7 M-A251, IgG1 κ 2.5 BD - 557741 
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A.5 NK cell functional activity and KIR panel 
NK functional activation panel   
Marker Fluorochrome 
Clone & 
Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 APC-H7 SK1, IgG1 κ 1.25 BD - 560179 
CD56 APC N901, IgG1 κ 5 BC - IM2474 
KIR:       
CD158a 143211, IgG1 κ 5 R&D FAB1844F 
CD158b CH-L, IgG2b κ 10 BD – 559784 
NKB1 
FITC 
DX9, IgG1 κ 10 BD - 555960 
IFN-γ PE-Cy7 4S.B3 IgG1 κ 1:80  20 BD - 557844 
A.6 NK cell maturation panel 
NK cell maturation panel    
Marker Fluorochrome Clone & Isotype 
Volume per 
test (µl) 
Manufacturer 
& Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD56 APC N901, IgG1 κ 5 BC - IM2474 
CD16 APC-H7 3G8, IgG1 κ 1 BD - 560195 
CD94 FITC HP-3D9, IgG1 κ 10 BD - 555888 
c-Kit(CD117) PE 104D2, IgG1 κ 10 BD - 332785 
CD25 PE-Cy7 M-A251, IgG1 κ 2.5 BD - 557741 
A.7 Innate T-cell activation panel 
Innate T-cell activation 
Marker Fluorochrome 
Clone & 
Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP 
SK7, IgG1 
κ 2.5 BD - 345766 
CD8 APC-H7 
SK1, IgG1 
κ 1.25 BD - 560179 
CD4 PE 
SK3, IgG1 
κ 2.5 BD - 345769 
γδ TCR FITC B1, IgG1 κ 1 BD - 559878 
CD69 PE-Cy7 
FN50, IgG1 
κ 2.5 BD - 557745 
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A.8 CD8+ T-cell maturation and activation panel 
 
CD8+ T-cell maturation panel   
Marker Fluorochrome Clone & Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 APC-H7 SK1, IgG1 κ 1.25 BD - 560179 
CD45RA PE-Cy7 L48, IgG1 κ 2.5 BD  - 337186 
CCR7 APC 150503, IgG2a κ 5 R&D - FAB197A 
CD62L FITC DREG56, IgG1 κ 10 BD - 555543 
CD69 PE FN50, IgG1 κ 10 BD - 555531 
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A.9  CD8+ T-cell/NK cell antigen specific activation panel 
Peptide-TLR activation    
Marker Fluorochrome 
Clone & 
Isotype 
Volume per 
test (µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 APC-H7 SK1, IgG1 κ 1.25 BD - 560179 
CD69 PE-Cy7 FN50, IgG1 κ 2.5 BD - 557745 
CD56 APC N901, IgG1 κ 5 BC - IM2474 
CD16 APC-H7 3G8, IgG1 κ 1 BD - 560195 
IFN-γ PE 4S.B3 IgG1 κ 10 BD - 559326 
 
A.10 Antigen specific CD8+ T-cell activation panel 
Pentamer stain    
Marker Fluorochrome 
Clone & 
Isotype 
Volume per test 
(µl) 
Manufacturer & 
Cat. No. 
CD3 PerCP SK7, IgG1 κ 2.5 BD - 345766 
CD8 APC-H7 LT8, IgG1 κ 1 
ProImmune 
A003-3B-G 
CD69 PE-Cy7 FN50, IgG1 κ 2.5 BD - 557745 
CD45RA APC-Cy7 H100 IgG2b κ 2.5 BD  - 560674 
CCR7 APC 
150503, 
IgG2a κ 5 R&D - FAB197A 
CD107a Pacific Blue H4A3, IgG1 κ 
1:50 
(RPMI)20µl/ml 
Biolegend - 
328624 
Pentamer PE MHC specific* 10 
ProImmune 
(various*) 
 
*Pentamer Sequence 
ProImmune cat. 
No. 
Negative - FN01-2A-G 
CMV NLVPMVATV F008-2A-G 
HIV-1 gag (1) SLYNTVATL F010-2A-G 
HIV-1 gag (2) TLNAWVKVV F174-2A-G 
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Peptide pool sequences 
A.11 FEC peptide pool 
CFAR FEC Peptides  
Peptide  Sequence  Antigen 
FEC1  GILGFVFTL  Flu M  
FEC2  FMYSDFHFI  Flu  
FEC3  SIIPSGPLK  Flu M  
FEC4  RVLSFIKGTK  Flu NP  
FEC5  KTGGPIYKR  Flu NP  
FEC6  LPFDKTTVM  Flu NP  
FEC7  ELRSRYWAI  Flu NP  
FEC8  SRYWAIRTE  Flu NP  
FEC9  ASCMGLIY  Flu M  
FEC10  CLGGLLTMV  EBV  
FEC11  GLCTLVAML  EBV  
FEC12  AVFDRKSDAK  EBV  
FEC14  DYCNVLNKEF  EBV  
FEC15  RAKFKQLL  EBV  
FEC16  FLRGRAYGL  EBV  
FEC17  QAKWRLQTL  EBV  
FEC18  RRIYDLIEL  EBV  
FEC19  YPLHEQHGM  EBV  
FEC20  NLVPMVATV  CMV  
FEC21  TPRVTGGGAM  CMV  
FEC22  SDEEEAIVAYTL  CMV  
FEC23  IPSINVHHY  CMV  
FEC24  VSDGGPNLY  Flu  
FEC25  CTELKLSDY  Flu  
FEC26  ILRGSVAHK  Flu  
FEC27  RVRAYTYSK  EBV  
FEC28  RLRAEAQVK  EBV  
FEC29  IVTDFSVIK  EBV  
FEC30  ATIGTAMYK  EBV  
FEC31  RPPIFIRRL  EBV  
FEC32  EENLLDFVRF  EBV  
FEC33  EFFWDANDIY  CMV  
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A.12 HIV-1 gag p24 20mer peptide pool 
CFAR HIV-1 gag p24 20mer peptides 
Peptide Sequence 
 ARP788.1  PIVQNLQGQMVHQAISPRTL  
ARP788.2  VHQAISPRTLNAWVKVVEEK  
ARP788.3  NAWVKVVEEKAFSPEVIPMF  
ARP788.4  AFSPEVIPMFSALSEGATPQ  
ARP788.5  SALSEGATPQDLNTMLNTVG  
ARP788.6  DLNTMLNTVGGHQAAMQMLK  
ARP788.7  GHQAAMQMLKETINEEAAEW  
ARP788.8  ETINEEAAEWDRVHPVHAGP  
ARP788.9  DRVHPVHAGPIAPGQMREPR  
ARP788.10  IAPGQMREPRGSDIAGTTST  
ARP788.11  GSDIAGTTSTLQEQIGWMTN  
ARP788.12  LQEQIGWMTNNPPIPVGEIY  
ARP788.13  NPPIPVGEIYKRWIILGLNK  
ARP788.14  KRWIILGLNKIVRMYSPTSI  
ARP788.15  IVRMYSPTSILDIRQGPKEP  
ARP788.16  LDIRQGPKEPFRDYVDRFYK  
ARP788.17  FRDYVDRFYKTLRAEQASQD  
ARP788.18  TLRAEQASQDVKNWMTETLL  
ARP788.19  VKNWMTETLLVQNANPDCKT  
ARP788.20  VQNANPDCKTILKALGPAAT  
ARP788.21  ILKALGPAATLEEMMTACQG  
ARP788.22  LEEMMTACQGVGGPGHKARV 
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A.13 HIV-1 gag 9mer peptide pool 
CFAR HIV-1 gag 9mer peptides 
Peptide Sequence Epitope 
 EVA7083.1  SPRTLNAWV  p24 148-156  
EVA7083.2  TPQDLNTML  p24 180-188  
EVA7083.3  AEWDRLHPV  p24 210-218  
EVA7083.4  ILGLNKIVR  p24 267-275  
EVA7083.5  RMYSPTSIL  p24 275-283  
EVA7083.6  ILDIKQGPK  p24 282-290 
   
Sigma-Genosys (Sigma-Aldrich) HIV-1 gag 
9mer peptides 
Peptide Sequence Epitope 
DR9 DRWEEKIRLR p17 14-22 
RK9 RLRPGGKKK p17 20-28 
GL9 GGKKKKYKL p17 24-31 
KI9 KKKYKLKHI p17 26-34 
KW9 KYKLKHIVW p17 28-36 
WF9 WASRELERF p17 36-44 
GY9 GSEELRSLY p17 71-79 
EV9 ELRSLYNTV p17 74-82 
SL9 SLYNTVATL p17 77-85 
TI9 TLYCVHQRI p17 84-92 
IL10 IEIKDTKEAL p17 92-101 
EL9 EIKDTKEAL p17 93-101 
QW11 QAISPRTLNAW p24 13-23 
IW9 ISPRTLNAW p24 15-23 
SW8 SPRTLNAW p24 16-24 
KF11 KAFSPEVIPMF p24 30-40 
FF9 FSPEVIPMF p24 32-40 
EL9 EVIPMFSAL p24 35-43 
SL9 SEGATPQDL p24 44-52 
GL9 GHQAAMQML p24 61-69 
EW10 ETINEEAAEW p24 71-80 
VA10 VHPVHAGPIA p24 83-92 
HA9 HPVHAGPIA p24 84-92 
TW10 TSTLQEQIGW p24 108-117 
TN10 TSTLQEQIGN p24 108-117 
PY9 PPIPVGDIY p24 122-130 
GI9 GEIYKRWII p24 127-135 
EL9 EIYKRWIIL p24 128-136 
KK10 KRWIILGLNK p24 131-140 
AW11 AEQASQVDKNW p24 174-184 
QW9 QASQVDKNW p24 176-184 
DL9 DCKTILKAL p24 197-205 
AK11 ACQGVGGPGHK p24 217-227 
VV9 VLAEAMSQV p24 230-231 / p2 1-7 
YL9 YPLTSLRSL p6 36-44 
RI9 RQANFLGKI p7 52-55 / p1 1-5 
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Chapter 3 Items 
A.14  
Comparison of early activation (CD69 frequency) responses between HIV-1 seronegative and 
seropositive, both treatment-naïve and experienced, individuals using optimal TLR agonist 
concentrations shown.  Comparisons between unstimulated controls and stimulated PBMC are also 
shown for each subject group (Wilcoxons matched pairs test was used for this analysis) *denotes 
statistically significant differences.  
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Chapter 4 Items 
A.15  
Median frequencies and ranges (%) of CD56hiC-Kit+ and CD56loC-Kit- NK cells from total CD3-CD56+ 
NK cell populations following six days in vitro culture of PBMC with the cytokines or TLR agonists (as 
shown). 
 
A.16  
Median frequencies and ranges (%) of CD56hiC94+, CD56loC94+ and CD56loC94- NK cells from total 
CD3-CD56+ NK cell populations following six days in vitro culture of PBMC with the cytokines or TLR 
agonists (as shown). 
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A.17  
Median (and range) quantities of C-Kit and stem cell factor (SCF) detected in plasma from HIV-1- control 
individuals and HIV-1+, both treatment-naïve and experienced individuals. u/d – undetectable.  
 
 
